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 1 
1 INTRODUCTION 
1.1 Cardiovascular disease: definition and prevalence 
“Cardiovascular disease (CVD) is a group of disorders of the heart and blood vessels, and includes 
coronary heart disease (CHD, disease of the blood vessels supplying the heart muscle), cerebro-
vascular disease (disease of the blood vessels supplying the brain), peripheral arterial disease (dis-
ease of blood vessels supplying the arms and legs), rheumatic heart disease (damage to the heart 
muscle and heart valves from rheumatic fever, caused by streptococcal bacteria), congenital heart 
disease (malformations of heart structure existing at birth), deep vein thrombosis and pulmonary 
embolism (blood clots in the leg veins, which can dislodge and move to the heart and lungs)” 
(World Health Organization, 2017, http://www.who.int/mediacentre/factsheets/fs317/en/).  
According to the World Health Organization (WHO), CVD is the most common cause of death 
worldwide. An estimated 17.9 million people died from CVD in 2016, representing 31 % of all 
global deaths (World Health Organization, 2017). Of these deaths, 85 % were due to acute CVD 
events, namely myocardial infarction and stroke (World Health Organization, 2017). In Europe, 
CVD accounts for 45 % of all deaths whereof 70 % were attributed to CHD and cerebrovascular 
disease (Townsend et al., 2016). Similarly, the vast majority of deaths in Germany in 2013 was 
caused by CVD (39.7 %) (Robert-Koch-Institut, 2015). Results of the German Health Update from 
2009 to 2012 showed that the overall prevalence of major CVD events (namely myocardial infarc-
tion, angina pectoris, heart failure, and stroke) was 12.0 % in the German population (Dornquast 
et al., 2016). 
1.2 Cardiovascular disease: risk factors and prevention 
There are numerous risk factors of CVD, which, according to the World Heart Federation, can be 
categorized into non-modifiable and modifiable risk factors (World Health Federation, 2017).  
The non-modifiable risk factors of CVD include age, male sex (with gender advantage disappear-
ing after menopause), positive CVD history of a first-degree relative, and African or Asian origin. 
Socioeconomic factors, such as education level, income, and poverty status, are increasingly con-
sidered “maybe modifiable risk factors” of CVD and thus strongly targeted by health politics and 
public health initiatives (Lennon et al., 2018, p. 2). 
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Modifiable risk factors comprise lifestyle factors such as tobacco use, physical inactivity, obesity, 
unhealthy diet, stress, and excessive alcohol use, as well as diseases of the metabolic syndrome, 
such as hypertension, diabetes or pre-diabetes, and hyperlipidaemia (Lennon et al., 2018). 
Primary prevention activities focus on these modifiable risk factors by targeting early detection of 
people at risk, as well as education and promotion of a healthier lifestyle. For example, the Global 
Action Plan, which was agreed by the World Health Assembly in May 2012, launched the fight 
against the major risk factors of non-communicable diseases (CVD, chronic respiratory diseases, 
cancers, and diabetes), namely tobacco use, hypertension, unhealthy diet, physical inactivity, and 
harmful use of alcohol (World Health Organization, 2013). Amongst prevalence reduction of these 
risk factors, the global action plan aims to reduce premature mortality due to non-communicable 
diseases by 25 % by the year 2025. If the risk factor targets are met, a reduction of 34 % of deaths 
from CVD is predicted by then. This would result in 11.4 million delayed deaths in those aged 
30 to 69 years and even 15.9 million prevented deaths in those aged 70 years and older (Kontis et 
al., 2014). 
The reduction of CVD deaths requires not only the modification of risk factors in order to prevent 
primary events, but also the use of therapeutic approaches to prevent recurrent events within the 
framework of secondary prevention. The latter is particularly important for managing acute CVD 
events such as myocardial infarction or stroke, but also in addition to prevention of primary events 
if several CVD risk factors concomitantly exist (Leong et al., 2017).  
First-line drugs for the treatment of stable CVD include aspirin, statins, and antihypertensive 
drugs, such as β-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II 
receptor blockers (ARB). All of these have shown to improve the clinical course (Fihn et al., 2014; 
McAlister, 2012). Given that hypertension is a major risk factor of CVD, antihypertensive therapy 
with β-blockers, ACE inhibitors, ARBs, calcium channel blockers, and diuretics has shown to 
positively impact on CVD and mortality. It is expected, for instance, that a reduction of 10 mmHg 
in systolic blood pressure reduces the stroke risk by 41 % and the CHD risk by 22 % (Law et al., 
2009). 
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1.3 Potassium: definition, hypokalemia, and hyperkalemia 
Beyond the background of CVD and CVD risk factors, I would like to draw attention to the chem-
ical element potassium, which plays an important role in heart function and heart rhythm. It is an 
essential mineral for the body, which must be supplied through food, as the body cannot produce 
it itself. Potassium-rich food comprises vegetables and fruits, such as apricots, avocados, bananas, 
carrots, kohlrabi, potatoes, spinach and tomatoes. Also hazelnuts, cashew nuts, peanuts and al-
monds as well as dark chocolate and some types of flour (spelt, rye, buckwheat wholemeal flour) 
are good sources of potassium (Deutsche Gesellschaft für Ernährung e.V., 2016). As a reference 
value for the daily potassium intake of an adult, the Deutsche Gesellschaft für Ernährung recom-
mends 4000 milligrams, which corresponds to about 7 bananas or 1200 grams of potatoes 
(Deutsche Gesellschaft für Ernährung e. V., 2017). Approximately 80 % of potassium from food 
is absorbed (Holbrook et al., 1984). In the body, potassium is present as a positively charged elec-
trolyte, the potassium cation (K+), as it is dissolved in extracellular and mainly intracellular fluids. 
As one of the major electrolytes in the body, potassium is involved in maintaining osmotic pres-
sure, electrolyte homeostasis and acid-base balance and thus regulates blood pressure. Potassium 
is further important for the transmission of nerve impulses and therefore plays a crucial role in 
muscle contractions, such as those of the heart muscle (Deutsche Gesellschaft für Ernährung e.V., 
2016). 
Under physiological conditions and as a requirement for physiological function, extracellular se-
rum potassium levels are in the range of 3.5 to 5.1 mmol/L (Lerma, 2014). Adequate levels are 
maintained by renal elimination and by the activity of an enzyme called sodium–potassium aden-
osine triphosphate synthase (Na+/ K+-ATPase) (Palmer and Clegg, 2016). By hydrolysing adeno-
sine triphosphate (ATP) to adenosine diphosphate (ADP) and phosphate (P) these enzymes gener-
ate energy which they can use to actively (meaning against the concentration gradient) transport 
potassium cations (K+) from extracellular fluids into the cells. In exchange, sodium cations (Na+) 
are pumped from inside the cells to outside. (Glitsch, 2001). Nevertheless, if these mechanisms 
fail to compensate potassium imbalances, this can result in abnormal serum potassium levels. 
Hypokalemia defines the condition when serum potassium levels fall below 3.5 mmol/L (Greenlee 
et al., 2009; Zacchia et al., 2016), whereas hyperkalemia is characterized by serum potassium 
levels above 5.1 mmol/L (Lerma, 2014). Although often asymptomatic, hypokalemia can be asso-
ciated with weakness, muscle pain or cramps, constipation, and arrhythmias (ventricular fibrilla-
tion) (Elliott and Braun, 2017; Marti et al., 2014). Similarly, hyperkalemia can be associated with 
unspecific symptoms such as palpitations, nausea, paraesthesia, and muscle pain, but also even 
fatal cardiac arrhythmias (Elliott and Braun, 2017; Lehnhardt and Kemper, 2011). 
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Figure 1.  Simplified graphical display of physiological and abnormal serum potassium levels. 
Sensitivity towards abnormal serum potassium levels seems to be important for the prognosis of 
CVD and may be different according to the patient’s history of morbidity. In patients with acute 
myocardial infarction (AMI), for instance, an intracellular shift of potassium is stimulated by ex-
cessively released catecholamines during this acute condition. This results in potassium depletion, 
which in turn can increase the risk of ventricular fibrillation (Brown et al., 1983; Obeid et al., 
1978). Moreover, patients with chronic kidney disease (CKD) are prone to experience imbalances 
in serum potassium levels (mainly hyperkalemia), due to impaired renal clearance and subsequent 
decreased excretion of serum potassium (Kovesdy, 2014). 
1.4 Drugs affecting potassium excretion: diuretics 
On the other hand, there are also drugs that have the potential to influence potassium excretion 
and thus to promote imbalances of serum potassium concentration. Diuretics are prescription drugs 
that initially block sodium reabsorption by acting at different tubular sites of the nephron, and 
thereby modulate the homeostasis of sodium and water in the body (diuresis) (Roush et al., 2014). 
Therefore, diuretics are successfully used to treat oedema, high blood pressure and heart failure 
(Brater, 1998; Ernst and Moser, 2009). Other electrolytes, such as potassium, are also affected by 
diuretic effects, because finally the reabsorption of sodium is increased via an exchange with po-
tassium. According to the type of diuresis they induce and their effects on serum potassium, diu-
retics can be classified into two groups: potassium-sparing and non-potassium-sparing diuretics. 
Potassium-sparing diuretics induce retention of serum potassium by decreased sodium re-absorp-
tion via the exchange with potassium. These diuretics comprise the substances amiloride and tri-
amterene, which directly block apical sodium channels, so-called ENaC channels, and the ARBs 
spironolactone, canrenone and eplerenone, which inhibit the effects of aldosterone by competi-
tively binding to its receptor. Aldosterone primarily promotes the synthesis of ENaC channels to 
re-absorb sodium and secondarily the secretion of potassium. In contrast to ARBs, amiloride and 
Hypokalemia Hyperkalemia
Physiological 
levels
< 3.5 mmol/L > 5.1 mmol/L
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triamterene affect sodium re-absorption and thus the retention of potassium independently of al-
dosterone (Tamargo et al., 2014b).  
Non-potassium-sparing diuretics, in contrast, promote diuresis by inhibiting re-absorption of so-
dium without the retention of potassium and thus decrease serum potassium levels. This group of 
diuretics comprises thiazides, such as hydrochlorothiazide, and sulphonamides, such as clopamide, 
chlortalidone, indapamide, furosemide, bumetanide, and torasemide (Brater, 1998; Tamargo et al., 
2014a; Tamargo et al., 2014b). While thiazide diuretics block the apical electroneutral sodium–
chloride co-transporter, sulphonamides block the apical sodium–potassium–chloride co-trans-
porter of the thick ascending limb of Henle’s loop. Due to this specific site of action within the 
nephron, sulphonamides are also called loop diuretics (Tamargo et al., 2014a; Tamargo et al., 
2014b). Given their mechanisms of action, non-potassium-sparing diuretics ultimately result in an 
increased secretion of potassium due to up-regulation of transporters that exchange potassium in 
favour of sodium, such as the sodium-potassium ATPase pump (Tamargo et al., 2014a; Tamargo 
et al., 2014b). 
According to current guidelines of the European Society for Cardiology, diuretics, with the excep-
tion of loop diuretics, are among the first-line drugs in hypertension as they have shown to improve 
the clinical course and to reduce mortality (Williams et al., 2018). Loop diuretics are in turn part 
of guideline recommendations for heart failure treatment as they offer great benefits for patients 
with symptoms of congestion (Ponikowski et al., 2016). 
1.5 Drugs affecting potassium excretion: laxatives 
Not only prescription drugs but also over-the-counter (OTC) drugs can have major effects on po-
tassium excretion and thus result in imbalances of serum potassium concentration. OTC drugs are 
medications that can be bought without a prescription, which consequently often happens without 
a physician’s advice or knowledge. Older individuals, in particular, frequently use OTC drugs 
(Malone et al., 2005; Thesing-Bleck and Hinneburg, 2012). 
One prominent example is laxatives. These OTC drugs are used to treat constipation, a symptom 
not only characterized by reduced bowel movement frequency, but also by “excessive straining, a 
sense of incomplete evacuation, failed or lengthy attempts to defecate, use of digital manoeuvres 
for evacuation of stool, abdominal bloating, and hard consistency of stools” (Sharma and Rao, 
2017). Available OTC laxatives can be classified into softeners, osmotic laxatives, and stimulant 
laxatives (Sharma and Rao, 2017, p. 3). 
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Softeners comprise natural fibres, such as bran and psyllium, methylcellulose, and polycarbophil. 
These substances act by binding water and thereby increase motility and transfer of stool through 
the colon (Xing and Soffer, 2001). 
Osmotic laxatives include lactulose, polyethylene glycol, and magnesium-containing substances, 
such as magnesium citrate or magnesium sulphate. This group of laxatives retains water into the 
stool in order to restore normal osmolality (Sharma and Rao, 2017; Xing and Soffer, 2001). 
Stimulants, such as senna, bisacodyl, and sodium picosulfate, are the most effective, but also the 
most aggressive types of laxatives. They inhibit water absorption in the colon, instead strongly 
stimulate water secretion, and thus result in a rapid transit through the colon (Sharma and Rao, 
2017). Increased water secretion simultaneously causes increased electrolyte secretion, which in a 
dose-dependent manner may result in hypokalemia (Ewe, 1987). 
In particular, the abuse of laxatives, i.e., overdosing or chronic use, can lead to hypokalemia, which 
in turn can decrease intestinal motility. As a consequence, the symptom of constipation may 
worsen and thus result in a need to continuously increase the effective dose of the laxative. This 
vicious circle can finally lead to a laxatives addiction (Dörr, 2010). 
Not lastly due to age-related factors, such as decreased intestinal motility, inadequate fluid and 
fibre intake, physical inactivity or use of constipating drugs (e.g. opioids and anticholinergic 
drugs), approximately 20 % of the elderly suffer from chronic constipation and therefore regularly 
use laxatives (Werth et al., 2017). 
1.6 Current state of scientific knowledge 
Given the high prevalence of CVD and the importance of adequate serum potassium levels for 
physiological heart function, many observational studies have assessed the association between 
serum potassium levels and cardiovascular outcomes. However, due to the diverse populations 
studied (e.g. AMI population, dialysis patients) and the various cardiovascular outcomes investi-
gated (e.g. arrhythmias, sudden cardiac death), results are contradictory and therefore comparisons 
are challenging. Neither a systematic review of this study type nor a statistical synthesis of the 
results has been done so far. A summary of these findings, though, could present a long-lasting 
reference work in the field of CVD risk factors and CVD mortality reduction. 
In addition, further strategies to reduce and prevent CVD mortality could include avoiding the 
combination of drugs that affect potassium excretion and thus serum potassium levels. Using two 
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or more drugs at the same time bears the potential risk of a drug-drug interaction (Becker et al., 
2007). Concurrent use of prescription and OTC drugs is present in 46 % of community-residing 
individuals aged 57 to 85 years, as reported by a study from the United States (Qato et al., 2008). 
Laxatives, for instance, could interact with non-potassium-sparing diuretics, which are prescribed 
to one in five of the elderly (Si et al., 2018), because both drug classes can decrease serum potas-
sium levels by affecting potassium excretion (Brater, 1998; Lacy et al., 2014). Due to the narrow 
range of physiological serum potassium levels (3.5 to 5.1 mmol/L), potassium depletion may result 
in hypokalemia (Greenlee et al., 2009; Zacchia et al., 2016), which subsequently can cause ar-
rhythmias and even cardiac death (Krijthe et al., 2013; Lai et al., 2015). Previous cohort studies 
have already shown an increased cardiovascular risk by non-potassium-sparing diuretics, which 
was explained by drug-induced hypokalemia (Ahmed et al., 2006; Cohen et al., 2001; Cooper et 
al., 1999). On the other hand, there is a lack of studies investigating the risk of regular laxatives 
use (Kubota et al., 2016), especially in combination with non-potassium-sparing diuretics. A rea-
son might be that most studies on drug exposure are based on medication claims databases, which 
do not record OTC drugs. Therefore, the risk of potentially serious drug-drug interactions may be 
underestimated by these studies (Bjorkman et al., 2002), and should preferably rather be estimated 
from observational studies, which often have information on both prescription and OTC drugs. 
1.7 Aims of the dissertation 
The first aim of this dissertation was to conduct a systematic review of observational studies re-
porting on the association of abnormal serum potassium levels with cardiovascular outcomes, 
namely supraventricular arrhythmias (SVA), ventricular arrhythmias (VA), cardiovascular mor-
tality (CVM), and composite cardiovascular (CV) outcomes. Meta-analyses for the data synthesis 
of each association were conducted separately for the older general population, and populations 
with a history of hypertension, AMI, heart failure, CKD, and dialysis. 
 
Figure 2.  Simplified visual illustration presenting the research question of the systematic review 
and meta-analysis. 
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Based on the assumption that serum potassium levels in cardiovascular patients might be affected 
by drug treatment, I secondly aimed to investigate the cardiovascular risk of drugs affecting po-
tassium excretion in an observational study setting. More precisely, I analysed the associations of 
diuretics overall, non-potassium-sparing diuretics in specific, and laxatives use with CVM in par-
ticipants receiving antihypertensive treatment, which includes individuals with hypertension or 
heart failure. For this purpose, the drug classes were first analysed distinctly and then jointly in 
order to detect potential drug-drug interactions between the aforementioned prescription and OTC 
drugs. Analyses were conducted separately in two large-scale cohort studies. While the German 
ESTHER study (Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und op-
timierten Therapie chronischer Erkrankungen in der älteren Bevölkerung [German]) was used as 
a derivation cohort to generate hypotheses, the larger UK Biobank served as replication cohort to 
confirm the findings. Results from both studies were then combined in an individual patient-data 
meta-analysis. 
 
Figure 3.  Simplified visual illustration presenting the research question of the original analyses 
in two large observational studies. 
Drugs affecting 
potassium 
excretion
Cardiovascular 
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2 SYSTEMATIC REVIEW 
This dissertation provides the first systematic overview about the association of abnormal serum 
potassium levels and cardiovascular outcomes, namely supraventricular arrhythmias and ventric-
ular arrhythmias, CVM, and composite CV outcomes. The content of the following chapters on 
material and methods (2.1), results (2.2), and discussion (2.3) has previously been published by 
myself and co-workers in the scientific article “Hoppe, L. K., Muhlack, D. C., Koenig, W., Carr, 
P. R., Brenner, H. and Schöttker, B. (2018). Association of Abnormal Serum Potassium Levels 
with Arrhythmias and Cardiovascular Mortality: a Systematic Review and Meta-Analysis of Ob-
servational Studies. Cardiovasc Drugs Ther 32, 197-212, doi: 10.1007/s10557-018-6783-0”. 
2.1 Material and methods 
This systematic review and meta-analysis was performed in accordance to the reporting guidelines 
for Meta-analysis Of Observational Studies in Epidemiology (MOOSE) (Stroup et al., 2000). The 
MOOSE checklist (Table 1) shows that specifications for reporting, which include background, 
search strategy, methods, results, discussion, and conclusions, were appropriately followed. 
Table 1.  Applied MOOSE checklist for meta-analyses of observational studies. 
Reporting of background should include  
Problem definition Introduction (1.1, 1.2, 1.3, 1.6) 
Hypothesis statement Introduction (1.6, 1.7) 
Description of study outcome(s) Introduction (1.7) 
Type of exposure or intervention used Introduction (1.7) 
Type of study designs used Introduction (1.7) 
Study population Introduction (1.7) 
Reporting of search strategy should include  
Qualifications of searchers (e.g. librarians and investigators) Methods (2.1.1, 2.1.2) 
Search strategy, including time period included in the 
synthesis and keywords 
Methods (2.1.1) 
Effort to include all available studies, including contact with 
authors 
Methods (2.1.2, 2.1.4) 
Databases and registries searched Methods (2.1.1) 
Search software used, name and version, including special 
features used (e.g. explosion) 
Methods (2.1.1), Table 2 
Use of hand searching (e.g. reference lists of obtained articles) Methods (2.1.2), Discussion (2.3.4) 
List of citations located and those excluded, including 
justification 
Table A1, Tables 12 to 17 
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Method of addressing articles published in languages other 
than English 
Methods (2.1.1) 
Method of handling abstracts and unpublished studies Methods (2.1.2, 2.1.4) 
Description of any contact with authors Methods (2.1.4) 
Reporting of methods should include  
Description of relevance or appropriateness of studies 
assembled for assessing the hypothesis to be tested 
Introduction (1.6, 1.7), Results (2.2.2),  
Tables 3 to 5 
Rationale for the selection and coding of data (e.g. sound 
clinical principles or convenience) 
Results (2.2.3, 2.2.4), Table 10,  
Tables 12 to 17 
Documentation of how data were classified and coded (e.g. 
multiple evaluators, blinding, and interrater reliability) 
Methods (2.1.2, 2.1.3), Results (2.2.3),  
Tables 7 to 9 
Assessment of confounding (e.g. comparability of cases and 
controls in studies where appropriate) 
Methods (2.1.3), Results (2.2.3),  
Tables 7 to 9 
Assessment of study quality, including blinding of quality 
assessors; stratification or regression on possible predictors of 
study results 
Methods (2.1.3), Results (2.2.4) 
Assessment of heterogeneity Methods (2.1.4) 
Description of statistical methods (e.g. complete description 
of fixed-effect or random-effects models, justification of 
whether the chosen models account for predictors of study 
results, dose-response models or cumulative meta-analysis) in 
sufficient detail to be replicated 
Methods (2.1.4), Results (2.2.5),  
Table 18 
Provision of appropriate tables and graphics Tables 3 to 5, Tables 7 to 9, Table 10,  
Tables 12 to 17, Table 18, Figures 4 to 
6 
Reporting of results should include  
Graphic summarizing individual study estimates and overall 
estimate 
Figure 5, Figure 6, Table 10, Table 18 
Table giving descriptive information for each study included Tables 3 to 5 
Results of sensitivity testing (e.g. subgroup analysis) Results (2.2.5), Table 18 
Indication of statistical uncertainty of findings Discussion (2.3.3) 
Reporting of discussion should include  
Quantitative assessment of bias (e.g. publication bias) Discussion (2.3.3) 
Justification for exclusion (e.g. exclusion of non-English-
language citations) 
Results (2.2.4), Tables 12 to 17 
Assessment of quality of included studies Tables 7 to 9, Discussion (2.3.4) 
Reporting of conclusions should include  
Consideration of alternative explanations for observed results Discussion (2.3.2) 
Generalization of the conclusions (meaning appropriate for 
the data presented and within the domain of the literature 
review) 
Discussion (2.3.5) 
Guidelines for future research Discussion (2.3.3, 2.3.5) 
Disclosure of funding source Not applicable, as no funding received 
MOOSE, Meta-analysis Of Observational Studies in Epidemiology. 
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2.1.1 Data sources and search strategy 
First of all, I conducted a systematic literature search using the databases Medline (Ovid Technol-
ogies, New York) and Web of Science (Clarivate Analytics© 2018, Boston) from inception until 
November 24, 2017. No language or publication date restrictions were imposed. After having con-
sulted a librarian, I developed the search strategy. It combined synonymous and related terms 
which describe the exposure (potassium), the outcomes (arrhythmias, and CVM), and the study 
type (observational study). In addition, the terms included different spellings as well as singular 
and plural forms. 
A complete version of the full electronic search strategy for Medline is shown in Table 2. Most of 
the search terms were enclosed in quotation marks inducing an exact search for the enclosed term. 
On the other hand, adding an asterisk at the end of a search term allowed to include different 
endings of the search term in the search, such as singular and plural forms. Additionally, a few 
search terms were connected with specific search field descriptions, such as “Mesh” (enlarging the 
search to specific and related topics that the articles are indexed with, so-called medical subject 
headings (Mesh)), “tiab” (restricting the search to the title, abstract, and keywords of articles) or 
“Publication type” (focussing the search on specific types of material that the articles present, such 
as reviews, editorials, observational studies etc.) (U.S. National Library of Medicine, 2018). 
The reference manager Endnote X7 (Thomson Scientific Technical Support, New York) was used 
throughout the literature search and screening process. 
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Table 2.  Details and results of the literature search in Medline until 24 November 2017. 
Steps Search term Search string Hits 
#1 Potassium "Potassium"[Mesh] 98,625 
#2  "Potassium"[tiab] 128,526 
#3 Hypokalemia "Hypokalemia"[Mesh] 8,098 
#4  "Hypokalemia"[tiab] 7,006 
#5  "Hypokalemias"[tiab] 10 
#6  "Hypokalaemia"[tiab] 1,935 
#7  "Hypokalaemias"[tiab] 0 
#8  "Hypopotassemia"[tiab] 260 
#9  "Hypopotassaemia"[tiab] 25 
#10  "Hypopotassaemias"[tiab] 1 
#11 Hyperkalemia "Hyperkalemia"[Mesh] 5,392 
#12  "Hyperkalemia"[tiab] 5,279 
#13  "Hyperkalemias"[tiab] 8 
#14  "Hyperkalaemia"[tiab] 1,267 
#15  "Hyperkalaemias"[tiab] 0 
#16  "Hyperpotassemia"[tiab] 148 
#17  "Hyperpotassaemia"[tiab] 15 
#18 OR (1-17) EXPOSURE 196,492 
#19 Arrhythmias "Arrhythmias, Cardiac"[Mesh] 188,213 
#20  "Arrhythmia"[tiab] 39,259 
#21  "Arrhythmias"[tiab] 48,117 
#22  Cardiac dysrhythmia*[tiab] 1,035 
#23  Cardiac dysrrhythmia*[tiab] 20 
#24  Cardiac dysrythmia*[tiab] 11 
#25  "Atrial fibrillation"[tiab] 55,816 
#26  "Atrial fibrillations"[tiab] 96 
#27  "Auricular fibrillation"[tiab] 1,538 
#28  "Auricular fibrillations"[tiab] 7 
#29  "Atrial flutter"[tiab] 5,168 
#30  "Atrial flutters"[tiab] 62 
#31  "Auricular flutter"[tiab] 503 
#32  "Ventricular fibrillation"[tiab] 17,200 
#33  "Ventricular fibrillations"[tiab] 113 
#34  Ventricular flutter*[tiab] 232 
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Table 2 continued, page 2/4 
#35 OR (19-34)  238,908 
#36 Myocardial Infarction "Myocardial Infarction"[Mesh] 161,335 
#37  "Myocardial infarct"[tiab] 19,387 
#38  "Myocardial infarcts"[tiab] 1,043 
#39  "Myocardial infarction"[tiab] 158,678 
#40  "Myocardial infarctions"[tiab] 4,956 
#41  "Cardiovascular stroke"[tiab] 13 
#42  Heart attack*[tiab] 4,870 
#43  Non fatal myocardial infarct*[tiab] 1,712 
#44  Non fatal MI*[tiab] 409 
#45  Fatal myocardial infarct*[tiab] 2,145 
#46  "Fatal MI" [tiab] 466 
#47  "Fatal MIs" [tiab] 45 
#48  Coronary death*[tiab] 1,177 
#49 Heart Arrest "Heart Arrest"[Mesh] 41,270 
#50  "Heart Arrest"[tiab] 2,044 
#51  "Heart Arrests"[tiab] 9 
#52  "Cardiac arrest"[tiab] 27,775 
#53  "Cardiac arrests"[tiab] 1,887 
#54  "Asystole"[tiab] 3,313 
#55  "Asystoles"[tiab] 61 
#56  "Cardiopulmonary arrest"[tiab] 2,021 
#57  "Cardiopulmonary arrests"[tiab] 144 
#58  "Sudden cardiac death"[tiab] 12,794 
#59  "Sudden cardiac deaths"[tiab] 478 
#60  "Cardiac sudden death"[tiab] 160 
#61  "Acute Coronary Syndrome"[Mesh] 11,907 
#62  "Acute coronary syndrome"[tiab] 17,440 
#63  "Angina Pectoris"[Mesh] 41,903 
#64  "Angina pectoris"[tiab] 19,538 
#65  "Stenocardia"[tiab] 878 
#66  "Stenocardias"[tiab] 20 
#67 OR (36-66)  326,154 
#68 Mortality "Mortality"[Mesh] 333,126 
#69  Mortality[tiab] 623,401 
#70  Mortalities[tiab] 7,890 
#71  Case Fatality Rate*[tiab] 5,653 
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Table 2 continued, page 3/4 
#72 Death "Death"[Mesh] 135,176 
#73  Death[tiab] 600,845 
#74 OR (68-73)  1,377,098 
#75 Cardiovascular diseases "Cardiovascular Diseases"[Mesh] 2,147,171 
#76  "Cardiovascular Diseases"[tiab] 42,973 
#77  "Cardiovascular Disease"[tiab] 105,662 
#78  Cardiovascular[tiab] 373,239 
#79  "Coronary heart disease"[tiab] 45,624 
#80  "Coronary heart diseases"[tiab] 798 
#81  "Coronary artery disease"[tiab] 75,152 
#82  "Coronary artery diseases"[tiab] 966 
#83  "Ischaemic heart disease"[tiab] 8,186 
#84  "Ischaemic heart diseases"[tiab] 172 
#85  "Ischemic heart disease"[tiab] 23,280 
#86  "Ischemic heart diseases"[tiab] 920 
#87  "Myocardial infarct"[tiab] 19,387 
#88  "Myocardial infarcts"[tiab] 1,043 
#89  "Myocardial infarction"[tiab] 158,678 
#90  "Myocardial infarctions"[tiab] 4,956 
#91  Heart attack*[tiab] 4,870 
#92  "Acute coronary syndrome"[tiab] 17,440 
#93 OR (75-92)  2,362,336 
#94 74 AND 93  297,737 
#95 Cardiovascular mortality Coronary heart disease death*[tiab] 309 
#96  Coronary artery disease death*[tiab] 24 
#97  Ischaemic heart disease death*[tiab] 32 
#98  Ischemic heart disease death*[tiab] 51 
#99  Fatal myocardial infarct*[tiab] 2,145 
#100  "Fatal MI"[tiab] 466 
#101  "Fatal MIs"[tiab] 45 
#102  Coronary death*[tiab] 1,177 
#103 OR (95-102)  3,922 
#104 94 OR 103  323,690 
#105 35 OR 67 OR 104 OUTCOME 727,386 
#106 Case-Control-Study "Case-Control-Studies"[Mesh] 877,429 
#107  "Case Control Study" 73,105 
#108  "Case Control Studies" 247,030 
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#109  Case Comparison Stud* 183 
#110  Case Compeer Stud* 2 
#111  Case Referent Stud* 546 
#112  Case Base Stud* 17 
#113  Nested Case Control Stud* 5,744 
#114  Matched Case Control Stud* 3,192 
#115 Cohort Study "Cohort Studies"[Mesh] 1,680,207 
#116  "Cohort Study" 129,890 
#117  "Cohort Studies" 227,654 
#118  Concurrent Stud* 293 
#119  "Cohort Analysis" 5,833 
#120  "Cohort Analyses" 459 
#121  "Incidence Studies" 462 
#122  "Incidence Study" 944 
#123  "Follow up study" 33,754 
#124  "Follow up studies" 585,455 
#125  "Longitudinal Study" 46,975 
#126  "Longitudinal Studies" 122,177 
#127  "Prospective Study" 120,453 
#128  "Prospective Studies" 480,442 
#129  "Retrospective Study" 114,208 
#130  "Retrospective Studies" 663,324 
#131  "Observational Study" [Publication Type] 40,303 
#132  "Observational Study" 82,800 
#133  "Observational studies" 22,276 
#134  "Observational Studies as Topic"[Mesh] 2,419 
#135  "Observational studies as topic" 2,422 
#136  "Population based Study" 24,094 
#137  "Population based Studies" 6,444 
#138 OR (106-137) STUDY TYPE 2,115,297 
#139 18 AND 105 EXPOSURE + OUTCOME 12,456 
#140 139 AND 138 EXPOSURE + OUTCOME + STUDY TYPE 1,220 
Mesh, medical subject heading; MI, myocardial infarction; Tiab, title and abstract. 
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2.1.2 Literature screening and selection criteria 
The literature was screened in four steps. First, publication types other than observational studies 
were deleted by the keyword search in Endnote (e.g. reviews, editorials, commentaries). In step 
two to four, the title, abstract, and full-text of studies were screened for content relevant to this 
review topic. Two reviewers (myself and Dana Clarissa Muhlack) independently performed the 
full-text screening by using the following exclusion criteria: A) no observational study design, B) 
study not conducted in humans, C) serum potassium levels not measured, D) no association of 
serum potassium levels with one of the defined outcomes (arrhythmias, CVM or composite CV 
outcomes) assessed, and E) intervention influencing serum potassium levels or outcome. 
2.1.3 Data extraction and risk of bias assessment 
Two reviewers (myself and Dana Clarissa Muhlack) independently extracted data from the studies 
included in the systematic review. Consensus was reached through discussion or consultation of 
the third reviewer (PD Dr. Ben Schöttker). Risk of bias and quality of the included studies were 
assessed by using a modified version of the Newcastle-Ottawa-Scale (Wells et al., 2008). This 
practical tool for assessing the quality of non-randomised observational studies uses a scoring sys-
tem to evaluate the studies in three overall topics: the study group selection, the comparability of 
the groups, and the determination of either the exposure (for case-control studies) or the outcome 
of interest (for cohort studies). For the assessment of cohort and case-control studies, the tool 
comprised eight categories and the studies could be rated by a maximum of nine points. The quality 
of cross-sectional studies was assessed by using only five categories and a maximum of six rating 
points. The exclusion of three categories was necessary, because evaluations of length and ade-
quacy of follow-up as well as absence of outcome at baseline were not applicable to cross-sectional 
studies. 
2.1.4 Statistical analysis 
Studies were included in meta-analyses if 1) serum potassium [mmol/L] was investigated as a 
categorical variable with a cut-off for low serum potassium of ≤ 4.0 mmol/L or lower and a cut-off 
for high serum potassium of ≥ 4.5 mmol/L or higher, if 2) a reference category for serum potassium 
was used that did not include hypokalemic (< 3.5 mmol/L) or hyperkalemic (> 5.5 mmol/L) serum 
potassium levels, if 3) effect estimates (risk ratio, hazard ratio or odds ratio) and confidence inter-
vals were reported, could be calculated or were provided by the authors when contacted, and if 4) 
sufficient information about the study outcome was provided. If a study reported effect estimates 
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for several categories in the hypokalemic (< 3.5 mmol/L) or the hyperkalemic (> 5.5 mmol/L) 
range, these estimates were pooled by fixed-effect model meta-analyses. The fixed-effect model 
is based on the assumption that there is one true intervention effect, which is similarly estimated 
by every study included in the meta-analysis (McKenzie et al., 2016). As the estimates are derived 
from the same study, the fixed-effect model is most appropriate to use. The pooled result of one 
study was then used for the meta-analyses with other studies. 
Meta-analyses were conducted separately for study outcome and study population, namely older 
general population and populations with a history of hypertension, AMI, heart failure, CKD or 
dialysis. For meta-analyses between studies, I applied random-effects model meta-analyses with 
inverse variance weighting to allow for between-study heterogeneity. The method of inverse var-
iance weighting assigns a weight to each study that corresponds to the inverse of its variance. Thus, 
studies with a smaller variance (that is with a higher precision of the effect size due to a smaller 
standard error and consequently tighter confidence intervals around the effect size) receive a higher 
weight and therefore contribute more to the calculated average effect size of the meta-analysis. 
Cochran’s Q test was used to test for statistically significant heterogeneity between studies (White-
head and Whitehead, 1991). Additionally, the I2 statistic was calculated as I2 = 100 % (Q – df)/ Q, 
where Q represents Cochran’s heterogeneity statistic and df the degrees of freedom. By definition, 
values of I2 range from 0 % (indicating no observed heterogeneity) to 100 % (Higgins et al., 2003). 
Publication bias was assessed with Kendall’s tau and Egger’s test of the intercept (one-tailed). 
The software Comprehensive Meta-Analysis 2.0 (Biostat, Englewood, NJ, USA) was used for all 
analyses. 
2.2 Results 
2.2.1 Screening results and study selection 
A flow diagram of the literature screening and study selection process is given in Figure 4. After 
removing duplicates, the literature search revealed 1,424 articles. Further exclusions during the 
screenings of study type, title, and abstract resulted in 103 remaining articles for the full-text se-
lection. 
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Figure 4.  Flow diagram showing the systematic literature screening process.  
 
  CVM, cardiovascular mortality; K+, potassium. 
The references of studies excluded during the full-text screening are summarized in Table A1 of 
the Appendix. In total, 54 studies did not meet the inclusion criteria, because 4 studies measured 
potassium elsewhere than in serum (e.g. in urine), another 40 studies assessed the association of 
serum potassium levels and other outcomes than those relevant for this systematic review, and 
10 studies had interventions influencing serum potassium levels, such as surgery procedures. 
Overall, this review included 54 studies (Ahmed et al., 2007; Ahmed et al., 2010; Aldahl et al., 
2017; Brezins et al., 1996; Bulpitt et al., 1986; Chen et al., 2016; Choi et al., 2014; Chow et al., 
2009; Cleland et al., 1987; Cohen et al., 2001; D'Elia et al., 1988; Dargie et al., 1987; Davidson 
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and Surawicz, 1967; Detrano et al., 1984; Dyckner et al., 1982; Fang et al., 2000; Friedensohn et 
al., 1991; Genovesi et al., 2009; Goyal et al., 2012; Gundling et al., 2012; Herlitz et al., 1988; 
Higham et al., 1993; Huang et al., 2015; Hughes-Austin et al., 2017; Janko et al., 1992; Kafka et 
al., 1987; Karaboyas et al., 2017; Keskin et al., 2016; Korgaonkar et al., 2010; Kovesdy et al., 
2007; Krijthe et al., 2013; Lai et al., 2015; Li et al., 2015; López Castro et al., 2010; Luo et al., 
2016; Madias et al., 2000; Nielsen et al., 1986; Nolan et al., 1998; Nordrehaug et al., 1985; Park 
et al., 2017; Reuben and Thomas, 1982; Ribeiro et al., 2015; Shlomai et al., 2016; Simpson et al., 
2002; Su et al., 2012; Thomas, 1983; Torlen et al., 2012; Tsuji et al., 1994; Uluganyan et al., 2016; 
Wagner et al., 2017; Walsh et al., 2002; Wannamethee et al., 1997; Xu et al., 2014; Yusuf et al., 
2016). Within these 54 studies, five were identified by cross-referencing (Aldahl et al., 2017; 
Huang et al., 2015; Hughes-Austin et al., 2017; Torlen et al., 2012; Xu et al., 2014). 
Finally, 24 studies were suitable for meta-analyses (Ahmed et al., 2007; Ahmed et al., 2010; Al-
dahl et al., 2017; Chen et al., 2016; Chow et al., 2009; Cohen et al., 2001; Fang et al., 2000; Goyal 
et al., 2012; Huang et al., 2015; Hughes-Austin et al., 2017; Karaboyas et al., 2017; Keskin et al., 
2016; Korgaonkar et al., 2010; Kovesdy et al., 2007; Krijthe et al., 2013; Lai et al., 2015; Luo et 
al., 2016; Ribeiro et al., 2015; Torlen et al., 2012; Uluganyan et al., 2016; Wagner et al., 2017; 
Walsh et al., 2002; Wannamethee et al., 1997; Xu et al., 2014). 
2.2.2 Study design of included studies 
Within the 54 included studies, I detected 28, 24 and 4 studies reporting on the association of 
abnormal serum potassium levels with arrhythmias (Brezins et al., 1996; Choi et al., 2014; Cleland 
et al., 1987; D'Elia et al., 1988; Dargie et al., 1987; Davidson and Surawicz, 1967; Detrano et al., 
1984; Dyckner et al., 1982; Friedensohn et al., 1991; Goyal et al., 2012; Gundling et al., 2012; 
Herlitz et al., 1988; Higham et al., 1993; Janko et al., 1992; Kafka et al., 1987; Keskin et al., 2016; 
Krijthe et al., 2013; Madias et al., 2000; Nielsen et al., 1986; Nordrehaug et al., 1985; Park et al., 
2017; Reuben and Thomas, 1982; Shlomai et al., 2016; Simpson et al., 2002; Su et al., 2012; 
Thomas, 1983; Tsuji et al., 1994; Uluganyan et al., 2016), with cardiovascular mortality (CVM) 
(Ahmed et al., 2007; Ahmed et al., 2010; Aldahl et al., 2017; Bulpitt et al., 1986; Chen et al., 
2016; Chow et al., 2009; Fang et al., 2000; Genovesi et al., 2009; Huang et al., 2015; Hughes-
Austin et al., 2017; Korgaonkar et al., 2010; Kovesdy et al., 2007; Lai et al., 2015; Li et al., 2015; 
López Castro et al., 2010; Madias et al., 2000; Nolan et al., 1998; Ribeiro et al., 2015; Torlen et 
al., 2012; Wagner et al., 2017; Walsh et al., 2002; Wannamethee et al., 1997; Xu et al., 2014; 
Yusuf et al., 2016), and with composite CV outcomes (Cohen et al., 2001; Karaboyas et al., 2017; 
Korgaonkar et al., 2010; Luo et al., 2016), respectively. Two studies (Korgaonkar et al., 2010; 
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Madias et al., 2000) appear twice. Details of included studies sorted by study outcome (arrhyth-
mias, CVM, and composite CV outcomes) and study population are shown in Table 3, Table 4, 
and Table 5, respectively. 
Among the studies assessing arrhythmias (Table 3), the study of Krijthe and colleagues was the 
only study with a prospective cohort design (Krijthe et al., 2013). All other studies reporting on 
arrhythmias were classified as cross-sectional studies because measurement of potassium was at 
the same hospital stay as the arrhythmia diagnosis, in most cases less than two days apart. Studies 
about “arrhythmias” were mainly performed in patients with AMI (Brezins et al., 1996; Choi et 
al., 2014; Dyckner et al., 1982; Friedensohn et al., 1991; Goyal et al., 2012; Herlitz et al., 1988; 
Higham et al., 1993; Kafka et al., 1987; Keskin et al., 2016; Madias et al., 2000; Nielsen et al., 
1986; Nordrehaug et al., 1985; Reuben and Thomas, 1982; Shlomai et al., 2016; Su et al., 2012; 
Thomas, 1983; Uluganyan et al., 2016). The study sizes ranged from 50 participants (Detrano et 
al., 1984) to 38,689 participants (Goyal et al., 2012) with an arrhythmia prevalence of 1.5 % (Park 
et al., 2017; Shlomai et al., 2016) to 61.0 % (Cleland et al., 1987; Dargie et al., 1987). With ex-
ception of one study (Krijthe et al., 2013) that investigated supraventricular arrhythmias (atrial 
fibrillation and atrial flutter), and one other study (Madias et al., 2000) that investigated both su-
praventricular arrhythmias (atrial fibrillation) and ventricular arrhythmias (ventricular fibrillation), 
all other studies investigated ventricular arrhythmias. 
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Table 3.  Details of included studies reporting on the association of serum potassium levels and arrhythmias. 
First author,  
(Year) 
Country 
(Baseline) 
Study type Study population  Outcome n 
(%) 
 Type of  
arrhythmiasa 
Population Age Female Size     
 [mean ± SD] n (%) n     
*Krijthe,  
(2013) 
Netherlands  
(1990-1993) 
Cohort Older general 69.2 ± 8.6 2,425 (59.7) 4,059  474 (11.7) 
 
AF, atrial flutter 
Simpson,  
(2002) 
USA  
(N.R) 
CS Older general 45.0 to 65.0 8,308 (55.1) 15,070  940 (6.2) 
 
PVCs 
Tsuji,  
(1994) 
USA 
(1979-1983) 
CS Older general 44.0 ± 10.0 1,723 (51.8) 3,327  183 (5.5) 
 
VPCs 
Brezins,  
(1996) 
Israel  
(1990-1994) 
CS AMI 64.0 ± 12.0 482 (30.3) 1,590  57 (3.6) 
 
Primary VF 
Choi,  
(2014) 
Korea  
(2006-2009) 
CS AMI 64.0 ± 12.8 589 (30.6) 1,924  54 (2.8)b 
 
VT, VF 
Dyckner,  
(1982) 
Sweden  
(1968; 1976) 
CS AMI 66.0 250 (37.0) 676  261 (38.6) 
 
VT, VF 
Friedensohn,  
(1991) 
Israel  
(N.R.) 
CS AMI 62.1 ± 11.0 212 (21.0) 1,011  606 (59.9) 
 
VT, VF 
*Goyal,  
(2012) 
USA  
(2000-2008) 
CS AMI 68.1 ± 14.0 15,714 (40.6) 38,689  1,707 (4.4) 
 
VT, VF 
Herlitz,  
(1988)  
Sweden  
(1976-1981) 
CS AMI 61.0c 161 (23.7) 679d  25 (3.8) 
 
VF 
Higham,  
(1993) 
UK  
(1982-1983) 
CS AMI 63.0 ± 10.0 164 (32.6) 504  17 (3.4) 
 
VF 
Kafka,  
(1987)  
Canada  
(N.R.) 
CS AMI N.R. N.R. 211  110 (52.1) 
 
VT, VF 
*Keskin,  
(2016) 
Turkey  
(2010-2012) 
CS AMI 58.0 ± 11.6 714 (19.0) 3,760  230 (6.1) 
 
VA 
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First author,  
(Year) 
Country 
(Baseline) 
Study type Study population  Outcome n 
(%) 
 Type of  
arrhythmiasa 
Population Age Female Size     
 [mean ± SD] n (%) n     
Madias,  
(2000) 
USA  
(1986-1989) 
CS AMI 63.1 ± 13.0 153 (29.6) 517  
72 (13.9)  
AF, VF 
72 (13.9) 
Nielsen,  
(1986) 
Denmark  
(1982) 
CS AMI 63.2 47 (22.0) 214  69 (32.2) 
 
N.R. 
Nordrehaug,  
(1985) 
Norway  
(N.R.) 
CS AMI 66.1 ± 9.7 6 (10.0) 60  18 (30.0) 
 
VT, PVCs 
Reuben,  
(1982) 
UK  
(N.R.) 
CS AMI ≥ 65.0 128 (31.6) 405  13 (3.2) 
 
VT 
Shlomai,  
(2016)  
Israel  
(N.R.) 
CS AMI 64.0 ± 13.0 286 (22.4) 1,277  22 (1.7) 
 
Primary VF 
Su,  
(2012) 
China  
(2002-2007) 
CS AMI 60.0 107 (22.9) 468  44 (9.4) 
 Ventricular flutter,  
VT, VF 
Thomas,  
(1983) 
UK  
(1974-1980) 
CS AMI 60.1 ± 10.4 N.R. 809  17 (2.1) 
 
VF 
*Uluganyan,  
(2016) 
Turkey  
(2011-2012) 
CS AMI 59.0 ± 13.6 84 (13.8) 611  65 (10.6) 
 
VT, VF 
Davidson,  
(1967) 
USA  
(1962-1966) 
CS Hospitalized N.R. N.R. 1,986e  391 (19.6) 
 Supraventricular or  
ventricular ectopic beats 
and rhythms 
Detrano,  
(1984)  
USA  
(1982) 
CS Hospitalized 59.0 13 (26.0) 50  24 (48.0) 
 
VT, PVCs 
Janko,  
(1992) 
Austria  
(1989) 
CS Hospitalized N.R. N.R. 745  127 (17.1) 
 Ectopic ventricular  
activity 
Park,  
(2017) 
Korea  
(2013) 
CS Hospitalized 59.7 8,227 (46.3) 17,777  260 (1.5) 
 In-hospital arrhythmia 
(not specified) 
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First author,  
(Year) 
Country 
(Baseline) 
Study type Study population  Outcome n 
(%) 
 Type of  
arrhythmiasa 
Population Age Female Size     
 [mean ± SD] n (%) n     
Gundling,  
(2012) 
Germany  
(2004-2008) 
CS Cirrhosis 62.1 ± 12.8 114 (38.9) 293  48 (16.4) 
 
Ventricular flutter, VF 
Cleland,  
(1987) 
UK  
(N.R.) 
CS Heart failure 59.0 ± 9.0 24 (16.0) 152  93 (61.0) 
 
VT 
Dargie,  
(1987)  
UK  
(N.R.) 
CS Heart failure 59.0 18 (21.4) 84  51 (61.0) 
 
VT 
D’Elia,  
(1988) 
USA  
(1981-1984) 
CS Dialysis 50.1 ± 2.2 60 (49.2) 122  32 (26.7) 
 Ventricular ectopy,  
AV-block 
* Studies included in meta-analyses. 
a Comprehensive list of arrhythmia outcome definitions is given in Table 6. 
b Choi, (2014): Only the results of ventricular arrhythmias occurring before coronary angiography were considered. 
c Herlitz, (1988): It was reported that of 1,318 participants in total, n = 690 were aged ≤ 61 years and n = 628 were aged > 61 years. 
d Herlitz, (1988): Study size was derived from a randomised placebo-controlled trial including 1,318 participants in total. Of these, 679 participants were randomised 
to placebo and used for the arrhythmia assessment. e Davidson, (1967): Study size derived from 107 patients with hypokalemia and a group of 1,879 controls. 
 
AF, atrial fibrillation; AMI, acute myocardial infarction; AV, atrioventricular; CS, cross-sectional; N.R., not reported; PVC, premature ventricular contraction; SD, 
standard deviation; UK, United Kingdom; USA, United States of America; VA, ventricular arrhythmias; VF, ventricular fibrillation; VPC, ventricular premature 
complex; VT, ventricular tachycardia. 
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Among the studies assessing CVM (Table 4), the study of Chow and colleagues was the only one 
with a case-control design (Chow et al., 2009), while the others were cohort studies. Most of the 
studies investigated populations of dialysis patients (Chow et al., 2009; Genovesi et al., 2009; 
Huang et al., 2015; Kovesdy et al., 2007; Li et al., 2015; Ribeiro et al., 2015; Torlen et al., 2012; 
Xu et al., 2014; Yusuf et al., 2016), older general individuals (Chen et al., 2016; Fang et al., 2000; 
Hughes-Austin et al., 2017; Lai et al., 2015; Walsh et al., 2002; Wannamethee et al., 1997), and 
heart failure patients (Ahmed et al., 2007; Ahmed et al., 2010; Aldahl et al., 2017; López Castro 
et al., 2010; Nolan et al., 1998). Additionally, there was one study in hypertensive patients (Bulpitt 
et al., 1986), one study in AMI patients (Madias et al., 2000), and another two studies in CKD 
patients (Korgaonkar et al., 2010; Wagner et al., 2017). The largest study comprised 74,219 par-
ticipants (Kovesdy et al., 2007), while the smallest study had 312 participants (Huang et al., 2015; 
Li et al., 2015). They were followed up for at least 0.3 years (Aldahl et al., 2017) and up to a 
maximum of 23.5 years (Chen et al., 2016). During the follow-up, the CVM rate ranged from 
1.5 % (Walsh et al., 2002) to 28.7 % (Ahmed et al., 2010). 
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Table 4.  Details of included studies reporting on the association of serum potassium levels and CVM. 
First author,  
(Year) 
Country 
(Baseline) 
Study type  Study population  Outcome 
n (%) 
Mean FUP 
[years] 
Population Age Female Size    
 [mean ± SD] n (%) n    
*Chen,  
(2016) 
USA  
(1987-1989) 
Cohort  Older general 54.2 ± 5.8 8,560 (55.1) 15,539  534 (3.4) 23.5 
*Fang,  
(2000) 
USA  
(1974-1975) 
Cohort  Older general 46.6 ± 13.9 1,578 (55.6) 2,836  272 (9.6) 15.9 
*Hughes-Austin,  
(2017) 
USA 
(1989-1993) CHS 
(2000-2002) MESA 
Cohort  Older general 66.0 ± 10.0 5,598 (58.0) 9,651  1,087 (11.3) 10.5 
*Lai,  
(2015) 
Taiwan  
(1999-2000) 
Cohort  Older general 72.8 ± 5.9 688 (33.3) 2,065  219 (10.6) 8.0 
*Walsh,  
(2002) 
USA  
(1979-1983) 
Cohort  Older general 43.0 ± 10.0 1,636 (51.9) 3,151  46 (1.5) 16.0 
*Wannamethee,  
(1997) 
UK  
(1978-1980) 
Cohort  Older general 40 to 59 0 (0.0) 7,262  370 (5.1) 11.5a 
Bulpitt,  
(1986) 
UK  
(1962-1966) 
Cohort  Hypertension 50.1 ± 12.2 211 (52.2) 404  52 (12.9) 15.0 
Madias,  
(2000)  
USA  
(1986-1989) 
Cohort  AMI 63.1 ± 13.0 153 (29.6) 517  80 (15.5) N.R. 
*Ahmed A.,  
(2007) 
USA; Canada  
(1991-1993) 
Cohort  Heart failure 63.5 ± 11.2 729 (30.7) 2,374b  653 (27.5) 3.1 
*Ahmed M. I.,  
(2010) 
USA; Canada  
(1991-1993) 
Cohort  Heart failure 65.0 ± 10.0 464 (21.3) 2,177c  625 (28.7) 3.2 
*Aldahl,  
(2017) 
Denmark  
(1994-2012) 
Cohort  Heart failure 75.8  8,316 (42.5) 19,549  1,384 (7.1)d 0.3 
López Castro,  
(2010) 
Spain 
(1999-2002) 
Cohort  Heart failure 74.8 1,111 (46.6) 2,384  79 (3.3) 4.8 
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First author,  
(Year) 
Country 
(Baseline) 
Study type  Study population  Outcome 
n (%) 
Mean FUP 
[years] 
Population Age Female Size    
 [mean ± SD] n (%) n    
Nolan,  
(1998) 
UK  
(1993-1995) 
Cohort  Heart failure 62.0 ± 9.6 N.R. 433  48 (11.1) 1.3 
*Korgaonkar,  
(2010) 
USA  
(2000-2006) 
Cohort  CKD 60.5 ± 15.4 372 (45.4) 820  N.R. 2.6 
*Wagner,  
(2017)  
France  
(2000-2012) 
Cohort  CKD 58.8 ± 15.2 700 (33.7) 2078  83 (4.0) 5.0 
*Chow,  
(2009) 
China 
(2003-2006) 
Case-Control  Dialysis 
Cases:  
61.4 ± 9.5 
Cases: 
6 (25.0) 
Cases: 
24 
 
24 (33.3) 3.6 
Controls: 
 56.2 ± 12.3 
Controls: 
27 (56.3) 
Controls: 
48 
 
Genovesi,  
(2009) 
Italy  
(2003) 
Cohort  Dialysis 20.0 to > 70.0 199 (41.8) 476  67 (14.1) 3.0 
*Huang,  
(2015)  
Taiwan  
(2006) 
Cohort  Dialysis 60.0 ± 15.0 163 (52.2) 312  31 (9.9) 4.8 
*Kovesdy,  
(2007) 
USA  
(2001)  
Cohort  Dialysis 61.2 ± 15.2e 26,417 (46.4)e 74,219  8,679 (11.7) 3.0 
Li,  
(2015) 
China  
(2007-2012) 
Cohort  Dialysis 50.3 ± 15.7 163 (45.7) 357  49 (13.7) 3.1 
*Ribeiro,  
(2015) 
Brazil  
(2004) 
Cohort  Dialysis 59.3 ± 15.9 1,145 (63.0) 1,817  169 (9.3) 7.0f 
*Torlén,  
(2012) 
USA  
(2001-2006) 
Cohort  Dialysis 56.0 ± 16.0 4,920 (47.0) 10,468  N.R. 2.3 
*Xu,  
(2014) 
China  
(2006-2010) 
Cohort  Dialysis 48.5 ± 15.4 380 (42.9) 886  69 (7.8) 2.6 
Yusuf,  
(2016) 
USA  
(2010) 
Cohort  Dialysis 62.9 ± 14.6 16,231 (44.0) 36,888  1,604 (4.4) 0.8 
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* Studies included in meta-analyses. 
a Wannamethee, (1997): Length of follow-up was reported as overall study duration instead of mean.  
b Ahmed A., (2007): The study size indicated was obtained by propensity score matching within a cohort of 6,845 patients. Hypokalemic participants (n = 1,187) were matched to 
normokalemic participants (n = 1,187). 
c Ahmed M. I., (2010): The study size indicated was obtained by propensity score matching within a cohort of 7,788 patients. Hyperkalemic participants (n = 548) were matched 
to normokalemic participants (n = 1,829). 
d Aldahl, (2017): Number indicates the total number of deaths. 
e Kovesdy, (2007): Indicated numbers were only reported for a subset of patients (n = 55,984). 
f Ribeiro, (2015): Length of follow-up was reported as overall study duration instead of mean. 
 
AMI, acute myocardial infarction; CHS, Cardiovascular Health Study; CKD, chronic kidney disease; CVM, cardiovascular mortality; FUP, follow-up; MESA, Multi-Ethnic Study 
of Atherosclerosis; N.R., not reported; SD, standard deviation; UK, United Kingdom; USA, United States of America. 
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The four studies with composite CV outcomes (Table 5) were prospective cohort studies in pa-
tients with hypertension (Cohen et al., 2001), CKD (Korgaonkar et al., 2010; Luo et al., 2016), 
and dialysis (Karaboyas et al., 2017) and had study sizes of 7,653 participants (Cohen et al., 2001), 
820 participants (Korgaonkar et al., 2010), 55,266 participants (Luo et al., 2016), and 45,511 par-
ticipants (Karaboyas et al., 2017), respectively. 
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Table 5.  Details of included studies reporting on the association of serum potassium levels and composite CV outcomes. 
First author,  
(Year) 
Country 
(Baseline) 
Study type  Study population  Outcome 
n (%) 
Mean FUP 
[years] 
Population Age Female Size    
 [mean ± SD] n (%) n    
*Cohen,  
(2001)a 
USA  
(1973-1996) 
Cohort  Hypertension 53.1 ± 9.5 2,960 (38.7) 7,653  470 (6.1) 6.7 
*Korgaonkar,  
(2010)b 
USA  
(2000-2006) 
Cohort  CKD 60.5 ± 15.4 372 (45.4) 820  190 (23.2) 2.6 
*Luo,  
(2016)c 
USA  
(2009-2013) 
Cohort  CKD 74.5 ± 11.3 32,353 (58.5) 55,266  N.R. 2.76 
*Karaboyas,  
(2017)d 
USA  
(1996-2001) 
Cohort  Dialysis 62.5 ± 15.2 23,221 (42.1) 45,511  3,300 (7.3) 1.4 
* Studies included in meta-analyses. 
a Cohen (2001): Definition of composite CV outcome: Admissions to hospital because of myocardial infarction, angioplasty or coronary bypass surgery, cerebro-
vascular disease, unstable angina, congestive heart failure, and deaths from all causes of cardiovascular disease. 
b Korgaonkar (2010): Definition of composite CV outcome: Death or any cardiovascular event defined as pre-specified coronary disease-, cerebrovascular disease- 
or peripheral vascular disease-related events that required hospitalization or revascularization procedures in any of the named three major arterial beds. 
c Luo (2016): Definition of composite CV outcome: Arrhythmia, myocardial infarction, stroke, and heart failure exacerbation. 
d Karaboyas (2017): Definition of composite CV outcome: Death due to either hyperkalemia, hypokalemia, cardiac arrhythmia or cardiac arrest (cause unknown); 
inpatient hospitalization due to atrial fibrillation or other arrhythmia; or a procedure for cardioversion or automatic implantable cardioverter-defibrillator or pace-
maker placement. 
 
CKD, chronic kidney disease; CV, cardiovascular; FUP, follow-up; N.R., not reported; SD, standard deviation; USA, United States of America. 
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A comprehensive list of outcome definitions of the included studies is provided in Table 6. The 
definitions in the second column of the table are original texts from the corresponding publications 
(see first column for the first author and publication year). 
Outcome definitions for ventricular arrhythmias mainly included ventricular tachycardia (VT), 
ventricular fibrillation (VF), and premature ventricular contractions (PVC) or ventricular prema-
ture complexes (VPC). CVM was mostly defined as deaths due to CVD or as sudden cardiac death 
(SCD). The definition of the composite CV outcome in all three studies included major CVD 
events as well as cardiovascular death. 
Table 6.  Detailed outcome definitions of studies included in this systematic review. 
Definitions of arrhythmias 
Krijthe, (2013) AF and atrial flutter diagnosed by electrocardiography (ECG) processing with 
the Modular ECG Analysis System (MEANS) and manual verification by two 
blinded specialists. 
Simpson, (2002) A single PVC was one PVC on the 2-minute ECG without a short coupling 
interval between the PVC and the preceding beat. A short coupling interval 
was arbitrarily defined as the upper 5 % of the distribution for the entire pop-
ulation of coupling intervals. Frequent PVCs are defined as 2 or more PVCs 
without consecutive PVCs or short-coupled PVCs. Complex PVCs are con-
secutive PVCs, multiple morphologic features of at least 2 PVCs, or the pres-
ence of a short coupled PVC on the 2-minute ECG. 
Tsuji, (1994) Definition included VPCs, multiform VPCs, and repetitive (≥ 2) VPCs. The 
primary outcome was complex or frequent VPCs, defined as > 30 VPCs/hour, 
multiform VPCs, or repetitive VPCs. 
Brezins, (1996) Primary VF. 
Choi, (2014) VT or VF. VT was further categorized into sustained and non-sustained VT, 
depending on the occurrence or not of tachycardia lasting more than 30 s and 
leading to haemodynamic collapse. Left ventricular ejection fraction was eval-
uated by echocardiogram that performed in 98 % patients at 1.08 ± 2.10 days 
after admission. 
Dyckner, (1982) VF, VT, defined as a rhythm with 3 or more consecutive ventricular ectopic 
beats, and asystole. 
Friedensohn, (1991) Non-sustained VT (3-15 consecutive ventricular beats at a rate greater than 
110 beats per minute), or sustained VT (more than 15 consecutive ventricular 
beats at a rate greater than 110 beats per minute), or VF (rapid irregular cardiac 
rhythm), or other VA requiring antiarrhythmic treatment (multiple ventricular 
premature beats, bigeminy or R-on-T) or high degree conduction disturbances 
(second degree block, Mobitz type II and third degree AV-block). 
Goyal, (2012) In-hospital VF or ventricular flutter (International Classification of Diseases 
(ICD)-9-Clinical Modification (CM) codes 427.4, 427.41 or 427.42) or car-
diac arrest (ICD-9-CM code 427.5). 
Herlitz, (1988) VF. 
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Table 6 continued, page 2/4 
Higham, (1993) VF defined as irregular, rapid, non-coherent ECG activity associated with hae-
modynamic collapse. 
Kafka, (1987) Major VA defined as consisting of VF, VT (more than three premature ven-
tricular beats in sequence), and complex premature ventricular beats (consist-
ing of frequent premature beats (more than six per minute)). 
Keskin, (2016) VA. 
Madias, (2000) AF and VF. 
Nielsen, (1986) Definition of arrhythmias followed E. Sandøe and B. Sigurd (1980). 
Nordrehaug, (1985)  Definition included VT, defined as three or more consecutive ventricular com-
plexes at a rate of greater than 120 beats/min and PVCs, sub-classed as fre-
quent (> 5 isolated uni-focal beats/min), bigeminy (alternate sinus and ven-
tricular beats), multifocal (multifocal beats in the same hour of recording), 
couplets (two consecutive ventricular beats, R-on-T according to R -R' R- T 
< 0.85), and overall frequency (total number of PVCs in the recording divided 
by the number of analysable hours and expressed as the number per hour). 
Reuben, (1982) VT defined as 10 or more consecutive ventricular ectopic beats occurring at a 
rate of 120 per minute or more. Multiple ventricular ectopic beats were re-
garded as being significant if they occurred at a rate greater than 5 per minute. 
Shlomai, (2016) Primary VF. 
Su, (2012)  Malignant VA including VF, ventricular flutter or VT. 
Thomas, (1983) VF. 
Uluganyan, (2016)  VT and VF. 
Davidson, (1967) Supraventricular or ventricular, or both, ectopic beats and rhythms. 
Detrano, (1984) Runs of VT, number of ventricular couplets, and PVCs. 
Janko, (1992) Ectopic ventricular activity. 
Park, (2017) In-hospital arrhythmias. 
Gundling, (2012) VF or ventricular flutter (or both in combination), AV-block, AV node  
re-entry-tachycardia or supraventricular and ventricular extrasystoles  
(> Lown IIIa). 
Cleland, (1987) VT defined as > 3 consecutive ventricular extrasystoles at > 120 beats/minute. 
Dargie, (1987)  Ventricular extrasystoles, couplets or salvoes of ventricular extrasystoles, or 
VT. 
D’Elia, (1988) Abnormal ambulatory ECG defined by second-degree or greater AV-block or 
by Lown grade 3 or greater ventricular ectopy. 
Definitions of cardiovascular mortality (CVM) 
Chen, (2016) SCD, defined as definite or possible arrhythmic death adjudicated by a panel 
of physicians who reviewed all fatal CHD events. 
Fang, (2000) Death due to CVD (codes 390-459). 
Hughes-Austin, (2017) Death from atherosclerotic CVD, stroke, atherosclerotic disease other than 
CHD or stroke (e.g. aortic aneurysm), or other CVD death (e.g. valvular heart 
disease). 
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Table 6 continued, page 3/4 
Lai, (2015)  Death caused by diabetes (ICD-9:250), hypertension (ICD-9: 401-405), is-
chemic heart disease (ICD-9: 410-414), heart failure (ICD-9: 428), and stroke 
(ICD-9: 430-438). 
Walsh, (2002) Death from CVD events including angina pectoris, coronary insufficiency, 
myocardial infarction, stroke, intermittent claudication, and death due to CHD 
or stroke. 
Wannamethee, (1997) Death from CVD received from the National Health Service registries. 
Bulpitt, (1986) Death from ischaemic heart disease. 
Madias, (2000) Death from pump failure, cardiac standstill, or VT and VF. 
Ahmed A., (2007) CVM does not include: progressive heart failure, even if the final event was 
an arrhythmia, deaths presumed to result from arrhythmia without evidence of 
progressive heart failure and deaths due to atherosclerotic coronary disease, 
bradyarrhythmias, low-output states, and cardiac surgery, and deaths due to 
stroke, embolism, peripheral vascular disease, vascular surgery, and carotid 
endarterectomy. 
Ahmed M.I., (2010) See Ahmed A., (2007). 
Aldahl, (2017) Cardiac death. 
López Castro, (2010) Not reported. 
Nolan, (1998)  Death classified as SCD if it occurred within 1 hour of a change in symptoms 
or if it occurred during sleep or while unobserved, if circumstantial evidence 
pointed to death from cardiovascular causes in the absence of clinical or post-
mortem evidence of AMI or increasing heart failure, death due to progressive 
heart failure if death occurred after a documented period of symptomatic or 
haemodynamic deterioration, and other cardiovascular death if it did not occur 
suddenly and was not associated with progressive heart failure. 
Korgaonkar, (2010) Death due to CVD events defined as pre-specified coronary disease-, cerebro-
vascular disease- or peripheral vascular disease-related events that required 
hospitalization or revascularization procedures in any of the named three ma-
jor arterial beds. 
Wagner, (2017)  Cardiovascular causes of death including ischemic heart disease, cerebrovas-
cular disease, heart failure, dysrhythmia, peripheral arterial disease, SCD, and 
valvular disease. 
Chow, (2009)  SCD defined as unexpected non-traumatic death occurring within 1 hour of 
the onset of symptoms and without any previous condition that would seem 
fatal. Also death during sleep and un-witnessed death occurring at home. 
Genovesi, (2009) Death due to causes including documented heart diseases. SCD was defined 
as unexpected natural death occurring within 1 h after the onset of symptoms. 
Huang, (2015) Death classified as SCD. 
Kovesdy, (2007) Not reported. 
Li, (2015) Death from acute heart failure, myocardial infarction, fatal arrhythmia, stroke, 
peripheral artery disease or SCD. 
Ribeiro, (2015) Death attributed to CVD. 
Torlén, (2012)  Not reported. 
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Xu, (2014) Death from acute heart failure, myocardial infarction, fatal arrhythmia, stroke, 
peripheral artery disease or SCD. 
Yusuf, (2016) Cardiovascular events as causes of death. 
Definitions of the composite cardiovascular (CV) outcome 
Cohen, (2001)  Hospital admissions due to myocardial infarction, angioplasty or coronary by-
pass surgery, cerebrovascular disease, unstable angina, congestive heart fail-
ure and death from all causes of CVD. 
Korgaonkar, (2010) Death or any cardiovascular event defined as pre-specified coronary disease-, 
cerebrovascular disease- or peripheral vascular disease-related events requir-
ing hospitalization or revascularization procedures. 
Luo, (2016) Arrhythmia, myocardial infarction, stroke, and heart failure exacerbation. 
Karaboyas, (2017) Death due to hyperkalemia, hypokalemia, cardiac arrhythmia or cardiac arrest; 
inpatient hospitalization due to AF or other arrhythmia; procedure for cardio-
version or automatic implantable cardioverter-defibrillator or pacemaker 
placement. 
AMI, acute myocardial infarction; AF, atrial fibrillation; AV, atrioventricular; CHD, coronary heart disease; 
CM, clinical modification; CV, cardiovascular; CVD, cardiovascular disease; CVM, cardiovascular mortal-
ity; ECG, electrocardiography; ICD, international classification of diseases; MEANS, Modular Electrocar-
diography Analysis System; PVC, premature ventricular contraction; SCD, sudden cardiac death; VA, ven-
tricular arrhythmias; VF, ventricular fibrillation; VPC, ventricular premature complex, VT, ventricular tach-
ycardia. 
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2.2.3 Risk of bias and quality assessment of included studies 
Results of the risk of bias and quality assessment of the included studies are shown in Table 7, 
Table 8, and Table 9. 
For the evaluation of cross-sectional studies I used a modified version of the Newcastle-Ottawa-
Scale restricted to five categories and a maximum of six accessible points (Table 7). The 27 cross-
sectional studies on “arrhythmias” were on average rated with 3.3 points (range: 1 to 5 points). 
Cohort studies (Table 8) and the case-control study (Table 9) were evaluated in eight categories 
and could be awarded a maximum of nine points. While the cohort study on supraventricular ar-
rhythmias was awarded 9.0 points (Krijthe et al., 2013), the average number of points per study 
was 6.9 (range: 5 to 9 points) and 6.8 (range: 5 to 8 points) for studies assessing CVM and studies 
assessing composite CV outcomes, respectively. 
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Table 7.  Risk of bias assessment of included cross-sectional studies according to a modified Newcastle-Ottawa-Scale. 
 
First author, 
(Year) 
Representativeness 
of the exposed  
cohorta 
Selection of the  
non-exposed 
cohort 
Ascertainment  
of exposureb 
Comparability of cohorts 
on the basis of the design  
or analysisc 
Assessment  
of outcomed 
Total scoree 
S
V
A
 
Madias, 
(2000) 
1 1 1 0 1 4 
V
A
 
Simpson, 
(2002) 
1 1 1 0 1 4 
Tsuji, 
(1994)  
1 1 0 1 1 4 
Brezins, 
(1996) 
1 1 0 0 1 3 
Choi, 
(2014)  
1 1 0 0 1 3 
Dyckner, 
(1982)  
1 1 0 0 0 2 
Friedensohn, 
(1991) 
1 1 1 0 1 4 
*Goyal, 
(2012)  
1 1 0 1 1 4 
Herlitz, 
(1988) 
1 1 1 0 0 3 
Higham, 
(1993) 
1 1 1 0 1 4 
Kafka, 
(1987) 
1 1 1 0 1 4 
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First author, 
(Year) 
Representativeness 
of the exposed  
cohorta 
Selection of the  
non-exposed 
cohort 
Ascertainment  
of exposureb 
Comparability of cohorts 
on the basis of the design  
or analysisc 
Assessment  
of outcomed 
Total scoree 
V
A
 
*Keskin, 
(2016)  
1 1 1 1 1 5 
Madias, 
(2000)  
1 1 1 0 1 4 
Nielsen,  
(1986) 
1 1 1 0 0 3 
Nordrehaug,  
(1985) 
1 1 1 0 1 4 
Reuben,  
(1982) 
1 0 0 0 1 2 
Shlomai,  
(2016) 
1 1 0 0 0 2 
Su,  
(2012) 
1 1 0 0 1 3 
Thomas,  
(1983) 
1 1 1 0 0 3 
*Uluganyan,  
(2016) 
1 1 1 2 0 5 
Davidson,  
(1967) 
0 0 0 0 1 1 
Detrano,  
(1984) 
1 1 1 0 0 3 
Janko,  
(1992) 
1 1 1 0 1 4 
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First author, 
(Year) 
Representativeness 
of the exposed  
cohorta 
Selection of the  
non-exposed 
cohort 
Ascertainment  
of exposureb 
Comparability of cohorts 
on the basis of the design  
or analysisc 
Assessment  
of outcomed 
Total scoree 
V
A
 
Gundling,  
(2012) 
1 1 0 0 1 3 
Cleland,  
(1987) 
1 1 0 0 1 3 
Dargie,  
(1987) 
1 1 0 0 1 3 
D’Elia,  
(1988) 
1 1 0 0 0 2 
N
.R
. 
Park,  
(2017) 
1 1 1 1 0 4 
* Studies included in meta-analyses. 
a If the analysed study population was representative, a point was assigned. No point was assigned to studies conducted in claims data of specific health insurance companies. 
b One point was assigned if serum potassium measurements were collected at baseline or derived from medical records and descriptions about the methods applied for the meas-
urements were provided. 
c If the study was adjusted for both age and sex, one point was assigned. Further, if the analyses were adjusted for at least five out of six important potential confounders (namely 
body mass index (BMI) or other weight measure, smoking, diabetes, history of CVD, hypertension, and kidney disease), an additional point was assigned. 
d If authors explained how the outcome was assessed, a point was assigned.  
e A study can be awarded a maximum of six points. 
 
BMI, body mass index; CVD, cardiovascular disease; N.R., not reported; SVA, supraventricular arrhythmias; VA, ventricular arrhythmias. 
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Table 8.  Risk of bias assessment of included cohort studies according to a modified Newcastle-Ottawa-Scale. 
 
First author, 
(Year) 
Representativeness 
of the exposed  
cohort a 
Selection of the 
non-exposed  
cohort 
Ascertainment 
of exposureb 
Demonstration that 
outcome of interest 
was not present at 
the start of studyc 
Comparability of 
cohorts on the  
basis of the design 
or analysisd 
Assessment 
of outcomee 
Was FUP long 
enough for  
outcomes to  
occurf 
Adequacy 
of FUP of 
cohortsg 
Total 
scoreh 
S
V
A
 
*Krijthe, 
(2013) 
1 1 1 1 2 1 1 1 9 
C
V
M
 
*Chen, 
(2016) 
1 1 1 1 1 1 1 1 8 
*Fang, 
(2000) 
1 1 1 1 1 1 1 0 7 
*Hughes-Austin,  
(2017) 
1 1 1 1 1 1 1 1 8 
*Lai, 
(2015) 
1 1 1 1 2 1 1 0 8 
*Walsh, 
(2002) 
1 1 1 1 2 1 1 0 8 
*Wannamethee,  
(1997) 
1 1 1 1 2 1 1 1 9 
Bulpitt, 
(1986)  
1 1 0 1 0 1 1 1 6 
Madias, 
(2000) 
1 1 1 1 0 1 0 0 5 
*Ahmed A., 
(2007)  
1 1 0 1 1 1 1 1 7 
*Ahmed M. I., 
(2010) 
1 1 0 1 2 1 1 1 8 
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First author, 
(Year) 
Representativeness 
of the exposed  
cohort a 
Selection of the 
non-exposed  
cohort 
Ascertainment 
of exposureb 
Demonstration that 
outcome of interest 
was not present at 
the start of studyc 
Comparability of 
cohorts on the  
basis of the design 
or analysisd 
Assessment 
of outcomee 
Was FUP long 
enough for  
outcomes to  
occurf 
Adequacy 
of FUP of 
cohortsg 
Total 
scoreh 
C
V
M
 
* Aldahl, 
(2017) 
1 1 1 1 1 1 0 1 7 
López Castro, 
(2010) 
1 1 0 1 0 1 1 0 5 
Nolan, 
(1998) 
1 1 0 1 0 1 1 0 5 
*Korgaonkar, 
(2010) 
1 1 0 1 1 1 1 0 6 
*Wagner, 
(2017) 
1 1 1 1 1 1 1 1 8 
Genovesi, 
(2009)  
1 1 0 1 0 1 1 0 5 
*Huang, 
(2015) 
1 1 1 1 1 1 1 0 7 
*Kovesdy, 
(2007) 
1 1 1 1 1 1 1 0 7 
Li, 
(2015) 
1 1 0 1 1 1 1 1 7 
*Ribeiro, 
(2015) 
1 1 0 1 1 0 1 0 5 
*Torlén,  
(2012)  
1 1 1 1 2 0 1 1 8 
*Xu,  
(2014) 
1 1 1 1 1 1 1 0 7 
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First author, 
(Year) 
Representativeness 
of the exposed  
cohort a 
Selection of the 
non-exposed  
cohort 
Ascertainment 
of exposureb 
Demonstration that 
outcome of interest 
was not present at 
the start of studyc 
Comparability of 
cohorts on the  
basis of the design 
or analysisd 
Assessment 
of outcomee 
Was FUP long 
enough for  
outcomes to  
occurf 
Adequacy 
of FUP of 
cohortsg 
Total 
scoreh 
C
V
M
 
Yusuf,  
(2016) 
0 1 1 1 1 1 0 1 6 
C
o
m
p
o
si
te
 C
V
 o
u
tc
o
m
e
 
*Cohen, 
(2001)  
1 1 1 1 2 1 1 0 8 
*Korgaonkar, 
(2010) 
1 1 0 1 1 1 1 0 6 
*Luo, 
(2016) 
0 1 0 1 1 1 1 0 5 
*Karaboyas,  
(2017) 
1 1 1 1 2 1 1 0 8 
* Studies included in meta-analyses. 
a If the analysed study population was representative, a point was assigned. No point was assigned to studies conducted in claims data of specific health insurance companies. 
b One point was assigned, if serum potassium measurements were collected at baseline or derived from medical records and descriptions about the methods applied for the meas-
urements were provided. 
c Regarding CVM, it is obvious, that this outcome is not present at the start of study. Therefore, all the studies assessing “CVM” were awarded one point. 
d If the study was adjusted for both age and sex, one point was assigned. Further, if the analyses were adjusted for at least five out of six important potential confounders (namely 
BMI or other weight measure, smoking, diabetes, history of CVD, hypertension, and kidney disease) an additional point was assigned.  
e If authors explained how the outcome was assessed, a point was assigned. 
f One point was assigned if the length of follow-up was at least 1 year. 
g If FUP rate was ≥ 90 % or information was ascertained through registration or other administrative offices, a point was assigned. 
h A study can be awarded a maximum of nine points. 
 
BMI, body mass index; CV, cardiovascular; CVD, cardiovascular disease; CVM, cardiovascular mortality; FUP, follow-up; SVA, supraventricular arrhythmias. 
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Table 9.  Risk of bias assessment of the included case-control study according to a modified Newcastle-Ottawa-Scale. 
 
First author, 
(Year) 
Is the case  
definition  
adequate?a 
Representativeness 
of the cases 
Selection 
of controls 
Definition 
of controls 
Comparability of cases and 
controls on the basis of the 
design or analysisb 
Ascertainment 
of exposurec 
Same method of 
ascertainment for 
cases and controls 
Non-Response 
rate 
Total 
scored 
C
V
M
 
*Chow, 
(2009) 
1 1 1 1 1 0 1 0 6 
* Studies included in meta-analyses. 
a One point was assigned when there was some independent validation (e.g. > 1 person/record/time/process to extract information or reference to primary record 
source such as medical/hospital records). 
b If the study was adjusted for both age and sex, one point was assigned. Further, if the analyses were adjusted for at least five out of six important potential 
confounders (namely BMI or other weight measure, smoking, diabetes, history of CVD, hypertension, and kidney disease) an additional point was assigned. 
c One point was assigned if serum potassium measurements were collected at baseline or derived from medical records and descriptions about the methods applied 
for the measurements were provided. 
d A study can be awarded a maximum of nine points. 
 
BMI, body mass index; CVD, cardiovascular disease; CVM, cardiovascular mortality. 
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2.2.4 Outcome details of included studies 
Results of 24 studies, which comprised 310,825 participants, were suitable for meta-analyses and 
are presented in Table 10. The studies are sorted by study outcome and study population. Risk 
ratios (RR) and confidence intervals (CI) are shown separately for the low and high serum potas-
sium category with preferably levels of < 3.5 and ≥ 5.5 mmol/L, but alternatively, cut-offs up to 
≤ 4.0 and ≥ 4.5 mmol/L, respectively, were also accepted if no stricter cut-offs were applied in the 
studies. If a study reported effect estimates for several categories in the hypokalemic 
(< 3.5 mmol/L) or the hyperkalemic (≥ 5.5 mmol/L) range, pooled estimates are shown. The risk 
categories were compared to a reference category that was not allowed to include abnormal serum 
potassium values < 3.5 or > 5.5 mmol/L. All studies were adjusted for age and sex. However, only 
2 studies (Cohen et al., 2001; Krijthe et al., 2013) out of 23 studies were adjusted for all eight 
covariates that I deemed important to consider in a model for the association of serum potassium 
levels and cardiovascular outcomes as they are themselves risk factors for CVD: age, sex, body 
mass index (BMI) or other weight measure, smoking, diabetes, history of CVD, hypertension, and 
kidney disease.  
2.2 Results 43 
 
Table 10.  Details of included studies for meta-analysis about the association of serum potassium levels and cardiovascular outcomes. 
 
First author, 
(Year) 
 
Population Outcome Reference  
serum K+ 
Low serum K+ High serum K+  Covariates 
  n (%) 
 
Definition 
[mmol/L] 
Definition 
[mmol/L] 
RR 
(95%-CI) 
Definition 
[mmol/L] 
RR 
(95%-CI) 
 
 
 
 
 
A
g
e
 
S
ex
 
B
M
I 
/ 
W
e
ig
h
t 
S
m
o
k
in
g
 
D
ia
b
et
es
 
H
is
to
ry
 o
f 
C
V
D
 
H
y
p
er
te
n
si
o
n
 
K
id
n
ey
 D
is
ea
se
 
O
th
er
sa
 
S
V
A
 
Krijthe, 
(2013)b 
Older  
general 
474 (11.7) 3.5 to 5.0 < 3.5 
1.62 
(1.02; 2.55) 
> 5.0 
0.96 
(0.24; 3.91) 
 X X X X X X X X X 
V
A
 
Goyal, 
(2012)c 
AMI 1,707 (4.4) 3.5 to < 4 < 3.5 
1.13 
(0.82; 1.55) 
≥ 5.5 
2.65 
(1.70; 4.13) 
 X X   X X X X X 
Keskin, 
(2016)d 
AMI 230 (6.1) 4.0 to < 4.5 < 3.5 
3.54 
(1.79; 7.02) 
≥ 5.5 
1.82 
(0.95; 4.18) 
 X X   X X X X X 
Uluganyan, 
(2016)e 
AMI 65 (10.6) 3.5 to < 4 < 3.5 
2.70 
(0.93; 7.80) 
≥ 5.0 
1.38 
(0.34; 5.50) 
 X X  X X X X X X 
C
V
M
 
Chen, 
(2016) 
Older  
general 
534 (3.4) 3.5 to < 5.5 < 3.5 
1.38  
(0.94; 2.03) 
≥ 5.5 
1.25  
(0.67; 2.32) 
 X X   X X X X X 
Fang, 
(2000)  
Older  
general 
272 (9.6) 3.8 to < 4.5 < 3.8 
0.96 
(0.61; 1.50) 
≥ 4.5 
1.54 
(1.03; 2.31)  
 X X  X  X X X X 
Hughes-Austin, 
(2017) 
Older  
general 
1,087 (11.3) 4.0 to < 4.5 < 3.5 
0.84  
(0.63; 1.12) 
≥ 5.0 
1.50  
(1.00; 2.26) 
 X X  X X  X X X 
Lai, 
(2015) 
Older  
general 
219 (10.6) 3.9 to < 4.5 < 3.5 
1.60 
(0.70; 3.40) 
≥ 4.5 
1.30 
(1.00; 1.80)  
 X X X  X X X X X 
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First author, 
(Year) 
 
Population Outcome Reference  
serum K+ 
Low serum K+ High serum K+  Covariates 
  n (%) 
 
Definition 
[mmol/L] 
Definition 
[mmol/L] 
RR 
(95%-CI) 
Definition 
[mmol/L] 
RR 
(95%-CI) 
 
 
 
 
 
A
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B
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n
 
K
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n
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 D
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O
th
er
sa
 
C
V
M
 
Walsh, 
(2002) 
Older  
general 
46 (1.5) > 4.0 to < 5.2 ≤ 4.0 
1.40 
(0.30; 5.90) 
≥ 5.2 
1.30 
(0.70; 2.60) 
 X X X X X  X X X 
Wannamethee, 
(1997) 
Older  
general 
370 (5.1) > 4.5 to < 4.9 < 4.0 
0.77 
(0.52; 1.15) 
≥ 5.2 
1.15 
(0.52; 2.80) 
 X X X X X X X  X 
Ahmed A., 
(2007)  
Heart failure 653 (27.5) 4.0 to 5.5 < 4.0 
1.27 
(1.06; 1.51) 
N.A. N.A.  X X X  X X X  X 
Ahmed, M.I., 
(2010) 
Heart failure 625 (28.7) 4.0 to < 5.0 N.A. N.A. ≥ 5.0 
1.08 
(0.89; 1.30) 
 X X X  X X X X X 
Aldahl, 
(2017) 
Heart failure N.R. 4.2 to < 4.5 < 3.5 
2.86 
(2.10; 3.89) 
> 5.5 
3.24 
(2.49; 4.23) 
 X X   X X  X X 
Korgaonkar, 
(2010) 
CKD N.R. > 4.0 to < 5.5 ≤ 4.0 
0. 97 
(0.62; 1.54) 
≥ 5.5 
1.49 
(0.91; 2.45) 
 X X   X X X X X 
Wagner, 
(2017)  
CKD 83 (4.0) 4.0 to 5.0 < 4 
1.01  
(0.52; 1.95) 
> 5 
1.47  
(0.67; 3.24) 
 X X X X X   X X 
Chow, 
(2009) 
Dialysis 24 (33.3) N.R. < 3.5 
3.36 
(0.59; 19.04) 
N.A. N.A.  X X  X X  X X X 
Huang,  
(2015) 
Dialysis 31 (9.9) 4.0 to 5.0 < 4.0 
2.82  
(0.52; 15.40) 
> 5.0 
4.11  
(1.62; 10.41) 
 X X X  X X  X X 
Kovesdy, 
(2007) 
Dialysis 8,679 (11.7) 4.6 to < 5.0 < 4.0 
1.11 
(1.01; 1.20) 
≥ 5.6 
1.25 
(1.17; 1.33) 
 X X X X X   X X 
Ribeiro, 
(2015) 
Dialysis 169 (9.3) 4.0 to 4.5 < 3.5 
1.49 
(1.01; 2.21) 
N.A. N.A.  X X X  X   X X 
2.2 Results 45 
 
 
First author, 
(Year) 
 
Population Outcome Reference  
serum K+ 
Low serum K+ High serum K+  Covariates 
  n (%) 
 
Definition 
[mmol/L] 
Definition 
[mmol/L] 
RR 
(95%-CI) 
Definition 
[mmol/L] 
RR 
(95%-CI) 
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C
V
M
 
Torlén, 
(2012)  
Dialysis N.R. 4.0 to < 4.5 < 3.5 
1.05  
(0.88; 1.25) 
≥ 5.5 
1.27  
(1.05; 1.52) 
 X X X X X X  X X 
Xu, 
(2014)  
Dialysis 69 (7.8) 4.0 to < 4.5 < 3.5 
1.10  
(0.63; 1,94) 
≥ 5,5 
2.29  
(0.80; 6.53) 
 X X X  X   X X 
C
o
m
p
o
si
te
 C
V
 o
u
tc
o
m
e
 Cohen, 
(2001)f 
Hypertensiong 470 (6.1) > 3.5 to < 5.1 ≤ 3.5 
2.57 
(1.51; 4.36) 
≥ 5.1 
1.65 
(1.02; 2.67) 
 X X X X X X X X X 
Korgaonkar, 
(2010)h 
CKD 190 (23.2) > 4.0 to < 5.5 ≤ 4.0 
1.13 
(0.76; 1.67) 
≥ 5.5 
1.69 
(1.09; 2.60) 
 X X   X X X X X 
Luo, 
(2016)i 
CKD N.R. 4.5 to < 5.0 < 3.5 
1.89 
(1.72; 2.09) 
≥ 5.5 
1.26 
(1.19; 1.34) 
 X X   X X  X X 
Karaboyas, 
(2017)j 
Dialysis 3,300 (7.3) 4.0 to 5.0 < 4.0 
0.94  
(0.83; 1.05) 
> 5.5 
1.12  
(1.03; 1.23) 
 X X X  X X X X X 
a A comprehensive list of covariates, which the studies were adjusted for, is given in Table 11. 
b Krijthe, (2013): Definition of arrhythmia: atrial fibrillation and atrial flutter diagnosed by ECG processing with the Modular ECG Analysis System and manual verification by 
two blinded specialists. 
c Goyal, (2012): Definition of arrhythmia: In-hospital ventricular fibrillation or ventricular flutter (documented by ICD-9-CM codes 427.4, 427.41 or 427.42) or cardiac arrest 
(ICD-9-CM code 427.5). 
d Keskin, (2016): Definition of arrhythmia: Ventricular arrhythmias were evaluated by a trained study coordinator. However, ventricular arrhythmias were not categorized by the 
respect of time and long-term ventricular arrhythmias were not included. 
e Uluganyan, (2016): Definition of arrhythmia: ventricular arrhythmias. 
f Cohen, (2001): Definition of composite CV outcome: Admissions to hospital because of myocardial infarction, angioplasty or coronary bypass surgery, cerebrovascular disease, 
unstable angina, congestive heart failure and deaths from all causes of CVD. 
g Cohen, (2001): hypertensive study population treated with mainly non-potassium-sparing diuretics (thiazides). 
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h Korgaonkar, (2010): Definition of composite CV outcome: Death or any cardiovascular event defined as pre-specified coronary disease-, cerebrovascular disease- or peripheral 
vascular disease-related events that required hospitalization or revascularization procedures in any of the named three major arterial beds. 
i Luo, (2016): Definition of composite CV outcome: Arrhythmia, myocardial infarction, stroke, and heart failure exacerbation. 
j Karaboyas, (2017): Definition of composite CV outcome: Death due to hyperkalemia, hypokalemia, cardiac arrhythmia or cardiac arrest; inpatient hospitalization due to atrial 
fibrillation or other arrhythmia; procedure for cardioversion or automatic implantable cardioverter-defibrillator or pacemaker placement. 
 
AMI, acute myocardial infarction; BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CM, clinical modification; CV, cardiovascular; CVD, cardiovascular 
disease; CVM, cardiovascular mortality; ECG, electrocardiography; ICD, international classification of diseases; K+, potassium; N.A., not applicable, N.R., not reported; RR, risk 
ratio; SVA, supraventricular arrhythmias; VA, ventricular arrhythmias. 
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An overview about the covariates, which the studies of the meta-analyses were adjusted for, is 
given in Table 11. In the first column, the studies are identified by the name of their first author 
and publication year, while the comprehensive lists of their covariates (original texts from the 
corresponding publications) are presented in the second column. Moreover, the structure of the 
table is as follows: the studies are first sorted by study outcome and then by study population. 
Table 11.  Comprehensive list of covariates of the studies included in meta-analyses. 
Outcome: Supraventricular arrhythmias / Population: Older general 
Krijthe, (2013) Age, sex, systolic blood pressure (SBP), diastolic blood pressure (DBP), 
ACE inhibitors, low-ceiling diuretics, high-ceiling diuretics, β-blocker 
and other blood pressure lowering drugs, BMI, total and high-density lip-
oprotein (HDL)-cholesterol, current smoking, past smoking, history of 
myocardial infarction, presence of heart failure, presence of diabetes, es-
timated glomerular filtration rate (eGFR), P-wave duration, and serum 
magnesium. 
Outcome: Ventricular arrhythmias / Population: AMI 
Goyal, (2012) Age, sex, race, comorbidities (diabetes, heart failure, hypertension, cere-
brovascular disease, peripheral vascular disease, chronic obstructive pul-
monary disease, dementia, dialysis), admission GFR, potassium, glucose, 
white blood cell count, haematocrit, peak troponin level, number of po-
tassium checks, presence of cardiogenic shock and acute respiratory fail-
ure on admission, cardiac catheterization, percutaneous coronary inter-
vention, coronary artery bypass graft surgery, acute kidney injury, length 
of hospital stay, medications (fibrinolytic therapy, aspirin, clopidogrel, 
ticlopidine, β-blockers, ACE inhibitors or sartans, calcium channel block-
ers, nitrates, diuretics, bronchodilators, statins, insulin, oral antihypergly-
cemic agents, and clustering by hospital site. 
Keskin, (2016)  Age, sex, first measurement during hospitalization of the following labor-
atory values (admission GFR calculated by Cockcroft Gault, C-reactive 
protein, potassium, glucose, white blood cell count, hematocrit), peak tro-
ponin level, presence of cardiogenic shock and acute respiratory failure 
on admission, procedures during hospitalization, acute kidney injury dur-
ing hospitalization, comorbidities (diabetes, heart failure, hypertension, 
cerebrovascular disease, peripheral vascular disease, chronic obstructive 
pulmonary disease, dialysis), medications during hospitalization. 
Uluganyan, (2016) Age, sex, eGFR, Killip class, left, ventricular ejection fraction, past his-
tory (hypertension, diabetes mellitus, coronary artery disease, hyperlipi-
daemia, and smoking status), diagnosis (anterior ST-elevation myocardial 
infarction (STEMI)), cardiac enzymes (peak creatinine kinase-myocar-
dial band (CK-MB) levels during hospitalization), and medication before 
hospitalization. 
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Table 11 continued, page 2/4 
Outcome: CVM / Population: Older general 
Chen, (2016) Age, sex, race, study centre, eGFR, diabetes, hypertension, history of 
CVD, use of ACE inhibitors, potassium-wasting diuretics (loop diuretics, 
thiazide and thiazide-like diuretics), potassium-sparing diuretics (aldos-
terone antagonists, triamterene and amiloride), β-blockers and non-steroi-
dal anti-inflammatory drugs (NSAIDs). 
Fang, (2000)  Age, sex, race, blood pressure, cholesterol, smoking status, diuretic use, 
renal function, renal disease, and heart disease. 
Hughes-Austin, (2017) Age, sex, race, eGFR, diabetes mellitus, SBP, current smoking, pack-
years smoking, ever having cancer, study cohort, ACE inhibitors/ ARBs, 
potassium-sparing diuretics, other diuretics, NSAIDs, potassium supple-
ments, β-blockers, β-agonists, and other antihypertensive medications. 
Lai, (2015) (Lai et al., 2015) Age, sex, BMI, serum low-density lipoprotein (LDL)-cholesterol, 
HDL-cholesterol, total cholesterol, triglycerides, glucose, uric acid, cre-
atinine, and sodium, SBP, DBP, hypertension, diabetes medication, self-
reported heart disease, kidney disease, and stroke. 
Walsh, (2002)  Age, sex, SBP, DBP, hypertension treatment, diabetes mellitus, cigarette 
smoking, alcohol consumption, serum creatinine level, BMI, total choles-
terol and HDL. 
Wannamethee, (1997) Age, social class, smoking, alcohol intake, BMI, physical activity, diabe-
tes mellitus, blood glucose, pre-existing ischemic heart disease, heart rate, 
forced expiratory volume in 1 second (FEV1), SBP. 
Outcome: CVM / Population: Heart failure 
Ahmed A., (2007)  Age, sex, non-white, BMI, duration of heart failure, primary cause of 
heart failure (ischaemic, hypertensive, idiopathic, others), prior myocar-
dial infarction, current angina, hypertension, diabetes, medications (pre-
trial digoxin use, trial use of digoxin, ACE inhibitors, hydralazine and 
nitrates, diuretics, potassium sparing diuretics, potassium supplements), 
symptoms and signs of heart failure, NYHA functional class I-IV, heart 
rate, SBP, DBP, chest radiograph findings, and serum creatinine. 
Ahmed M. I., (2010)  Age, sex, non-white, BMI, duration of heart failure, aetiology of heart 
failure (ischaemic, hypertensive), prior myocardial infarction, current an-
gina pectoris, hypertension, diabetes mellitus, CKD, medications (pre-
trial digoxin use, trial use of digoxin, ACE inhibitors, hydralazine and 
nitrates, diuretics, potassium sparing diuretics, potassium supplements), 
symptoms and signs of heart failure, NYHA functional class III-IV, heart 
rate, SBP, DBP, chest radiograph findings, serum creatinine, and left ven-
tricular ejection fraction. 
Aldahl, (2017)  Age, sex, AMI, chronic obstructive pulmonary disease, diabetes, atrial 
fibrillation, ventricular fibrillation, AV-block (2nd and 3rd degree), rele-
vant concomitant pharmacotherapy (β-blockers, mineralocorticoid recep-
tor antagonists, thiazides, digoxin and potassium supplements) and a high 
serum creatinine level. 
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Table 11 continued, page 3/4 
Outcome: CVM / Population: CKD 
Korgaonkar, (2010) Age, sex, race, diabetes status, history of CVD, hypertension, eGFR, and 
serum albumin. 
Wagner, (2017) Age, sex, centre, ethnicity, smoking status, BMI, diabetes, baseline GFR, 
albuminemia, urinary potassium, log albumin/creatinine ratio, medication 
that may decrease plasma potassium (non-potassium-sparing diuretics, 
bicarbonate treatment, potassium-binding resins), and medication that 
may increase plasma potassium (potassium-sparing diuretics, ACE inhib-
itors or ARBs, β-blockers) 
Outcome: CVM / Population: Dialysis 
Chow, (2008) Age, sex, smoking history, diabetes mellitus, DBP, corrected QT interval, 
Kt/V (total), residual GFR, aspirin, blood transfusion within 1 month and 
within 1 year, and units of red blood cells transfused within 1 year. 
Huang, (2015) Age, sex, dialysis vintage, BMI, exposure to 1.0 mEq/L potassium or 
2.5 mEq/L calcium dialysate, coronary artery disease, diabetes mellitus, 
Kt/V, serum levels of albumin, haemoglobin, potassium, creatinine, phos-
phate and alkaline phosphatase. 
Kovesdy, (2007) Age, sex, race, ethnicity, diabetes, vintage categories, primary insurance 
(Medicare, Medicaid, private and other), marriage status (married, single, 
divorced, widowed and other), standardized mortality status of the dialy-
sis clinic during entry quarter, comorbid conditions, tobacco smoking, re-
sidual renal function during entry quarter, Kt/V (single pool), 10 indica-
tors of nutritional state and inflammation, including normalized protein 
nitrogen appearance (nPNA) and serum albumin, bicarbonate, total iron-
binding capacity (TIBC), ferritin and creatinine, white blood cell count, 
lymphocyte percentage, haemoglobin level, and BMI. 
Ribeiro, (2015)  Age, BMI, centre experience, Davies score, diabetes, family income, sex, 
literacy, peritoneal dialysis modality, race, previous haemodialysis, dura-
tion of pre-dialysis care, and year of initiation of peritoneal dialysis. 
Torlén, (2012)  Age, sex, race, diabetes, dialysis vintage, primary insurance, marital sta-
tus, atherosclerotic heart disease, congestive heart failure, cerebrovascu-
lar disease, other cardiac diseases, peripheral vascular disease, chronic 
obstructive pulmonary disease, cancer, current smoking, BMI, serum al-
bumin, total iron binding capacity, ferritin, creatinine, calcium, phospho-
rus, parathyroid hormone, alkaline phosphatase, haemoglobin, white 
blood cell count, and percentage lymphocyte count. 
Xu, (2014) Age, sex, BMI, diabetic status, Charlson Comorbidity Index (CCI), hae-
moglobin, serum albumin level, high-sensitivity C-reactive protein, and 
peritoneal dialysis volume per unit of body surface area (PDV/BSA). 
Outcome: Composite CV outcome / Population: Hypertension 
Cohen, (2001)  Age, sex, race, history of CVD, diabetes, previous treatment, smoking 
status, left ventricular hypertrophy, blood sugar, cholesterol, uric acid, se-
rum creatinine, BMI, SBP, and diuretic use. 
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Table 11 continued, page 4/4 
Outcome: Composite CV outcome / Population: CKD 
Korgaonkar, (2010)  Age, sex, race, diabetes status, history of CVD, hypertension, eGFR, and 
serum albumin. 
Luo, (2016)  Age, sex, race, diabetes, congestive heart failure, coronary artery disease, 
cerebrovascular disease, β-blocker use, RAAS blocker use, non-di-hydro-
pyridine calcium channel blocker use, thiazide diuretic use, loop diuretic 
use, and estimated GFR. 
Outcome: Composite CV outcome / Population: Dialysis 
Karaboyas, (2017) Age, sex, dialysis vintage, comorbid conditions (cancer, other CVDs, cer-
ebrovascular disease, heart failure, diabetes, gastrointestinal bleeding, hy-
pertension, lung disease, neurologic disease, psychiatric disorder, periph-
eral vascular disease, recurrent cellulitis, gangrene), vascular access, 
BMI, albumin level, normalized protein catabolic rate, serum calcium 
level, serum phosphorus level, serum phosphorus squared, serum bicar-
bonate level, dialysate bicarbonate concentration, haemoglobin level, ses-
sion duration, and Kt/V. 
ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin II receptor 
blocker; AV, atrioventricular; BMI, body mass index; CCI, Charlson Comorbidity Index; CKD, chronic 
kidney disease; CK-MB, creatinine kinase-myocardial band; CV, cardiovascular; CVD, cardiovascular dis-
ease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; FEV1, forced expiratory 
volume in one second; GFR, glomerular filtration rate; HDL, high-density lipoprotein; Kt/V, formula to 
calculate the efficacy of dialysis (K, Clearance; t, time of dialysis; V, volume of 60 % of body mass); LDL, 
low-density lipoprotein; nPNA, normalized protein nitrogen appearance; NSAID, non-steroidal anti-inflam-
matory drug; NYHA, New York Heart Association; PDV/BSA, peritoneal dialysis volume per unit of body 
surface area; RAAS, Renin-Angiotensin-Aldosterone System; SBP, systolic blood pressure; STEMI, ST-
elevation myocardial infarction; TIBC, total iron-binding capacity. 
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Results from 30 studies could not be included in the meta-analyses and are summarized in Tables 
12 to 17. The studies statistically compared either frequencies of outcomes in serum potassium cat-
egories (Brezins et al., 1996; Choi et al., 2014; D'Elia et al., 1988; Davidson and Surawicz, 1967; 
Dyckner et al., 1982; Friedensohn et al., 1991; Gundling et al., 2012; Herlitz et al., 1988; Janko et 
al., 1992; Kafka et al., 1987; Madias et al., 2000; Nielsen et al., 1986; Reuben and Thomas, 1982; 
Shlomai et al., 2016; Thomas, 1983) (Table 12) or mean serum potassium levels in case and control 
groups (Bulpitt et al., 1986; Detrano et al., 1984; Higham et al., 1993) (Table 13). Other studies 
either assessed the correlation of serum potassium with an outcome (Cleland et al., 1987; Dargie et 
al., 1987) (Table 14), or modelled serum potassium as a continuous variable in a regression analysis 
(Kafka et al., 1987; Nolan et al., 1998; Nordrehaug et al., 1985; Tsuji et al., 1994) (Table 15). 
Additionally, six studies (Genovesi et al., 2009; Li et al., 2015; López Castro et al., 2010; Simpson 
et al., 2002; Su et al., 2012; Yusuf et al., 2016), which included either hypo- or hyperkalemic values 
in the reference group, were excluded from meta-analyses (Table 16). One study (Park et al., 2017) 
could not be included in meta-analyses, as the corresponding outcome “in-hospital arrhythmia” was 
not further specified (Table 17). The results of these 30 studies are not regarded further in this re-
view. 
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Table 12.  Results of studies comparing outcome frequencies in defined potassium categories. 
 
First author, 
(Year) 
Population Study 
size 
 Low serum K+  Reference serum K+  High serum K+  p-value Statistical test 
 Definition 
[mmol/L] 
Frequency 
outcome 
n (%) 
 
Definition 
[mmol/L] 
Frequency  
outcome 
n (%) 
 Definition 
[mmol/L] 
Frequency 
outcome 
n (%) 
 
  
S
V
A
 
Madias, 
(2000) 
AMI 517 
 
< 3.5 6 (14.6)  ≥ 3.5 66 (13.9)  N.R. N.R.  0.89 Chi2-test 
V
A
 
Brezins,  
(1996) 
AMI 1,590 
 
< 4.0 26 (14.1)  ≥ 4.0 31 (2.2)  N.R. N.R.  < 0.001 Chi2-test 
Choi, 
(2014) 
AMI 1,924 
 
< 3.5 3 (3.1)  3.5 to < 4.0 21 (2.7)  ≥ 5.0 2 (8.7)  0.447 
Chi2-test or 
Fisher’s exact 
test 
Dyckner,  
(1982) 
AMI 676 
 
< 3.6 46 (50.0)  3.6 to < 4.4 158 (39.0)  > 5.1 11 (50.0)  < 0.01a Chi2-test 
Friedensohn, 
(1991) 
AMI 1,011 
 
< 3.6 N.R. (68.5)  3.6 to < 4.4 N.R. (60.7)  > 5.1 N.R. (50.2)  N.R. Chi2-test 
Herlitz,  
(1988) 
AMI 679 
 
< 3.5 3 (10.0)  ≥ 3.5 22 (3.5)  N.R. N.R.  N.R. 
Pitman’s non-
parametric test 
Kafka, 
(1987) 
AMI 211 
 
< 3.5 22 (62.0)  3.5 to 4.8 79 (49.0)  > 4.8 6 (43.0)  < 0.03 
Univariate lo-
gistic regres-
sion 
Madias, 
(2000) 
AMI 517 
 
< 3.5 10 (24.4)  ≥ 3.5 62 (13.0)  N.R. N.R.  0.04 Chi2-test 
Nielsen,  
(1986) 
AMI 214 
 
< 3.6 12 (27.9)  3.6 to 5.0b 57 (33.3)  N.R. N.R.  N.S. Chi2-test 
Reuben,  
(1982) 
AMI 405 
 
< 4.0 12 (6.9)  ≥ 4.0 1 (0.43)  N.R. N.R.  < 0.001 N.R. 
Shlomai, 
(2016) 
AMI 1,277c 
 
< 3.9 8 (2.4)  3.9 to 4.2 5 (1.6)  > 4.5 7 (2.2)  0.26 Chi2-test 
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First author, 
(Year) 
Population Study 
size 
 Low serum K+  Reference serum K+  High serum K+  p-value Statistical test 
 Definition 
[mmol/L] 
Frequency 
outcome 
n (%) 
 
Definition 
[mmol/L] 
Frequency  
outcome 
n (%) 
 Definition 
[mmol/L] 
Frequency 
outcome 
n (%) 
 
  
V
A
 
Thomas,  
(1983) 
AMI 809 
 
< 4.0 14 (3.7)  ≥ 4.0 3 (0.70)  N.R. N.R.  < 0.005 Chi2-test 
Davidson, 
(1967) 
Hospitalized 1,986 
 
≤ 3.2 53 (49.5)  > 3.2 338 (18.0)  N.R. N.R.  N.R. Chi2-test 
Janko, 
(1992) 
Hospitalized 745 
 
< 2.5 13 (21.0)  2.6 to 3.5 73 (17.33)  > 3.5 41 (15.6)  N.S. Chi2-test 
Gundling, 
(2012) 
Cirrhosis 293 
 
< 3.0 16 (12.5)  3.5 to 5.0 21 (19.4)  > 5.0 6 (33.3)  N.R. Chi2-test 
D’Elia, 
(1988) 
Dialysis 122 
 
< 3.6 9 (29.0)d  3.6 to 5.4 23 (25.8)  > 5.4 9 (29.0)d  N.S. Chi2-test 
C
V
M
 
Madias, 
(2000) 
AMI 517 
 
< 3.5 7 (17.1) 
 
 
≥ 3.5 73 (15.3)  N.R. N.R.  0.52 Chi2-test 
a Dyckner, (1982): The p-value refers to the difference between the hypokalemic group and the group with a high normal serum potassium concentration. 
b Nielsen, (1986): Of 171 patients in the normokalemic group 169 had serum potassium values within the reference category. In addition, two patients were included with hyper-
kalemic serum potassium values of 5.1 and 5.6 mmol/L. 
c Shlomai, (2016): Only patients with serum potassium levels within the range of 3.5 to 5.2 mmol/L at presentation were included in the study. 
d D’Elia, (1988): Only a combined category of abnormal serum potassium levels was used and the frequency shown in the table was reported for the combined group. 
 
AMI, acute myocardial infarction; CVM, cardiovascular mortality; K+, potassium; N.R., not reported; N.S., not significant; SVA, supraventricular arrhythmias; VA, ventricular 
arrhythmias.  
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Table 13.  Results of studies comparing mean serum potassium values in case and control group. 
 
First author, 
(Year) 
Population Study size Outcome  Case Control p-value  Statistical method 
  
n (%) 
 
Serum K+ mean 
[mmol/L] 
Serum K+ mean 
[mmol/L] 
  
 
V
A
 
Higham, 
(1993) 
AMI 504 17 (3.4)  3.58 ± 0.41 3.89 ± 0.61 < 0.05  Wilcoxon rank sum test 
Detrano, 
(1984) 
Heart disease 50 24 (48.0)  
4.40a 4.35a 0.30a  
Wilcoxon rank sum testb 
4.33c 4.44c 0.44c  
C
V
M
 
Bulpitt, 
(1986) 
Hypertensiond 404 52 (12.9)  3.93 ± 0.05 3.85 ± 0.03 N.R.  
Nonparametric test of Lee & Desu 
(1972) 
a Detrano, (1984): Outcome: Ventricular tachycardia runs > 0. 
b Detrano, (1984): Additional results of the Spearman rank test: R = -0.34, p = 0.02. 
c Detrano, (1984): Outcome: Couplets > 0. d Bulpitt, (1986): Study population with untreated hypertension. 
 
AMI, acute myocardial infarction; CVM, cardiovascular mortality; K+, potassium; N.R., not reported; VA, ventricular arrhythmias. 
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Table 14.  Results of studies assessing the correlation of serum potassium levels and ventricular arrhythmia case status. 
First author, 
(Year) 
Population Study 
size 
Outcome  Serum K+  
as continuous variable 
 Covariates 
 
  n (%) 
 
SD 
[mmol/L] 
R-valuea p-value 
 
 
 
 
 
 
 
A
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e
 
S
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W
e
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n
 
K
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n
ey
 D
is
ea
se
 
O
th
er
s 
Cleland, 
(1987) 
Heart failure 152 93 (61.0)  N.R. - 0.38 < 0.001  N.R. 
Dargie, 
(1987) 
Heart failure 84 51 (61.0)  N.R. - 0.44 < 0.001  N.R. 
a R-value calculated by method of Spearman or Pearson. 
 
BMI, body mass index; CVD, cardiovascular disease; K+, potassium; N.R., not reported; SD, standard deviation. 
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Table 15.  Results of studies modelling serum potassium as a continuous variable in a regression analysis. 
 
First author, 
(Year) 
Population Study 
size 
Outcome  Association per 1 SD increase  
of serum K+ 
 Covariates 
 
  n (%) 
 
SD 
[mmol/L] 
RR 
(95%-CI) 
p-value 
 
 
 
 
 
  A
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 D
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O
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s 
V
A
 
Tsuji,  
(1994) 
Older general 3,327 183 (5.5)  0.48 
1.27 
(1.06; 1.51) 
0.008  X X  X     Xa 
Kafka, 
(1987) 
AMI 211 110 (52.1)  0.57 N.R. 0.020  N.R. 
Nordrehaug, 
(1985) 
AMI 60 18 (30.0)  N.R. N.R. 0.016  N.R. 
C
V
M
 
Nolan, 
(2015) 
Heart failure 433 48 (11.1)  0.49 
1.64 
(1.03; 2.63) 
0.039  X        Xb 
a Tsuji, (1994): Age, sex, systolic blood pressure, cigarette smoking, caffeinated coffee consumption, alcohol consumption, diuretic use, and left ventricular mass. 
b Nolan, (2015): Age, NYHA functional class, furosemide dose, LVESD (Left ventricular end-systolic diameter), LVEDD (Left ventricular end-diastolic diameter), FSI (Fractional 
shortening index), serum sodium, cardiothoracic ratio, heart rate, sNN50 (the number of increases in successive normal-to-normal RR intervals > 50ms in the 24-hour recording, 
an index of parasympathetic activity), rMSSD (the square root of the mean of the squares of the differences between adjacent normal-to-normal RR intervals in the 24-hour 
recording, a complementary index of parasympathetic activity), SDNN (the SD of all normal-to-normal RR intervals in the entire 24-hour recording, an index of the total amount 
of heart rate variability present in the 24-hour recording period, which is modulated by multiple factors). 
 
AMI, acute myocardial infarction; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; CVM, cardiovascular mortality; K+, potassium; N.R., not reported; 
NYHA, New York Heart Association; RR, risk ratio; SD, standard deviation; VA, ventricular arrhythmias.  
2.2 Results 57 
 
Table 16.  Results of studies using a reference category for serum potassium that included low (< 3.5 mmol/L) or high (> 5.5 mmol/L) levels. 
 
First author, 
(Year) 
Population Outcome Reference 
serum K+ 
Low serum K+ High serum K+  Covariates 
  n (%) Definition 
[mmol/L] 
Definition 
[mmol/L] 
RR 
(95%-CI) 
Definition 
[mmol/L] 
RR 
(95%-CI) 
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 D
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V
A
 
Simpson, 
(2002)b 
Older general 940 (6.2) ≥ 3.5 < 3.5 
1.76 
(1.43; 2.09) 
N.A. N.A.  X         
Su, 
(2012)c 
AMI 44 (9.4) ≥ 3.5 < 3.5 
6.21 
(2.67; 14.44) 
N.A. N.A.  X  X  X X X  X 
C
V
M
 
López Castro, 
(2010) 
Heart failure 79 (3.3) < 4.0 N.A. N.A. ≥ 4.0 
3.07 
(1.25; 7.53) 
 X     X  X X 
Genovesi, 
(2009) 
Dialysis 67 (14.1) < 6.0 N.A. N.A. ≥ 6.0 
2.70 
(1.28; 5.85) 
 X    X X X  X 
Li, 
(2015) 
Dialysis 49 (13.7) ≥ 4.0 < 4.0 
1.50 
(0.78; 2.89) 
N.A. N.A.  X X X  X    X 
Yusuf, 
(2016) 
Dialysis 1,604 (4.4) < 5.5 N.A. N.A. ≥ 5.5 
1.00 
(0.86; 1.17) 
 X X X  X X   X 
a A comprehensive list of covariates, which the studies were adjusted for, is given in Table 11. 
b Simpson, (2002): Definition of arrhythmia: Single, frequent or complex premature ventricular contractions. 
c Su, (2012): Definition of arrhythmia: Malignant ventricular arrhythmias included ventricular fibrillation, ventricular flutter or ventricular tachycardia. 
 
AMI, acute myocardial infarction; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; CVM, cardiovascular mortality; K+, potassium; N.A., not applicable; 
RR, risk ratio; VA, ventricular arrhythmias.  
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Table 17.  Results of studies with study outcomes not possible to assign to a specific arrhythmia category. 
 First  
author, 
(Year) 
Population Outcome Reference 
serum K+ 
Low serum K+ High serum K+  Covariates 
 
  n (%) Definition 
[mmol/L] 
Definition 
[mmol/L] 
RR 
(95%CI) 
Definition 
[mmol/L] 
RR 
(95%CI) 
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N
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Park,  
(2017) 
Hospitalized 260 (1.5) 3.6 to 4.0 N.A. N.A. > 5.5 
4.85 
(2.16; 10.84) 
 X X   X  X X X 
a Park, (2017): Age, sex, history of cancer, ischemic heart disease, heart failure, hypertension, diabetes mellitus, baseline estimated GFR and total carbon dioxide, presence of 
hypoalbuminemia, anaemia, and baseline use of ACE inhibitors/ ARBs, β-blockers, diuretics and NSAIDs. 
 
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CI, confidence interval; CVD, cardiovascular disease; GFR, glomerular filtration 
rate; K+, potassium; N.A., not applicable; N.R., not reported; NSAID, non-steroidal anti-inflammatory drug; RR, risk ratio. 
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2.2.5 Results of meta-analyses by study outcome and specific population 
Pooled effect estimates and 95%-confidence intervals of study results for low and high serum 
potassium levels are shown separately by study outcome and study population in Table 18. Pooled 
estimates and corresponding heterogeneity statistics are presented if there was more than one study 
per meta-analysis. 
Additionally, meta-analyses of studies are presented in forest plots sorted by study outcome and 
study population in Figure 5. Moreover, the associations of hypokalemia (coloured in blue) and 
hyperkalemia (coloured in ochre) are illustrated in one plot for each outcome and population. The 
effect estimates of the single studies and the pooled effect estimates of the meta-analyses (sum-
mary measures) originate from Table 10 and Table 18, respectively. 
No publication bias was detected in any of the meta-analyses (all p > 0.05). 
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Table 18.  Effect estimates for the association of serum potassium levels and cardiovascular outcomes. 
 Population Low serum K+   High serum K+ 
  
No. of 
studies 
ntotal ncases 
RR 
(95%-CI) 
 
Heterogeneity  
Q; P; I² [%] 
 
No. of 
studies 
ntotal ncases 
RR 
(95%-CI) 
 
Heterogeneity  
Q; P; I² [%] 
               
S
V
A
 
Older general 1a 4,059 474 
1.62 
(1.02; 2.55) 
 N.A.  1a 4,059 474 
0.96 
(0.24; 3.91) 
 N.A. 
V
A
 
AMI 3b 43,060 2,002 
2.08 
(0.89; 4.85) 
 10.23; 0.01; 80.4  3b 43,060 2,002 
2.33 
(1.60; 3.38) 
 1.24; 0.54; 0.0 
C
V
M
 
Older general 6c 40,504 2,528 
1.00 
(0.79; 1.26) 
 7.26; 0.20; 31.1  6c 40,504 2,528 
1.38 
(1.14; 1.66) 
 0.89; 0.97; 0.0 
Heart failure 2d 21,932 653e 
1.87 
(0.85; 4.18) 
 20.04; 0.00; 95.0  2f 21,726 625g 
1.86 
(0.64; 5.47) 
 43.70; 0.00; 97.7 
CKD 2h 2,898 83i 
0.98 
(0.68; 1.43) 
 0.01; 0.92; 0.0  2h 2,898 83i 
1.48 
(0.98; 2.26) 
 0.00; 0.98; 0.0 
Dialysis 6j 87,774 8,972k 
1.11 
(1.02; 1.21) 
 5.33; 0.38; 6.1  4l 85,885 8,779k 
1.36 
(1.10; 1.68) 
 7.53; 0.06; 60.2 
C
o
m
p
o
si
te
 C
V
 
o
u
tc
o
m
e
 
Hypertensionm 1n 7,653 470 
2.57 
(1.51; 4.36) 
 N.A.  1n 7,653 470 
1.65 
(1.02; 2.67) 
 N.A. 
CKD 2o 56,086 190p 
1.52 
(0.92; 2.50) 
 6.18; 0.01; 83.8  2o 56,086 190p 
1.34 
(1.06; 1.71) 
 1.72; 0.19; 41.9 
Dialysis 1q 45,511 3,300 
0.94  
(0.83; 1.05) 
 N.A.  1q 45,511 3,300 
1.12  
(1.03; 1.23) 
 N.A. 
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A pooled effect estimate is shown if there is more than one study per population. 
Bold printed effect estimates indicate statistically significant results (P < 0.05). 
a Krijthe, (2013). 
b Goyal, (2012); Keskin, 2016; Uluganyan, (2016). 
c Chen, (2016); Fang, (2000); Hughes-Austin, (2017); Lai, (2015); Walsh, (2002); Wannamethee, (1997). 
d Ahmed A., (2007); Aldahl (2017). 
e Ahmed A., (2007): ncases = 653; Aldahl (2017): ncases = N.R. 
f Ahmed, M. I., (2010); Aldahl (2017). 
g Ahmed, M. I., (2010): ncases = 625; Aldahl (2017): ncases = N.R. 
h Korgaonkar, (2010); Wagner, (2017). 
i Korgaonkar, (2010): ncases = N.R.; Wagner, (2017): ncases = 83. 
j Chow, (2008); Huang, (2015); Kovesdy, (2007); Ribeiro, (2015); Torlén, (2012); Xu, (2014). 
k Torlén, (2012): ncases = N.R. 
l Huang, (2015); Kovesdy, (2007); Torlén, (2012); Xu, (2014). 
m Cohen, (2001): Hypertensive study population treated with mainly non-potassium-sparing diuretics (thiazides). 
n Cohen, (2001). 
o Korgaonkar, (2010); Luo, (2016). 
p Korgaonkar, (2010): ncases = 190; Luo, (2016): ncases = N.R. 
q Karaboyas, (2017). 
 
AMI, acute myocardial infarction; CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; CVM, cardiovascular mortality; K+, potassium; N.A., not applicable; 
RR, risk ratio; SVA, supraventricular arrhythmias; VA, ventricular arrhythmias. 
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Figure 5.  Forest plots of studies assessing the association of abnormal serum potassium levels 
with ventricular arrhythmias, cardiovascular mortality, and composite cardiovascular 
outcomes in specific populations.  
 
 The associations of hypokalemia (coloured in blue) and hyperkalemia (coloured in 
ochre) are shown in the same plot for each study outcome and population. 
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2.2.5.1 Supraventricular and ventricular arrhythmias  
In the older general population, the low serum potassium group had an increased risk of supra-
ventricular arrhythmias by 62 % (1.62 [1.02; 2.55]). When an AMI was diagnosed, risk of ventric-
ular arrhythmias was increased by even 108 % (2.08 [0.89; 4.85]). However, this result was not 
statistically significant. In addition, there was a 133 % increased risk of ventricular arrhythmias in 
AMI patients with high serum potassium levels (2.33 [1.60; 3.38]). Contrarily, no increased risk 
of supraventricular arrhythmias was observed for hyperkalemia in the older general population 
(0.96 [0.24; 3.91]). 
2.2.5.2 Cardiovascular mortality 
In contrast to supraventricular arrhythmias, high serum potassium levels in the older general pop-
ulation were associated with a 1.4-fold increased CVM [1.38 (1.14; 1.66)], while no association 
was detected for low serum potassium levels and CVM. Furthermore, CVM was significantly in-
creased in dialysis patients for both low (1.11 [1.02; 1.21]) and high (1.36 [1.10; 1.68]) serum 
potassium levels. The same pattern of increased CVM for low or high serum potassium levels was 
observed in heart failure patients but effect estimates were not statistically significant. 
2.2.5.3 Composite CV outcome 
In hypertensive patients, the risk of composite CV outcomes was significantly increased by 157 % 
(2.57 [1.51; 4.36]) and 65 % (1.65 [1.02; 2.67]) for the low and the high serum potassium category, 
respectively. Moreover, both CKD patients (1.34 [1.06; 1.71]) and dialysis patients 
(1.12 [1.03; 1.23]) with high serum potassium had an increased risk of composite CV outcomes. 
2.2.6 Shape of the relationship of serum potassium levels and cardiovascular outcomes 
For a visual assessment of the associations of serum potassium levels and cardiovascular outcomes, 
the risk ratios and confidence intervals reported in Table 18 have been illustrated in Figure 6. The 
plots are sorted by study population, namely older general population, and populations with hyper-
tension, AMI, heart failure, CKD, and dialysis. 
A U-shaped relationship was found in a population with hypertension for a composite CV outcome 
(3C), in patients with AMI for ventricular arrhythmias (3D), in heart failure patients for CVM (3E), 
in a population with CKD for a composite CV outcome (3F), and in patients receiving dialysis for 
CVM (3H). However, it should be noted that some risk ratios were not statistically significant as 
their confidence intervals included the value 1. 
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No U-shaped association was found for the risk of supraventricular arrhythmias in the older gen-
eral population. Instead, there was an increased risk for individuals in the low serum potassium 
category only (3A). 
In contrast, only the high serum potassium category was associated with increased CVM in both 
the older general population (3B) and in CKD patients (3G). Likewise, high serum potassium was 
associated with a composite CV outcome in dialysis patients (3I). 
 
Figure 6.  Risk ratios of cardiovascular outcomes for low and high serum potassium levels in 
specific populations.  
 
  Cardiovascular outcomes are shown for the older general population (A, B), and pop-
ulations with hypertension (C), acute myocardial infarction (D), heart failure (E), 
chronic kidney disease (F, G), and dialysis treatment (H, I). A pooled estimate is shown 
if there is more than one study per population.  
 
  AMI, acute myocardial infarction; CKD, chronic kidney disease; CV, cardiovascular; 
CVM, cardiovascular mortality; K+, potassium; SVA, supraventricular arrhythmias. 
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2.3 Discussion 
2.3.1 Summary of the findings 
This systematic review and meta-analysis examined the association of abnormal serum potassium 
levels with cardiovascular outcomes in the older general population and populations with hyper-
tension, AMI, heart failure, CKD, and dialysis treatment. Results showed partly strong associa-
tions of abnormal serum potassium levels with supraventricular and ventricular arrhythmias, CVM 
and composite CV outcomes. 
2.3.2 Discussion of results of the meta-analyses 
2.3.2.1 Older general population 
While hypokalemia was associated with an increased risk of supraventricular arrhythmias (defined 
as atrial flutter and atrial fibrillation) (Krijthe et al., 2013) in the older general population, it was 
not associated with CVM. Therefore, I presume that hypokalemia-induced arrhythmias, especially 
atrial arrhythmias, rarely have a fatal course in the older general population. 
In contrary, hyperkalemia was not associated with an increased risk of supraventricular arrhyth-
mias defined as atrial flutter and atrial fibrillation in one small study (Krijthe et al., 2013). As no 
other study assessed the association of hyperkalemia and arrhythmias, it cannot be ruled out that 
hyperkalemia is possibly associated with ventricular arrhythmias in the older general population. 
In fact, it is well-known that hyperkalemia can cause fatal cardiac arrhythmias (Dunn et al., 2015; 
Rossignol et al., 2016; Weisberg, 2008). Moreover, ventricular fibrillation represents the main 
cause of sudden cardiac death (John et al., 2012; Koplan and Stevenson, 2009). Consistent with 
this, is the observation that hyperkalemia was associated with increased CVM. Hence, the ob-
served increased CVM could result at least partly from fatal ventricular arrhythmias in the course 
of hyperkalemia. 
2.3.2.2 Participants with acute myocardial infarction (AMI) 
A different systematic review identified low serum potassium levels as a risk factor for primary 
ventricular fibrillation during AMI (Gheeraert et al., 2006). Even if only on the border to statistical 
significance, analyses similarly revealed an increased risk of ventricular arrhythmias in hypoka-
lemic patients with AMI (Goyal et al., 2012; Keskin et al., 2016; Uluganyan et al., 2016). During 
AMI, hypokalemia-induced arrhythmias are known to result from the effects of highly released 
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catecholamines, which cause an intracellular shift of potassium (Brown et al., 1983). Interestingly, 
the risk of ventricular arrhythmias during AMI was also increased under hyperkalemic conditions. 
This result supports my aforementioned hypothesis that the association between hyperkalemia and 
the risk of arrhythmias might be restricted to specific arrhythmias. 
2.3.2.3 Participants with heart failure 
Two studies evaluated the association between hypokalemia and CVM in heart failure patients 
(Ahmed et al., 2007; Aldahl et al., 2017). Both studies individually reported statistically signifi-
cantly increased associations of hypokalemia and CVM, while the pooled result was not statisti-
cally significant. This was due to high heterogeneity (I2 = 95.0 %) between the two studies, which 
could originate from different serum potassium categories used. The study of Ahmed A. and col-
leagues reported a slightly increased CVM (1.27 [1.06, 1.51]) in patients with chronic heart failure 
who had serum potassium levels below 4.0 mmol/L (Ahmed et al., 2007), whereas the study of 
Aldahl and colleagues reported a very strongly increased CVM (2.86 [2.10; 3.89]) in heart failure 
patients with serum potassium levels below 3.5 mmol/L (Aldahl et al., 2017). Moreover, in the 
first study, the majority of the study population received ACE inhibitors and mainly non-potas-
sium-sparing diuretics, such as thiazides and loop diuretics. However, these diuretics, especially 
if used in higher doses, are able to lower serum potassium levels, which then may induce fatal 
arrhythmias and ultimately increase CVM through this mechanism.  
Similarly, the meta-analysis of the two studies on the association of hyperkalemia and CVM also 
showed high heterogeneity (I2 = 97.7 %) and the pooled result lacked statistical significance 
(1.86 [0.64; 5.47]). While Ahmed M. I. and colleagues (Ahmed et al., 2010) did not observe an 
increased CVM in a group with serum potassium levels above 5.0 mmol/L (1.08 [0.89; 1.30]), the 
study of Aldahl and colleagues showed statistically significant associations with CVM for serum 
potassium levels above 4.5 mmol/L, with the strongest association in a group with levels above 
5.5 mmol/L (3.24 [2.49; 4.23] (Aldahl et al., 2017). Therefore, further studies are needed for the 
endpoint CVM in heart failure patients because of the high heterogeneity of the limited number of 
studies. 
According to current guidelines of the European Society of Cardiology (ESC) (Ponikowski et al., 
2016), first-choice drugs in heart failure patients include ACE inhibitors, β-blockers, ARBs, and 
aldosterone antagonists. Apart from β-blockers, these disease-modifying drugs all retain serum 
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potassium. Low-dose (non-potassium-sparing) diuretics are additionally used for symptomatic re-
lief in patients with signs and/or symptoms of congestion. Thus, theoretically, instead of hypoka-
lemia rather hyperkalemia becomes the more serious problem in heart failure patients.  
2.3.2.4 Participants with chronic kidney disease (CKD) 
As renal elimination is crucial to maintain physiological serum potassium levels, individuals with 
impaired kidney function are at increased risk of hyperkalemia (Kovesdy, 2014; Lehnhardt and 
Kemper, 2011). Consequently, hyperkalemia can be regarded as a symptom of progressive CKD, 
which is known to be a risk factor for CVD (Gansevoort et al., 2013). Accordingly, non-significant 
increased CVM (1.48 [0.98, 2.26]) and a significantly increased risk for composite CV outcomes 
(1.34 [1.06, 1.71]) were detected for hyperkalemic participants with CKD in this review. In con-
trast, while no significant association of hypokalemic conditions and CVM was found, the associ-
ation with an increased risk of composite CV outcomes was on the border to statistical significance 
(1.52 [0.92, 2.50]). 
2.3.2.5 Participants receiving dialysis 
In patients with end-stage renal disease, dialysis is used to imitate kidney function. During dialytic 
procedures, waste products and excessive substances from the blood are filtered into an individu-
ally mixed dialysate solution. Due to a concentration gradient between the dialysate potassium and 
the serum potassium, excessive potassium is removed and the serum potassium level normalizes. 
Many studies have already assessed the association between dialysate potassium and risk of car-
diovascular outcomes, such as sudden cardiac death (Abuelo, 2015; Al-Ghamdi et al., 2010; 
Bleyer et al., 2006; Hung and Hakim, 2015; Karaboyas et al., 2017; Karnik et al., 2001; Kovesdy 
et al., 2007; Pun et al., 2011). Although low dialysate potassium is needed to normalize pre-dial-
ysis hyperkalemia, excessive filtering of serum potassium can result in hypokalemia. Therefore, 
individuals on dialysis are at an increased risk of both hypo- and hyperkalemia, which both may 
cause arrhythmias leading even to sudden cardiac death. Accordingly, the results from the meta-
analyses showed that both low and high serum potassium levels were statistically significantly 
associated with increased CVM in patients on dialysis. 
  
68  2 SYSTEMATIC REVIEW 
 
2.3.2.6 Participants with hypertension 
Amongst other drugs, (non-potassium-sparing) diuretics are used as a first-line treatment in pa-
tients with hypertension (Williams et al., 2018). One study (Cohen et al., 2001) specifically fo-
cused on individuals with hypertension receiving diuretic treatment and observed a highly in-
creased risk of a composite CV outcome for both hypo- and hyperkalemia. Moreover, this study 
detected that diuretic use was more prevalent in hypokalemic participants and less prevalent in 
hyperkalemic participants when compared to participants with normokalemic levels. This finding 
supports the assumption that hypertensive individuals who receive diuretic treatment have a par-
ticularly high risk of hypokalemia. However, it should be considered, that the aforementioned 
observational study covered more than 20 years (1973 to 1996) with crucial changes concerning 
the usage and dosage of (non-potassium-sparing) diuretics. Nowadays, treatment of hypertension 
includes only low-dose hydrochlorothiazides, which have minor potential effects on serum potas-
sium. 
In addition, the increased cardiovascular risk by hyperkalemia in hypertension might be explained 
by renal co-morbidity, which is frequent in hypertensive patients because high blood pressure can 
damage renal blood vessels (American Heart Association, 2016). Therefore, also in patients with 
hypertension, the association of hyperkalemia and cardiovascular endpoints may not be causal 
because hyperkalemia could be a symptom of progressive CKD, which is known to be a risk factor 
for CVD (Gansevoort et al., 2013). 
2.3.3 Research gaps and implications for future studies 
Due to various outcomes and populations, a maximum of six studies was pooled per meta-analysis. 
Future research should therefore continue to add studies on populations and outcomes where sta-
tistically significant results are currently lacking in the meta-analyses or where no study has been 
conducted so far. In addition, future studies on arrhythmias should have a prospective design by 
performing regular follow-up investigations with ECG recordings. New studies on abnormal se-
rum potassium levels and cardiovascular outcomes are still needed to close these gaps of evidence 
in literature. 
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2.3.4 Strengths and limitations 
2.3.4.1 Literature search 
As I only searched two medical databases, I could have missed potentially relevant studies. How-
ever, as only five additional studies were identified through a thorough cross-referencing, I am 
confident that no important study was missed. 
2.3.4.2 Reported study results 
Many studies included were quite old and lacked adequate statistical analyses and reporting of 
results. In particular, many studies on arrhythmias originate from the 1980s and had low scores in 
the risk of bias assessment. Moreover, in former studies among patients receiving diuretics, higher 
doses of non-potassium-sparing diuretics were prescribed until the late 1980s, which may explain 
the high arrhythmia rate and possibly resulting cardiovascular deaths. Furthermore, cut-off values 
for low, reference, and high serum potassium levels differed between the included studies. How-
ever, by including only studies with appropriate reference categories of serum potassium levels in 
the meta-analyses, I managed to make the studies mostly comparable and similar to the limits 
proposed by the American Heart Association (3.5 to 5.1 mmol/L (Lerma, 2014)). New studies 
should categorise serum potassium levels according to recommended clinical cut-off values and 
thoroughly report risk estimates and confidence intervals. 
2.3.4.3 Control of confounding 
The studies included in the meta-analyses were quite heterogeneous with regard to covariate ad-
justment. While all of the studies were adjusted for at least age and sex, only few studies had 
comparable additional adjustments for important confounders. Therefore, I suggest a set of key 
covariates, which future studies on this topic could use, namely age, sex, BMI or other weight 
measure, smoking, diabetes, hypertension, history of CVD, and kidney disease. 
2.3.4.4 Heterogeneity 
Despite the differences in study designs described, heterogeneity was low in most of the meta-
analyses. However, significant heterogeneity (p < 0.05) was detected among the three studies as-
sessing the association of low serum potassium levels and ventricular arrhythmias in AMI patients 
(I2 = 80.4 %), the two studies on CVM in hypokalemic heart failure patients (I2 = 95.0 %) and the 
two studies on CVM and hyperkalemic heart failure patients (I2 = 97.7 %). Furthermore, there was 
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significant heterogeneity among the two studies investigating the association of low serum potas-
sium levels and a composite CV outcome in CKD patients (I2 = 83.8 %). Of note is that all four 
meta-analyses revealed non-significant increased associations of abnormal serum potassium levels 
and the corresponding outcome. One possible explanation of the heterogeneity in the latter meta-
analysis is that definitions of the composite CV outcomes were quite different in the studies in-
cluded (Table 6). 
2.3.4.5 Composite outcomes 
In addition, atherosclerotic events, namely myocardial infarction and non-specified stroke, were 
part of the composite CV outcomes. Although there is no plausible association for low serum 
potassium levels and myocardial infarction, the latter was part of the search strategy in order to 
identify cardiovascular deaths due to myocardial infarction. However, I did not explicitly imple-
ment “cerebrovascular diseases” in the search strategy, as except for embolic stroke, which may 
develop in the course of hypokalemia-induced atrial fibrillation, abnormal serum potassium levels 
have not been reported to be risk factors for cerebrovascular disease events. Therefore, I suspect 
that the studies with composite CV outcomes included might have underestimated the risk of hypo- 
and hyperkalemia. Thus, I suggest that future studies with composite CV endpoints should con-
sider excluding atherosclerotic events, such as myocardial infarction and ischemic stroke, from 
their endpoint definitions. 
Similarly, the definitions of ventricular arrhythmias were heterogeneous between the studies in-
cluded (Table 6). While some studies investigated ventricular tachycardia, ventricular flutter or 
ventricular fibrillation, others measured abnormal ectopic ventricular activity or premature ven-
tricular complexes. Consequently, the percentages of participants experiencing ventricular ar-
rhythmias ranged widely in the studies included. I intended to do arrhythmia subtype-specific 
meta-analyses, but this was not completely possible, because only three studies had sufficient data 
for meta-analysis and used composite arrhythmia outcomes (Goyal et al., 2012; Keskin et al., 
2016; Uluganyan et al., 2016). These three studies had quite comparable arrhythmia rates (4.4 %, 
6.1 %, and 10.6 %, respectively) and were finally pooled in a meta-analysis. Future studies should 
be large enough to address clearly defined arrhythmia subtypes instead of composite arrhythmia 
definitions. 
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2.3.5 Clinical implications for maintaining serum potassium levels in specific ranges 
As recommended by experts with an affiliation to the American Heart association (Lerma, 2014), 
serum potassium levels should be maintained between 3.5 and 5.1 mmol/L in the older general 
population in order to prevent supraventricular arrhythmias and ventricular arrhythmias, as well 
as CVM. For patients with hypertension or heart failure, a higher cut-off of 4.0 mmol/L has been 
suggested for hypokalemia (Cohn et al., 2000; Hunt et al., 2005). This recommendation is sup-
ported by the observed increased cardiovascular risk for low serum potassium levels in these two 
aforementioned patient groups sometimes treated with non-potassium-sparing diuretics. As the 
corresponding studies had been conducted before current guidelines for the management of hyper-
tension (Mancia and Fagard, 2013; Williams et al., 2018) and heart failure (Ponikowski et al., 
2016) were published, the study results need to be interpreted with caution. In patients with hy-
pertension, non-potassium-sparing diuretics are nowadays used in low doses and often in combi-
nation with potassium-sparing agents. In patients with heart failure, the aforementioned cardiovas-
cular risk for hypokalemia should no longer exist since they receive ACE inhibitors, ARBs or 
aldosterone antagonists, all retaining serum potassium. However, it seems to be important to cau-
tiously monitor serum potassium levels when thiazide or even loop diuretics, especially in higher 
doses, are prescribed for patients with hypertension or heart failure. 
For patients with AMI, an even higher threshold for hypokalemia has been suggested, namely 
4.5 mmol/L during or shortly after AMI (Macdonald and Struthers, 2004). As I detected a border-
line significant 2-fold increased risk of arrhythmias in AMI patients with low serum potassium 
levels, I agree with this recommendation to target serum potassium levels in the high-normal range 
in these patients. However, hyperkalemia could also be a threat because AMI patients showed a 
strongly increased arrhythmia risk with serum potassium levels ≥ 5.5 mmol/L (Goyal et al., 2012).  
For patients with CKD or end-stage renal disease requiring dialysis, it is difficult to reach serum 
potassium levels ≤ 5.1 mmol/L. Therefore, some studies suggested a higher cut-off of 
> 5.5 mmol/L for hyperkalemia in these patients (Abuelo, 2015; Van Harrison et al., 2014). How-
ever, this systematic review included large cohort studies in patients with impaired kidney function 
(Luo et al., 2016) and dialysis treatment (Kovesdy et al., 2007), which assessed the shape of the 
association of serum potassium levels and cardiovascular outcomes and did observe an increased 
risk for serum potassium levels above 5.0 mmol/L (Kovesdy et al., 2007; Luo et al., 2016). In 
addition, it should be noted that another large observational study with almost 100,000 CKD pa-
tients (Collins et al., 2017) showed in a spline analysis that all-cause mortality of CKD patients 
already started to increase at serum potassium levels above 5.0 mmol/L. 
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2.3.6 Conclusion 
My findings from this systematic review and meta-analysis highlight the clinical relevance of 
monitoring serum potassium levels especially in cardiac patients at high risk of hypokalemia, such 
as patients with hypertension or heart failure, who frequently receive diuretic treatment. Controlled 
clinical trials are needed to determine if these patient populations may profit from more frequent 
potassium-monitoring and subsequent interventions, such as change or withdrawal of potassium-
influencing drugs, in order to restore normal values and prevent cardiovascular outcomes. 
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3 ORIGINAL STUDY 
In summary, the results of the systematic review and meta-analysis showed that the association of 
hypokalemia and CVM appears to be restricted to subpopulations with hypertension or heart fail-
ure (Hoppe et al., 2018). Both conditions are frequently treated with diuretics (Williams et al., 
2018), which is why hypokalemia due to use of non-potassium-sparing diuretics might explain the 
increased CVM in these patients (Schulman and Narins, 1990). Therefore, the second aim of this 
dissertation was to investigate the association of drugs affecting potassium excretion and CVM. 
More precisely, I analysed the associations of diuretics overall, non-potassium-sparing diuretics 
in specific, and laxatives use with CVM in individuals receiving antihypertensive treatment, in-
cluding individuals with hypertension or heart failure. For this purpose, the drug classes were first 
analysed distinctly and then jointly in order to detect potential drug-drug interactions between 
these two potassium-influencing drug classes. 
The content of the following chapters on material and methods (3.1), results (3.2), and discussion 
(3.4) are currently under consideration for publication in the scientific article “Hoppe, L. K., 
Muhlack, D. C., Koenig, W., Brenner, H. and Schöttker, B. (2019). The Associations of Diuretics 
and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-Analysis of 
Two Large Cohort Studies. (Submitted)”. 
3.1 Material and methods 
3.1.1 Design and setting 
The ESTHER study (Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und 
optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung [German]) is an on-
going epidemiological cohort study performed in the older general population of the federal state 
of Saarland, Germany (Löw et al., 2004). At baseline (2000 to 2002), 9,940 men and women, aged 
50 to 75 years, were recruited by their general practitioner when presenting for a routine health 
check-up (Muhlack et al., 2018). Data collection at baseline included physical measurements and 
blood sampling. Additionally, both the general practitioner and the participant provided infor-
mation via detailed standardized questionnaires. Follow-up contacts were realized after 2, 5, 8, 11, 
and 14 years, of which the latter was used for the current analysis. 
The UK Biobank is also a general population cohort study and recruited participants aged between 
40 and 69 years (Collins, 2012). Recruitment of 502,616 individuals took place from 2006 to 2010 
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throughout the United Kingdom (UK) (Sudlow et al., 2015). Data collection included a self-com-
pleted touchscreen questionnaire, a computer-assisted interview, physical and functional 
measures, and biological samples, as described in detail elsewhere (Sudlow et al., 2015). A follow-
up after 7 years was realised through linked population-level UK medical and other health-related 
records (Palmer, 2007; Sudlow et al., 2015). 
3.1.2 Mortality ascertainment 
Vital status of ESTHER participants was collected until the end of 2015 by querying the residents’ 
registration offices resulting in a completeness of follow-up for all-cause mortality of 99.7 %. Death 
certificates were available from public health departments for 98.9 % of ESTHER participants who 
had died. In the UK Biobank, almost complete mortality follow-up until 15 February 2016 was 
guaranteed by embedding the study within the UK’s National Health Service (Collins, 2012). The 
primary cause of death was available for all but six UK Biobank participants (99.99 % complete-
ness). 
The International Statistical Classification of Diseases and Related Health Problems (ICD) is the 
most important globally acknowledged classification system for medical diagnoses (World Health 
Organization, 2019). According to the 10th revision of the ICD, deaths coded with ICD-10 codes 
I00-I99, which comprise diseases of the circulatory system, were considered as cardiovascular 
deaths. Hereinafter these deaths are collectively considered and also referred to as cardiovascular 
mortality (CVM). 
3.1.3 Medication assessment 
In the ESTHER study, prescribed drugs were collected from the physician’s questionnaire. In the 
UK Biobank, an interview of the study participants with a trained nurse was conducted to get 
information on drug utilization. The Anatomical Therapeutic Chemical (ATC) classification sys-
tem, developed and maintained by the WHO Collaborating Centre for Drug Statistics Methodol-
ogy, systematically classifies drugs according to their anatomical, therapeutic, pharmacological, 
and chemical properties into five levels (WHO Collaborating Centre for Drug Statistics Method-
ology, 2018). An ATC code presented in one to four levels defines a group of drugs acting on the 
same organ, treating the same disease, having the same pharmacological effect, and showing the 
same chemical structure, respectively. An ATC code in five levels identifies exactly one specific 
active substance. To define the study population of individuals treated with antihypertensive drugs, 
I used the following drug classes with their corresponding ATC codes: Agents acting on the renin-
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angiotensin system (C09), calcium channel blockers (C08), β-blocking agents (C07), diuretics 
(C03), and miscellaneous antihypertensive agents (C02). 
Diuretics were studied in two groups: (i) non-potassium-sparing diuretics (C03AA, C03AH, 
C03AX, C03BA, C03BC, C03BD, C03BK, C03BX, C03CA, C03CC, and C03CX), and (ii) po-
tassium-sparing diuretics (C03D), combinations of non-potassium-sparing diuretics with potas-
sium (C03AB, C03BB, and C03CB) or combinations of non-potassium-sparing diuretics with po-
tassium-sparing diuretics (C03E). 
Laxatives use was assessed with the following question in the participant questionnaire of the 
ESTHER study: “Do you sometimes or regularly take laxatives?” The answering options “Yes, 
sometimes” and “Yes, regularly” were used to identify regular laxatives users. The UK Biobank 
assessed laxatives use via the touchscreen questionnaire with the following question: “Do you 
regularly take any of the following? (You can select more than one answer)”. Answering options 
included “Laxatives (e.g. Dulcolax, Senokot)” and other OTC drugs. 
3.1.4 Covariate assessment 
Socio-demographic characteristics and lifestyle factors were assessed as self-reported information 
with detailed standardized participant questionnaires in the ESTHER study and with touchscreen 
questionnaires in the UK Biobank. 
The smoking status was assessed by questions about the participant’s past and current tobacco 
smoking history and finally defined via the following three categories: “never”, “previous” or 
“current”. Physical activity was measured in hours of vigorous physical activity per week in the 
ESTHER study. Participants doing any amount of vigorous physical activity per week were de-
fined as physically active. In the UK Biobank, physical activity was assessed as the number of 
days per week of at least 10 minutes of vigorous physical activity. Participants who had answered 
with one to seven days were defined as physically active. Alcohol consumption was assessed by 
questions about the participants’ weekly and monthly consumption of pints of beer, glasses of 
wine, and measures of spirits. I used the amounts of beverages to estimate grams of consumed 
ethanol per day and subsequently grouped participants into the WHO drinking categories as  
follows: Abstainers, category I (mild) including women with an alcohol consumption of 
0-19.99 g/d or men with 0-39.99 g/d, and category II/III (moderate/ heavy) including women with 
≥ 20 g/d or men with ≥ 40 g/d (Rehm et al., 2003). 
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In the ESTHER study, measurements of systolic blood pressure (in mmHg) were available from 
the physician’s medical conditions report of the health check-up. In the UK Biobank, systolic 
blood pressure measurements were conducted by automated reading at the left upper arm (range 
returned by the Omron device is 0-255 mmHg). BMI (in kg/m2) was calculated based on weight 
[kg] and height [m] and categorized according to a slightly modified version of the WHO standards 
as follows: < 25, 25 to < 30, and ≥ 30 kg/m2 (World Health Organization, 2000). Potential kidney 
damage was defined by urinary albumin levels ≥ 20 mg/L. In the ESTHER study, urinary albumin 
was measured by nephelometry with the BN II system using OSAL N antiserum against albumin 
(both Siemens, Marburg, Germany). In the UK Biobank, urinary albumin was determined with 
immunoturbidimetry on a Beckman Coulter AU5400 (Brea, United States). 
Information on diseases (diabetes mellitus, heart failure, and CHD) and a history of cardiovascular 
events (myocardial infarction and stroke) were based on physician-reported information in the 
ESTHER study and on self-reported information from a verbal interview in the UK Biobank. To 
identify participants with diabetes mellitus, I additionally used the reported information on antidi-
abetic drugs (physician-reported in the ESTHER study and self-reported in the UK Biobank). CHD 
was defined as a composite of angina pectoris and myocardial infarction. The heart failure preva-
lence in the UK Biobank was implausibly low (0.03 %) most probably because of self-reporting 
and was therefore not used in these analyses. 
Anticholinergic drug use included use of drugs classified as having a moderate (score 2) or severe 
(score 3) anticholinergic potential according to the anticholinergic cognitive burden (ACB) scoring 
(Cai et al., 2013). The ACB score was developed in the course of a systematic review summarizing 
the results of 27 studies about the association of anticholinergic activities of drugs and cognition. 
Subsequently, a list of those anticholinergic drugs identified to affect cognition was presented to 
an interdisciplinary expert panel, who finally classified the drugs into three ordered groups 
(1 = mild, 2 = moderate, 3 = severe) (Boustani et al., 2008; Campbell et al., 2009). 
Opioid use was identified via the ATC codes N02A (opioids) and N07BC (drugs used in opioid 
dependence). 
3.1.5 Statistical analysis 
To have a more comparable baseline age in the two studies, n = 117,894 participants younger than 
50 years were excluded from the total UK Biobank sample of n = 502,616. Furthermore, in order 
to have a comparable baseline cardiovascular risk of diuretics users and a control group, only users 
of antihypertensive drugs were included in the current analysis (nexcluded = 279,348). A further 15 
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participants were excluded as their causes of death were unknown (ICD-10 codes R98 and R99) 
or missing. Finally, the analytical sample size for the UK Biobank was n = 105,359. 
Likewise, participants of the ESTHER study (n = 9,940 at baseline) were excluded if they had no 
antihypertensive treatment (nexcluded = 5,622), an unknown cause of death (nexcluded = 56) or a loss 
to follow-up (nexcluded = 9), leaving an analytical sample size of n = 4,253 participants. 
Figure 7 graphically shows the aforementioned inclusions and exclusions of the study participants 
to determine the final analysis samples. 
 
Figure 7.  Flow chart showing the study populations of the ESTHER study (baseline: 2000-2002) 
and the UK Biobank (baseline: 2006-2010) with inclusion and exclusion procedures 
that resulted in the final analytical sample sizes.  
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Exposure to diuretics and laxatives was assessed in two ways: distinctly and jointly. In distinct 
analyses, laxatives and diuretics were put separately into models. Furthermore, I analysed diuretics 
use overall and more specifically sub-divided into two groups: 
(1) Users of non-potassium-sparing diuretics 
(2) Users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with 
potassium or potassium-sparing diuretics. 
In a sensitivity analysis conducted in the large UK Biobank only, the second group was further 
divided into its three subgroups. 
For joint analyses of concurrent diuretics and laxatives use, study participants were allocated to 
six mutually exclusive treatment groups (Figure 8): 
(1) Non-potassium-sparing diuretics and laxatives 
(2) Non-potassium-sparing diuretics and no laxatives 
(3) Potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potas-
sium or potassium-sparing diuretics and laxatives 
(4)  Potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potas-
sium or potassium-sparing diuretics and no laxatives 
(5) No diuretics and laxatives 
(6) No diuretics and no laxatives. 
Where characteristics were described by dichotomous or categorical variables, Chi²-tests were 
used to assess differences in baseline characteristics in selected drug user groups.  
Moreover, the associations of the aforementioned drug exposure groups with CVM were assessed 
in a time-to-event analysis using Cox proportional hazard regression models to estimate hazard 
ratios and 95%-confidence intervals. All analyses were adjusted for age, sex, smoking status, phys-
ical activity, alcohol consumption, systolic blood pressure, BMI, potential kidney damage, diabe-
tes mellitus, heart failure (in the ESTHER study only), CHD, history of myocardial infarction, 
history of stroke, anticholinergic drug use, and use of opioids. I adjusted for the latter two drug 
classes because they can cause chronic constipation and are known to be associated with mortality 
(Ray et al., 2016; Ruxton et al., 2015). Age and systolic blood pressure were modelled continu-
ously and all other co-variables with the categorizations shown in Table 19. 
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In a further sensitivity analysis, the aforementioned covariates were combined in propensity scores 
and the Cox models of the distinct analyses were adjusted for the propensity scores. 
Furthermore, subgroup analyses were conducted for age (≥ 65 years vs. < 65 years), sex (men vs. 
women), potential kidney damage (urinary albumin ≥ 20 mg/L vs. < 20 mg/L), CHD (Yes vs. No), 
and heart failure (Yes vs. No). 
Results of both studies were combined by random-effects model meta-analyses with inverse vari-
ance weighting to allow for between-study heterogeneity. Data synthesis was performed by using 
the software Comprehensive Meta-Analysis 2.0 (Biostat, Englewood, NJ, USA). 
In another sensitivity analysis, the follow-up time of the ESTHER study (14 years) was restricted 
to the follow-up time of the UK Biobank (7 years) to check whether the different lengths of follow-
up had a significant influence on the results. 
All analyses were performed with the software package SAS (version 9.4; SAS Institute Inc., Cary, 
NC, USA). Missing values were imputed using the MCMC algorithm of the SAS procedure PROC 
MI. Finally, five imputed datasets were created and analyses of these five datasets were combined 
by the SAS procedure PROC MIANALYZE. All statistical tests were two-sided with an α-level 
of 0.05. 
3.2 Results 
3.2.1 Characteristics of the study population 
Baseline characteristics of antihypertensive medication users of both study populations are shown 
in Table 19. The mean age of the 4,253 ESTHER participants and the 105,359 UK Biobank par-
ticipants was 64 years (Standard deviation (SD) = 6 years) and 62 years (SD = 5 years), respec-
tively. Sexes (men/women) were almost equally distributed within each study, while there was a 
higher proportion of men in the UK Biobank (52.9 %) than in the ESTHER study (45.1 %). The 
proportions of physically active participants and moderate/heavy drinkers (WHO category II/III) 
were higher in the UK Biobank. The prevalence of diseases and cardiac events was higher in the 
ESTHER study, while elevated urinary albumin levels (≥ 20 mg/L) were more prevalent in the UK 
Biobank indicating a higher proportion of participants with potential kidney damage in this cohort. 
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Table 19.  Baseline characteristics of the analysed participants with antihypertensive treatment of 
the ESTHER study (Germany, baseline: 2000-2002) and the UK Biobank (UK, base-
line: 2006-2010). 
 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Characteristics ntotala nchar (%) Mean (SD)  ntotala nchar (%) Mean  (SD) 
Age (years) 4,253   64 (6)  105,359   62  (5) 
Age ≥ 65 years 4,253 2,024 (47.6)    105,359 38,203 (36.3)   
Sex (male) 4,253 1,917 (45.1)    105,359 55,751 (52.9)   
Smoking 4,128      104,621     
Never  2,136 (51.7)     50,280 (48.1)   
Former  1,440 (34.9)     45,054 (43.1)   
Current  552 (13.4)     9,287 (8.9)   
Vigorous physical  
activityb 
4,240  
 
 
 
 96,972  
 
 
 
No   2,455 (57.9)     44,401 (45.8)   
Yes  1,785  (42.1)     52,571 (54.2)   
Alcohol consumptionc 3,803      88,913     
Abstainer  1,381 (36.3)     10,804 (12.2)   
WHO category I  2,196 (57.7)     55,816 (62.8)   
WHO category II/III  226 (5.9)     22,293 (25.1)   
SBP (mmHg) 4,246   145 (20)  98,147   147 (19) 
BMI (kg/m2) 4,253   28.9 (4.5)  104,683   29.5 (5.2) 
< 25  771 (18.1)     18,823 (18.0)   
25 to < 30  1,996 (47.0)     44,376 (42.4)   
≥ 30  1,483 (34.9)     41,484 (39.6)   
Urinary albumin (mg/L) 4,220      41,488     
< 20  3,303 (78.3)     27,495 (66.3)   
≥ 20   917 (21.7)     13,993 (33.7)   
Diabetes mellitus 4,192 944 (22.5)    105,359 11,375 (10.8)   
Heart failure 4,206 748 (17.8)    104,935 N.A.d    
CHD 4,252 946 (22.3)    104,935 17,627 (16.8)   
History of MI 4,079 417 (10.2)    104,935 9,345 (8.9)   
History of stroke 4,066 222 (5.5)    104,935 2,940 (2.8)   
Anticholinergic drug use 4,253 224 (5.3)    105,359 7,160 (6.8)   
Opioid use 4,253 35 (0.8)    105,359 9,615 (9.1)   
Laxatives use 4,253 352 (8.2)    105,359 4,322 (4.1)   
Diuretics use 4,253 897 (21.1)    105,359 38,227 (36.3)   
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 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Characteristics ntotala nchar (%) Mean (SD)  ntotala nchar (%) Mean  (SD) 
Non-potassium-sparing  
diuretics 
 455 (10.7)     35,821 (34.0) 
 
 
Potassium-sparing diuretics 
or combinationse 
 442 (10.4)     2,406 (2.3) 
 
 
a Does not always add up to the total study sizes (n) due to missing values. 
b Vigorous physical activity was measured in hours per week (ESTHER) or in the number of days per week of at least 
10 min of activity (UK Biobank): “No”: Participants not doing any amount of vigorous physical activity, “Yes”: 
Participants doing any amount of vigorous physical activity. 
c Alcohol consumption in categories of the WHO (Rehm et al., 2003): Category I including women with an alcohol 
consumption of 0-19.99 g/d or men with 0-39.99 g/d, category II including women with an alcohol consumption of 
20-39.99 g/d or men with 40-59.99 g/d, and category III including women with an alcohol consumption of ≥ 40 g/d 
or men with ≥ 60 g/d. 
d Not sufficiently assessed in the UK Biobank (unreliable self-report) and therefore not applicable for use. 
e Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with po-
tassium or potassium-sparing diuretics. 
 
BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction; N.A., not applicable; nchar, number 
of participants with the characteristics; ntotal, number of participants with data for the characteristic; SBP, systolic 
blood pressure; SD, standard deviation; UK, United Kingdom; WHO, World Health Organization 
Further, Table 19 shows that self-reported, regular laxatives use was higher in the ESTHER study 
(8.2 %) than in the UK Biobank (4.1 %). In addition, one out of five ESTHER participants used 
diuretics (21.1 %), whereas in the UK Biobank more than every third participant did (36.3 %). The 
difference can mostly be explained by lower β-blocker use in the UK Biobank (30.6 %) compared 
to 49.3 % in the ESTHER study (Table 20). One might conclude that treatment of hypertension in 
the UK is preferably managed by use of diuretics as they are much cheaper than β-blockers. All 
other antihypertensive drug classes (calcium channel blockers, ACE inhibitors, and ARBs) were 
similarly frequently used (Table 20). Interestingly, Table 19 shows that the diuretics users in the 
ESTHER study (n = 897) consisted to equal parts of non-potassium-sparing diuretics users 
(50.7 %) and potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with 
potassium or potassium-sparing diuretics users (49.3 %), while the diuretics users in the  
UK Biobank (n = 38,227) mainly took non-potassium-sparing diuretics (93.7 %) and only few 
diuretics users (6.3 %) had potassium-sparing diuretics / combinations of non-potassium-sparing 
diuretics with potassium or potassium-sparing diuretics. 
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Table 20.  Use of antihypertensive drug classes at baseline in the ESTHER study (Germany, base-
line: 2000-2002, mean baseline age: 64 years) and the UK Biobank (UK, baseline: 
2006-2010, mean baseline age: 62 years). 
Drug class ESTHER  
(n = 4,253) 
 UK BIOBANK  
(n = 105,359) 
 n (%)  n (%) 
Diuretics 897 (21.1)  38,227 (36.3) 
β-blockers 2,095 (49.3)  32,193 (30.6) 
Calcium channel blockers 1,168 (27.5)  33,463 (31.7) 
Angiotensin-converting enzyme (ACE) inhibitors 1,660 (39.0)  46,001 (43.7) 
Angiotensin II receptor blockers (ARBs) 513 (12.1)  19,963 (19.0) 
UK, United Kingdom. 
Population characteristics that were statistically significantly associated with regular laxatives use 
in both studies were age ≥ 65 years, female sex, mild alcohol consumption (category I), history of 
stroke, anticholinergic drug use, opioid use, and diuretics use (Table 21). 
Table 21.  Baseline characteristics of laxatives users compared to non-users of laxatives of the 
analysed participants with antihypertensive treatment in the ESTHER study (Ger-
many, baseline: 2000-2002) and the UK Biobank (UK, baseline: 2006-2010). 
 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Laxatives use 
Yes  
(n = 345) 
No  
(n = 3,908) 
 
 
Yes  
(n = 4,322) 
No  
(n = 101,037) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
Age ≥ 65 years 57.1 46.8 < 0.001  41.6 36.0 < 0.001 
Sex (male) 25.8 46.8 < 0.001  32.3 53.8 < 0.001 
Smoking   0.181    < 0.001 
Never 54.8 51.5   46.1 48.1  
Former 30.4 35.3   42.6 43.1  
Current 14.9 13.2   11.4 8.8  
Vigorous physical  
activitya 
  0.218    < 0.001 
No  61.1 57.6   57.5 45.3  
Yes 39.0 42.4   42.6 54.7  
Alcohol consumptionb   < 0.001    < 0.001 
Abstainer 48.0 35.3   22.5 11.7  
WHO category I 47.3 58.6   57.3 63.0  
WHO category II/III 4.7 6.1   20.2 25.3  
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 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Laxatives use 
Yes  
(n = 345) 
No  
(n = 3,908) 
 
 
Yes  
(n = 4,322) 
No  
(n = 101,037) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
SBP (mmHg)   0.176    < 0.001 
< 140 34.3 32.4   44.2 35.9  
140 to < 160 44.3 41.6   36.4 39.6  
≥ 160 21.4 26.0   19.4 24.6  
BMI (kg/m2)   0.060    < 0.001 
< 25 20.6 17.9   20.8 17.9  
25 to < 30 40.9 47.5   38.2 42.6  
≥ 30 38.6 34.6   41.0 39.6  
Urinary albumin (mg/L)   0.575    0.615 
< 20 79.5 78.2   66.9 66.3  
≥ 20  20.5 21.8   33.2 33.8  
Diabetes mellitus 26.3 22.2 0.080  10.9 10.8 0.788 
Heart failurec 25.4 17.1 < 0.001  N.A. N.A. N.A. 
CHD 25.5 22.0 0.129  21.3 16.6 < 0.001 
History of MI 12.6 10.0 0.138  9.6 8.9 0.130 
History of stroke 8.9 5.2 0.005  3.9 2.8 < 0.001 
Anticholinergic drug use 9.0 4.9 0.001  18.5 6.3 < 0.001 
Opioid use 2.0 0.7 0.010  26.1 8.4 < 0.001 
Diuretics use 29.6 20.3 < 0.001  43.6 36.0 < 0.001 
Non-potassium-sparing  
diuretics 
15.4 10.3 0.004  39.3 33.8 < 0.001 
Potassium-sparing  
diuretics or  
combinationsd 
14.2 10.1 0.016  4.3 2.2 < 0.001 
Bold printed: statistically significant (p < 0.05). 
a Vigorous physical activity was measured in hours per week (ESTHER study) and in the number of days per week 
of at least 10 min of activity (UK Biobank): “No”: Participants not doing any amount of vigorous physical activity, 
“Yes”: Participants doing any amount of vigorous physical activity. 
b Alcohol consumption in categories of the WHO: Category I including women with an alcohol consumption of 
0-19.99 g/d or men with 0-39.99 g/d, category II including women with an alcohol consumption of 20-39.99 g/d or 
men with 40-59.99 g/d, and category III including women with an alcohol consumption of ≥ 40 g/d or men with 
≥ 60 g/d. 
c Not sufficiently assessed in the UK Biobank (unreliable self-report) and therefore not applicable for use. 
d Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with po-
tassium or potassium-sparing diuretics. 
 
BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction; N.A., not applicable; SBP, systolic 
blood pressure; UK, United Kingdom; WHO, World Health Organization.  
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The use of diuretics was statistically significantly positively associated with older age (≥ 65 years), 
female sex, lower alcohol consumption, higher BMI, history of stroke, opioid use, and laxatives 
use in both cohorts (Table 22). 
Table 22.  Baseline characteristics of diuretics users compared to non-users of diuretics of the 
analysed participants with antihypertensive treatment in the ESTHER study (Ger-
many, baseline: 2000-2002) and the UK Biobank (UK, baseline: 2006-2010). 
 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Diuretics use 
Yes  
(n = 897) 
No  
(n = 3,356) 
 
 
Yes  
(n = 38,227) 
No  
(n = 67,132) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
Age ≥ 65 years 56.6 45.2 < 0.001  38.9 34.8 < 0.001 
Sex (male) 40.5 46.3 0.002  42.7 58.7 < 0.001 
Smoking   0.251    < 0.001 
Never 54.0 51.2   49.2 47.4  
Former 34.0 35.1   42.2 43.6  
Current 12.1 13.7   8.6 9.0  
Vigorous physical activitya   0.094    < 0.001 
No  60.4 57.3   48.7 44.2  
Yes 39.6 42.8   51.4 55.8  
Alcohol consumptionb   < 0.001    < 0.001 
Abstainer 42.6 34.7   13.6 11.4  
WHO category I 53.7 58.8   61.2 63.6  
WHO category II/III 3.7 6.5   25.2 25.0  
SBP (mmHg)   0.797    < 0.001 
< 140 33.4 32.3   34.9 36.9  
140 to < 160 41.0 42.1   40.2 39.0  
≥ 160 25.6 25.6   25.0 24.1  
BMI (kg/m2)   < 0.001    < 0.001 
< 25 12.7 19.6   15.1 19.6  
25 to < 30 40.9 48.6   39.5 44.0  
≥ 30 46.4 31.8   45.4 36.4  
Urinary albumin (mg/L)   0.007    < 0.001 
< 20 75.0 79.2   67.4 65.7  
≥ 20  25.1 20.8   32.6 34.3  
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 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Diuretics use 
Yes  
(n = 897) 
No  
(n = 3,356) 
 
 
Yes  
(n = 38,227) 
No  
(n = 67,132) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
Diabetes mellitus 30.9 20.3 < 0.001  10.2 11.2 < 0.001 
Heart failurec 28.5 15.0 < 0.001  N.A. N.A. N.A. 
CHD 31.2 19.9 < 0.001  11.0 20.1 < 0.001 
History of MI 15.4 8.9 < 0.001  5.8 10.7 < 0.001 
History of stroke 8.2 4.7 < 0.001  3.2 2.6 < 0.001 
Anticholinergic drug use 5.5 5.2 0.768  7.4 6.5 < 0.001 
Opioid use 1.6 0.6 0.006  11.1 8.0 < 0.001 
Laxatives use 11.4 7.2 < 0.001  4.9 3.6 < 0.001 
Bold printed: statistically significant (p < 0.05). 
a Vigorous physical activity was measured in hours per week (ESTHER study) and in the number of days per week 
of at least 10 min of activity (UK Biobank): “No”: Participants not doing any amount of vigorous physical activity, 
“Yes”: Participants doing any amount of vigorous physical activity. 
b Alcohol consumption in categories of the WHO: Category I including women with an alcohol consumption of 
0-19.99 g/d or men with 0-39.99 g/d, category II including women with an alcohol consumption of 20-39.99 g/d or 
men with 40-59.99 g/d, and category III including women with an alcohol consumption of ≥ 40 g/d or men with 
≥ 60 g/d. 
c Not sufficiently assessed in the UK Biobank (unreliable self-report) and therefore not applicable for use. 
 
BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction; N.A., not applicable; SBP, systolic 
blood pressure; UK, United Kingdom; WHO, World Health Organization. 
Comparing more specifically users of non-potassium-sparing diuretics and users of potassium-
sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-
sparing diuretics, most characteristics were comparable (Table 23). Interestingly, participants with 
potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or 
potassium-sparing diuretics more frequently had blood pressure < 140 mmHg in both cohorts. 
However, a different pattern in the two studies was observed for the CVD burden. Whereas CHD 
and a history of myocardial infarction in users of non-potassium-sparing diuretics were more prev-
alent in the ESTHER study, these CVDs were statistically significantly substantially less prevalent 
in the UK Biobank. 
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Table 23.  Baseline characteristics of users of non-potassium-sparing diuretics compared to users of potassium-sparing diuretics / combinations of 
non-potassium-sparing diuretics with potassium or potassium-sparing diuretics of the analysed participants with antihypertensive treat-
ment in the ESTHER study (Germany, baseline: 2000-2002) and the UK Biobank (UK, baseline: 2006-2010). 
 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Users of 
Non-potassium-
sparing diuretics  
(n = 455) 
Potassium-sparing diuretics or 
diuretics combinationsa  
(n = 442) 
 
 
Non-potassium-
sparing diuretics  
(n = 35,821) 
Potassium-sparing diuretics or 
diuretics combinationsa  
(n = 2,406) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
Age ≥ 65 years 58.2 55.0 0.324  38.8 40.4 0.112 
Sex (male) 43.7 37.1 0.043  42.8 41.0 0.074 
Smoking   0.054    < 0.001 
Never 52.6 55.4   49.5 45.6  
Former 37.2 30.6   42.1 43.9  
Current 10.1 14.0   8.5 10.5  
Vigorous physical activityb   0.976    < 0.001 
No  60.3 60.4   47.9 59.4  
Yes 39.7 39.6   52.1 40.6  
Alcohol consumptionc   0.880    < 0.001 
Abstainer 41.7 43.4   13.1 20.9  
WHO category I 54.5 53.0   61.5 56.5  
WHO category II/III 3.8 3.6   25.4 22.7  
SBP (mmHg)   0.013    < 0.001 
< 140 29.0 38.0   33.8 51.0  
140 to < 160 42.7 39.2   40.6 33.2  
≥ 160 28.3 22.8   25.6 15.8  
BMI (kg/m2)   0.479    < 0.001 
< 25 12.1 13.4   15.1 15.7  
25 to < 30 39.6 42.3   39.8 34.5  
≥ 30 48.4 44.3   45.1 49.9  
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 ESTHER (n = 4,253)  UK BIOBANK (n = 105,359) 
Users of 
Non-potassium-
sparing diuretics  
(n = 455) 
Potassium-sparing diuretics or 
diuretics combinationsa  
(n = 442) 
 
 
Non-potassium-
sparing diuretics  
(n = 35,821) 
Potassium-sparing diuretics or 
diuretics combinationsa  
(n = 2,406) 
 
Characteristics n [%] n [%] p-value  n [%] n [%] p-value 
Urinary albumin (mg/L)   0.002    0.124 
< 20 70.4 79.6   67.6 65.1  
≥ 20  29.6 20.4   32.4 34.9  
Diabetes mellitus 35.3 26.3 0.004  10.0 12.7 < 0.001 
Heart failured 31.5 25.4 0.046  N.A. N.A. N.A. 
CHD 35.2 27.2 0.010  10.1 24.0 < 0.001 
History of MI 17.2 13.4 0.119  5.1 15.5 < 0.001 
History of stroke 9.0 7.4 0.393  3.2 3.5 0.305 
Anticholinergic drug use 4.8 6.1 0.401  7.2 10.6 < 0.001 
Opioid use 1.3 1.8 0.553  10.7 17.1 < 0.001 
Laxatives use 11.7 11.1 0.791  4.7 7.8 < 0.001 
Bold printed: statistically significant (p < 0.05). 
a Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
b Vigorous physical activity was measured in hours per week (ESTHER study) and in the number of days per week of at least 10 min of activity (UK Biobank): “No”: Participants 
not doing any amount of vigorous physical activity, “Yes”: Participants doing any amount of vigorous physical activity. 
c Alcohol consumption in categories of the WHO: Category I including women with an alcohol consumption of 0-19.99 g/d or men with 0-39.99 g/d, category II including women 
with an alcohol consumption of 20-39.99 g/d or men with 40-59.99 g/d, and category III including women with an alcohol consumption of ≥ 40 g/d or men with ≥ 60 g/d. 
d Not sufficiently assessed in the UK Biobank (unreliable self-report) and therefore not applicable for use. 
 
BMI, body mass index; CHD, coronary heart disease; MI, myocardial infarction; N.A., not applicable; SBP, systolic blood pressure; UK, United Kingdom; WHO, World Health 
Organization. 
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3.2.2 Associations of laxatives and diuretics use with CVM in distinct analyses 
During a median follow-up time of 14 years, 476 cardiovascular deaths were observed in the  
ESTHER study (rate per 1,000 person-years: 8.7). In the UK Biobank, 1,616 cardiovascular deaths 
were observed during a median follow-up of 7 years (rate per 1,000 person-years: 2.2). Hazard 
ratios (HR) and 95%-confidence intervals (95%-CI) for the associations of laxatives and diuretics 
use with CVM are shown in Table 24. 
3.2.2.1 Laxatives 
In both studies, no statistically significantly increased CVM was observed in laxatives users com-
pared to non-users. The association of laxatives use and CVM was also not statistically significant 
when combining the results of both studies by random-effects model meta-analysis (HR [95%-CI]: 
1.13 [0.94; 1.36]). 
3.2.2.2 Diuretics 
I observed a statistically significantly increased CVM in users of diuretics overall in both studies. 
The corresponding pooled effect estimate revealed a 1.6-fold increased CVM of diuretics users 
compared to non-users, who used other antihypertensive drugs (HR [95%-CI]: 1.57 [1.29; 1.90]). 
Furthermore, there was a statistically significant association of non-potassium-sparing diuretics 
use and CVM in both studies and the pooled hazard ratio [95%-CI] was 1.39 [1.26; 1.53]. Results 
of the ESTHER study and UK Biobank diverged for users of potassium-sparing diuretics / combi-
nations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics and 
when pooling these results of both studies by random-effects model meta-analysis, the hazard ratio 
point estimate was not statistically significant (HR [95%-CI]: 1.84 [0.68; 4.96]). The strong, sta-
tistically significant association for this group in the UK Biobank (HR [95%-CI]: 3.03 [2.52; 3.64]) 
was based on both participants taking potassium-sparing diuretics only and participants using po-
tassium-sparing diuretics in combination with non-potassium-sparing diuretics (Table 25). Users 
of a combination of non-potassium-sparing diuretics and potassium had no statistically signifi-
cantly increased CVM (Table 25). 
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Table 24.  Associations with CVM comparing users and non-users of laxatives, diuretics overall, and diuretics in specific in the ESTHER study 
(Germany, baseline: 2000-2002, mean baseline age: 64 years, 14 years of mortality follow-up), in the UK Biobank (UK, baseline: 2006-
2010, mean baseline age: 62 years, 7 years of mortality follow-up) and in a meta-analysis of the two studies. 
Drug class ESTHER 
(n = 4,253; 476 cases) 
 
UK BIOBANK 
(n = 105,359 1,616 cases) 
 
META-ANALYSIS 
(n = 109,612; 2,092 cases) 
 na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Laxatives            
Non-users 3,890 433 Ref.  101,003 1,526 Ref.  104,893 1,959 Ref. 
Users 363 43 0.99 (0.70; 1.41)  4,356 90 1.19 (0.96; 1.48)  4,719 133 1.13 (0.94; 1.36) 
Diuretics overall            
Non-users 3,356 327 Ref.  67,132 887 Ref.  70,488 1,214 Ref. 
Users 897 149 1.39 (1.13; 1.70)  38,227 729 1.70 (1.53; 1.88)  39,124 878 1.57 (1.29; 1.90) 
Diuretics in specific            
Non-users 3,356 327 Ref.  67,132 887 Ref.  70,448 1,214 Ref. 
Users of non-potassium-sparing  
diuretics 
455 90 1.49 (1.17; 1.89)  35,821 597 1.37 (1.23; 1.52)  36,276 687 1.39 (1.26; 1.53) 
Users of potassium-sparing diuretics or 
combinationsd 
442 59 1.10 (0.83; 1.46)  2,406 132 3.03 (2.52; 3.64)  2,848 191 1.84 (0.68; 4.96) 
Bold printed: statistically significant (ρ < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. 
b Adjusted for age, sex, smoking status, physical activity, alcohol consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin ≥ 20 mg/L), 
diabetes mellitus, heart failure (in ESTHER study only), coronary heart disease, history of myocardial infarction, history of stroke, anticholinergic drug use, and use of opioids. 
c Results of the two studies combined by random-effects model meta-analysis. 
d Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
 
CI, confidence interval; CVM, cardiovascular mortality; HR, hazard ratio; Ref., reference; UK, United Kingdom.  
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Table 25.  Associations with CVM in users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or 
potassium-sparing diuretics compared to non-users of diuretics in the UK Biobank (UK, baseline: 2006-2010, mean baseline age: 62 years, 
7 years of mortality follow-up). 
Drug class UK BIOBANK 
(n = 105,359; 1,616 cases) 
 na ncasesb HR (95%-CI)c 
Non-users of diuretics 67,132 887 Ref. 
Users of potassium-sparing diuretics 490 26 2.76 (1.87; 4.07) 
Users of non-potassium-sparing diuretics combined with potassium-sparing diuretics 1,675 101 3.15 (2.56; 3.87) 
Users of non-potassium-sparing diuretics combined with potassium 241 5 1.51 (0.63; 3.62) 
Bold printed: statistically significant (p < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. 
b Case numbers do not add up to the total study case number (n=1,616) due to 597 cases within the users of non-potassium-sparing diuretics (not shown). 
c Adjusted for age, sex, smoking status, physical activity, alcohol consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin ≥ 20  mg/L), 
diabetes mellitus, coronary heart disease, history of myocardial infarction, history of stroke, anticholinergic drug use, and use of opioids. 
 
CI, confidence interval; CVM, cardiovascular mortality; HR, hazard ratio; Ref., reference; UK, United Kingdom. 
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3.2.2.3 Subgroup analyses 
I further assessed the aforementioned associations of laxatives and diuretics use with CVM in 
subgroups by age, sex, urinary albumin levels, CHD, and heart failure (Table 26). The subgroup 
analysis for heart failure was only carried out in the ESTHER study because of an insufficient 
heart failure assessment in the UK Biobank (unreliable self-reports). 
The lack of an association of laxatives use and CVM was also observed in all subgroups after 
pooling the two studies by meta-analyses. In analyses on diuretics, participants aged 65 and older 
as well as study participants with potential kidney damage (urinary albumin levels ≥ 20 mg/L) did 
not have substantially stronger associations of diuretics use and CVM. However, males, partici-
pants with CHD, and participants with heart failure had substantially stronger associations with 
CVM in all diuretics analyses with only one exception (sex-stratified analysis in the UK Biobank 
for users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with 
potassium or potassium-sparing diuretics). 
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Table 26.  Associations with CVM comparing users and non-users of laxatives, diuretics overall, and diuretics in specific assessed in subgroups by 
age, sex, urinary albumin levels and heart failure (the latter only in the ESTHER study). 
Users of laxatives compared to non-users of laxatives 
  
ESTHER 
(n = 4,253; ncases = 476) 
 
UK BIOBANK 
(n = 105,359; ncases = 1,616) 
 META-ANALYSIS 
(n = 109,612; ncases = 2,092) 
Characteristic Subgroup na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Age (years) < 65 2,229  126 0.94 (0.46; 1.92)  67,156  818 1.55 (1.16; 2.06)  69,385 944 1.35 (0.87; 2.09) 
 ≥ 65 2,024  350  0.97 (0.65; 1.46)  38,203  798 0.88 (0.63; 1.25)  40,227 1,148 0.92 (0.71; 1.19) 
Sex Female 2,336  207  0.93 (0.56; 1.52)  49,608  365 1.11 (0.77, 1.60)  51,944 572 1.04 (0.78; 1.40) 
 Male 1,917  269 1.09 (0.66; 1.78)  55,751  1,251 1.23 (0.93, 1.62)  57,668 1,520 1.20 (0.94; 1.52) 
Albumin (mg/L) < 20 3,328  316  1.02 (0.68; 1.54)  64,433  820  1.25 (0.90; 1.74)  67,761 1,136 1.15 (0.89; 1.49) 
 ≥ 20 925  160  0.90 (0.48; 1.69)  40,926  796 1.13 (0.80; 1.60)  41,851 956 1.07 (0.79; 1.45) 
CHD No  3,307 304 1.07 (0.70; 1.64)  87,731 967 1.23 (0.91; 1.66)  91,038 1,271 1.17 (0.92; 1.50) 
 Yes 946 172 0.82 (0.47; 1.45)  17,628 649 1.17 (0.84; 1.62)  18,574 821 1.06 (0.77; 1.45) 
Heart failure No 3,489 326 1.07 (0.71; 1.61)  - - -  - - - 
 Yes 764 150 0.83 (0.46; 1.49)  - - -  - - - 
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Table 26 continued, page 2/4 
Users of diuretics overall compared to non-users of diuretics 
  
ESTHER 
(n = 4,253; ncases = 476) 
 
UK BIOBANK 
(n = 105,359; ncases = 1,616) 
 
META-ANALYSIS 
(n = 109,612; ncases = 2,092) 
Characteristic Subgroup na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Age (years) < 65 2,229  126 1.52 (1.01; 2.29)  67,156  818 1.69 (1.46; 1.95)  69,385 944 1.67 (1.46; 1.91) 
 ≥ 65 2,024 350  1.38 (1.09; 1.75)   38,203  798 1.71 (1.48; 1.97)  40,227 1,148 1.57 (1.28; 1.93) 
Sex Female 2,336  207  1.20 (0.88; 1.64)  49,608  365 1.34 (1.09; 1.66)  51,944 572 1.29 (1.09; 1.54) 
 Male 1,917  269 1.55 (1.18; 2.03)  55,751  1,251 1.84 (1.64; 2.07)  57,668 1,520 1.77 (1.53; 2.04) 
Albumin (mg/L) < 20 3,328  316  1.33 (1.03; 1.72)  64,433  820 1.68 (1.41; 2.00)  67,761 1,136 1.52 (1.22; 1.91) 
 ≥ 20 925  160  1.53 (1.08; 2.17)  40,926  796 1.72 (1.46; 2.03)  41,851 956 1.68 (1.45; 1.95) 
CHD No 3,307 304 1.11 (0.84; 1.46)  87,731 967 1.33 (1.17; 1.51)  91,038 1,271 1.27 (1.09; 1.48) 
 Yes 946 172 1.85 (1.36; 2.54)  17,628 649 2.53 (2.15; 2.98)  18,574 821 2.23 (1.65; 3.01) 
Heart failure No 3,489 326 1.08 (0.82; 1.41)  - - -  - - - 
 Yes 764 150 2.15 (1.53; 3.02)  - - -  - - - 
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Table 26 continued, page 3/4 
Users of non-potassium-sparing diuretics compared to non-users of diuretics 
  
ESTHER 
(n = 3,811; ncases = 417) 
 
UK BIOBANK 
(n = 102,953; ncases = 1,484) 
 META-ANALYSIS 
(n = 106,764; ncases = 1,901) 
Characteristic Subgroup na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Age (years) < 65 2,030  115  2.01 (1.24; 3.24)  65,722  752  1.48 (1.27; 1.72)  67,752 867 1.58 (1.24; 2.02) 
 ≥ 65 1,781  302  1.48 (1.11; 1.97)  37,231  732 1.53 (1.32; 1.78)  39,012 1,034 1.52 (1.33; 1.74) 
Sex Female 2,058 182  1.46 (1.00; 2.12)  48,188  339  1.26 (1.02; 1.57)  50,246 521 1.31 (1.08; 1.58) 
 Male 1,753 235  1.63 (1.17; 2.28)  54,765  1,145  1.61 (1.42; 1.82)  56,518 1,380 1.61 (1.44; 1.81) 
Albumin (mg/L) < 20 2,977 272 1.47 (1.07; 2.03)  62,978  750  1.47 (1.22; 1.76)  65,955 1,022 1.47 (1.25; 1.72) 
 ≥ 20 834 145  1.84 (1.24; 2.73)  39,975  734  1.55 (1.30; 1.84)  40,809 879 1.59 (1.36; 1.87) 
CHD No 2,985 270 1.15 (0.81; 1.64)  85,895 908 1.21 (1.06; 1.39)  88,880 1,178 1.20 (1.06; 1.36) 
 Yes 826 147 2.27 (1.58; 3.27)  17,058 576 2.22 (1.87; 2.65)  17,884 723 2.23 (1.91; 2.61) 
Heart failure No 3,161 294 1.14 (0.80; 1.61)  - - -  - - - 
 Yes 650 123 2.60 (1.76; 3.84)  - - -  - - - 
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Table 26 continued, page 4/4 
Users of potassium-sparing diuretics or diuretics combinationsd compared to non-users of diuretics 
  
ESTHER 
(n = 3,798; ncases = 386) 
 
UK BIOBANK 
(n = 69,538; ncases = 1,019) 
 META-ANALYSIS 
(n = 73,336; ncases = 1,405) 
Characteristic Subgroup na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Age (years) < 65 2,039  103 1.03 (0.54; 1.95)  45,221  532 3.68 (2.82; 4.82)  47,260 635 2.02 (0.58; 7.01) 
 ≥ 65 1,759 283 1.24 (0.90; 1.72)  24,317  487  3.51 (2.67; 4.60)  26,076 770 2.09 (0.76; 5.81) 
Sex Female 2,080 167  0.92 (0.59; 1.43)  29,134  203 2.22 (1.45; 3.39)  31,214 370 1.43 (0.60; 3.40) 
 Male 1,718 219  1.47 (1.01; 2.14)  40,404  816  1.40 (1.10; 1.78)  42,122 1,035 1.42 (1.16; 1.74) 
Albumin (mg/L) < 20 3,007 264  1.16 (0.83; 1.63)  42,145  530  3.91 (2.95; 5.19)  45,152 794 2.14 (0.65; 7.03) 
 ≥ 20 791 122  1.13 (0.65; 1.96)  27,393  489  3.37 (2.52; 4.51)  28,184 611 2.00 (0.69; 5.84) 
CHD No 3,012 262 1.03 (0.71; 1.50)  55,521 593 3.28 (2.49; 4.33)  58,533 855 1.85 (0.60; 5.76) 
 Yes 786 124 1.39 (0.88; 2.18)  14,017 426 3.95 (3.02; 5.18)  14,803 550 2.38 (0.86; 6.63) 
Heart failure No 3,178 285 1.01 (0.70; 1.46)  - - -  - - - 
 Yes 620 101 1.61 (1.00; 2.59)  - - -  - - - 
Bold printed: statistically significant (ρ < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. 
b Adjusted for age, sex, smoking status, physical activity, alcohol consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin 
≥ 20 mg/L), diabetes mellitus, heart failure (in ESTHER study only), coronary heart disease, history of myocardial infarction, history of stroke, anticholinergic drug 
use, and use of opioids. 
c Results of the two studies combined by random-effects model meta-analysis. 
d Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
 
CHD, coronary heart disease; CI, confidence interval; CVM, cardiovascular mortality; HR, hazard ratio. 
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3.2.3 Association of laxatives and diuretics use with CVM in joint analyses  
Figure 8 provides a flow diagram showing the categorization of the study participants into six 
mutually exclusive treatment groups of possible combinations of non-potassium-sparing diuretics, 
potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or 
potassium-sparing diuretics, and laxatives. Concurrent use of non-potassium-sparing diuretics and 
laxatives was comparably rare in both cohorts (56 participants (1.3 %) in the ESTHER study and 
1,709 participants (1.6 %) in the UK Biobank). 
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Figure 8.  Flow chart showing the categorization of the study participants into six mutually exclusive treatment groups within the ESTHER study 
and the UK Biobank. 
Any antihypertensive drug
(3) Non-potassium-sparing diuretics 
and no laxatives
Any diuretics and no laxativesAny diuretics and laxatives (5) No diuretics and laxatives (6) No diuretics and no laxatives
ESTHER: n = 389 (9.1 %)
UK BIOBANK: n = 2,217 (2.1 %)
(4) Potassium-sparing diuretics or 
combinations of non-potassium-
sparing diuretics with potassium or 
potassium-sparing diuretics 
and no laxatives
(1) Non-potassium-sparing diuretics 
and laxatives
(2) Potassium-sparing diuretics or 
combinations of non-potassium-
sparing diuretics with potassium or 
potassium-sparing diuretics 
and laxatives
ESTHER: n = 4,253
UK BIOBANK: n = 105,359 
ESTHER: n = 399 (9.4 %)
UK BIOBANK: n = 34,112 (32.4 %)
ESTHER: n = 788 (18.5 %)
UK BIOBANK: n = 36,329 (34.5 %)
ESTHER: n = 254 (6.0 %)
UK BIOBANK: n = 2,458 (2.3 %) 
ESTHER: n = 3,102 (72.9 %)
UK BIOBANK: n = 64,674 (61.4 %)
ESTHER: n = 109 (2.6 %)
UK BIOBANK: n = 1,898 (1.8 %)
ESTHER: n = 56 (1.3 %)
UK BIOBANK: n = 1,709 (1.6 %) 
ESTHER: n = 53 (1.2 %)
UK BIOBANK: n = 189 (0.2 %)
98  3 ORIGINAL STUDY 
 
The associations of the comparisons between the mutually exclusive treatment groups with CVM, 
using study participants taking neither diuretics nor laxatives (group 6) as the control group, are 
presented in Table 27. 
Concurrent users of non-potassium-sparing diuretics and laxatives had a higher CVM in both stud-
ies (HR [95%-CI] for meta-analysis: 2.05 [1.55; 2.71]) than those who only used non-potassium-
sparing diuretics (HR [95%-CI] for meta-analysis: 1.50 [1.36; 1.66]), which speaks for a drug-
drug interaction. However, the difference between these groups was not statistically significant. 
Similarly, a test for interaction of the variables “non-potassium-sparing diuretics use” and “laxa-
tives use” was not statistically significant either (β, p for meta-analysis: +0.718, 0.075) but not far 
from the cut-off for statistical significance (p=0.05). 
Additional laxatives use of participants taking potassium-sparing diuretics / combinations of non-
potassium-sparing diuretics with potassium or potassium-sparing diuretics resulted in lower CVM 
(HR [95%-CI] for meta-analysis: 1.43 [0.33; 6.22]) than no additional laxatives use (HR [95%-CI] 
for meta-analysis: 2.19 [0.79; 6.08]). Although confidence intervals overlapped widely, the 
p-value for an interaction test was again not far from a statistically significant finding (β, p for 
meta-analysis: -0.580, 0.076).  
The different directions of the β-coefficients for the two interaction terms are biologically plausible 
because they suggest an additional risk by comparing laxatives and non-potassium-sparing diuret-
ics and a protective effect by comparing laxatives and potassium-sparing diuretics / combinations 
of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. In the latter 
group, the hypokalemic effects of laxatives may counteract diuretic-induced hyperkalemia. 
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Table 27.  Associations with CVM in mutually exclusive treatment groups in the ESTHER study (Germany, baseline: 2000-2002, mean age: 64 
years) and the UK Biobank (UK, baseline: 2006-2010, mean age: 62 years). 
 ESTHER 
(n = 4,253; 476 cases) 
 UK BIOBANK 
(n = 105,359; 1,616 cases) 
 META-ANALYSIS 
(n = 109,612; 2,092 cases) 
Treatment group na ncases (%) HR (95%-CI)b  na ncases (%) HR (95%-CI)b  na ncases (%) HR (95%-CI)c 
Non-potassium-sparing  
diuretics and laxatives 
56 15 (26.8) 2.26 (1.31; 3.90)  1,709 39 (2.3) 1.98 (1.43; 2.75)  1,765 54 (3.1) 2.05 (1.55; 2.71) 
Non-potassium-sparing  
diuretics and no laxatives 
399 75 (18.8) 1.44 (1.10; 1.87)  34,112 558 (1.6) 1.51 (1.35; 1.68)  34,511 633 (1.8) 1.50 (1.36; 1.66) 
Potassium-sparing diuretics or 
combinationsd and laxatives 
53 3 (5.7) 0.59 (0.15; 2.33)  189 9 (4.8) 2.70 (1.39; 5.23)  242 12 (5.0) 1.43 (0.33; 6.22) 
Potassium-sparing diuretics or 
combinationsd and no laxatives 
389 56 (14.4) 1.29 (0.95; 1.75)  2,217 123 (5.6) 3.66 (3.01; 4.44)  2,606 179 (6.9) 2.19 (0.79; 6.08) 
No diuretics and laxatives 254 25 (9.8) 0.93 (0.61; 1.42)  2,458 42 (1.7) 1.15 (0.84; 1.58)  2,712 67 (2.5) 1.07 (0.83; 1.37) 
No diuretics and no laxatives 3,102 302 (9.7) Ref.  64,674 845 (1.3) Ref.  67,776 1,147 (1.7) Ref. 
Bold printed: statistically significant (ρ < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. 
b Adjusted for age, sex, smoking status, physical activity, alcohol consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin ≥ 20 mg/L), 
diabetes mellitus, heart failure (in ESTHER study, only), coronary heart disease, history of myocardial infarction, history of stroke, anticholinergic drug use, and use of opioids. 
c Results of the two studies combined by random-effects model meta-analysis. 
d Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
 
CI, confidence interval; CVM, cardiovascular mortality; HR, hazard ratio; Ref.; reference; UK, United Kingdom. 
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3.2.4 Sensitivity analyses 
In a sensitivity analysis using only data from the first 7 years of follow-up of the ESTHER study, 
the effect estimates were comparable or slightly stronger than those from the analysis with the 
complete follow-up time of 14 years (Table 28). 
In a further sensitivity analysis, the Cox models for distinct analyses of laxatives and diuretics 
were adjusted for a propensity score (propensity to use drug class of interest), but results did not 
change substantially (Table 29). Methods, results, and discussion of the sensitivity analysis using 
propensity scores are presented in greater detail in chapter 3.3 (Excursus: Propensity scores). 
 
Results 101 
 
Table 28.  Associations with CVM comparing users and non-users of laxatives, diuretics overall, and diuretics in specific in the ESTHER study using 
only the first 7 years of follow-up or the complete follow-up of 14 years. 
Drug class ESTHER (7 years of FUP) 
(n = 4,253; 169 cases) 
 
ESTHER (14 years of FUP)  
(n = 4,253; 476 cases) 
 na ncases HR (95%-CI)b  na ncases HR (95%-CI)b 
Laxatives        
Non-users 3,890 153 Ref.  3,890 433 Ref. 
Users 363 16 1.09 (0.64; 1.87)  363 43 0.99 (0.70; 1.41) 
Diuretics overall        
Non-users 3,356 109 Ref.  3,356 327 Ref. 
Users 897 60 1.45 (1.06; 2.06)  897 149 1.39 (1.13; 1.70) 
Diuretics in specific        
Non-users 3,356 109 Ref.  3,356 327 Ref. 
Users of non-potassium-sparing diuretics 455 40 1.75 (1.21; 2.53)  455 90 1.49 (1.17; 1.89) 
Users of potassium-sparing diuretics or combinationsc 442 20 0.96 (0.59; 1.54)  442 59 1.10 (0.83; 1.46) 
Bold printed: statistically significant (p < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. 
b Adjusted for age, sex, smoking status, physical activity, alcohol consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin ≥ 20 mg/L), 
diabetes mellitus, heart failure, coronary heart disease, history of myocardial infarction, history of stroke, anticholinergic drug use, and use of opioids.  
c Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
 
CI, confidence interval; CVM, cardiovascular mortality; FUP, follow-up; HR, hazard ratio; Ref.; reference. 
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3.3 Excursus: Propensity scores 
Before presenting the methods, results, and discussion of the sensitivity analysis using propensity 
scores, this chapter briefly provides an introduction to propensity scores. 
3.3.1 Introduction to propensity scores 
3.3.1.1 Aiming for internal validity in observational studies (i.e., to avoid confounding) 
There is widespread agreement in medical research that treatment efficacy and more generally 
causality should be tested primarily in randomised controlled trials. A reason is that only random-
isation guarantees an even distribution of all known and unknown patient characteristics between 
a treatment group and a control group, and thus allows causal statements about treatment effects 
(Kuss et al., 2016). 
Although randomised controlled trials are the gold standard to assess causality, they are in some 
instances “unnecessary, inappropriate, impossible or inadequate” (Black, 1996, p. 1), such as when 
assessing the effect of smoking on lung cancer or mortality. Moreover, lack of external validity 
(generalisability) is a major criticism of randomised controlled trials, as the patients included often 
do not represent the average patient regarding age and health (McKee et al., 1999; Rothwell, 2005). 
Therefore, observational studies may present an important alternative in specific research settings, 
such as in a study population of elderly or children, or when investigating a potential risk factor. 
Nevertheless, observational studies have the problem of missing internal validity. This means that, 
instead of randomly, physicians variably select treatment with regard to the individual patient 
characteristics. Consequently, treatment and control group can be systematically different with 
regard to their baseline characteristics (Kuss et al., 2016). 
Given that these systematically different characteristics do not only influence the decision for 
treatment but also increase the risk of experiencing the outcome, this is where confounding comes 
into play. Consequently, a characteristic or covariate is then considered a confounder if it is asso-
ciated with both the treatment and the outcome. Therefore, the relationship between treatment and 
outcome is not independent, and is finally mixed up by these confounding factors. Due to con-
founding, “the observed effect measure will differ from the true causal effect measure of the treat-
ment” (Kurth and Seeger, 2008, p. 2). 
According to Kurth and Seeger, confounding is often graphically presented as a triangle with each 
corner representing one variable (treatment, outcome, and confounder) (Figure 9). The association 
3.3 Excursus: Propensity scores 103 
 
of interest (treatment and outcome) is shown as the arrow representing the base of the triangle, 
whereas other associations, such as confounder to treatment or confounder to outcome, are pre-
sented by the two other sides (arrows) of the triangle (Kurth and Seeger, 2008, p. 2). 
 
Figure 9.  Confounding in observational studies illustrated as a triangle with each corner repre-
senting a variable, namely treatment, outcome, and confounder. 
Although challenged by confounding, the congruence of findings in randomised controlled trials 
and observational studies is one major goal in epidemiologic research (Williamson and Forbes, 
2014). To accomplish this aim, design and analytic techniques that create balance among charac-
teristics of the treatment and control group at baseline are of extraordinary importance in order to 
remove confounding as far as possible (Weinberg, 1993). For this purpose, analyses in real-world 
data could be restricted, adjusted, matched, stratified or weighted on a small number of variables 
(Norgaard et al., 2017). Graphically spoken, these techniques address confounding by aiming to 
remove the confounder–treatment arrow in observational settings (Williamson and Forbes, 2014). 
However, if the number of potential confounders is large, this becomes nearly impossible. The 
reason is that methods, such as restriction, regression adjustment, matching, stratification or 
weighting, can only handle a restricted number of covariates per outcome to be included in the 
analysis (Harrell et al., 1984; Harrell et al., 1996). To address this issue, methods have been sug-
gested that combine multiple covariates into one variable, such as comorbidity scores summarizing 
several comorbidities into one score (Schneeweiss et al., 2001). Another such technique is the 
propensity score, which collapses multiple confounders associated with the treatment into a single 
score. 
3.3.1.2 Definition and estimation of a propensity score 
A patient’s propensity to be treated (propensity score) is defined as his/her predicted probability 
to receive the treatment of interest with respect to his/her available baseline characteristics (Ros-
enbaum and Rubin, 1983). This consequently means that the propensity score is a number ranging 
from 0 to 1, inclusively. While a patient’s probability to receive the treatment in a 1:1 randomised 
controlled trial is 0.5, this probability remains unknown in an observational non-randomised study 
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in which the probability to be treated depends on a patient’s individual characteristics (Kuss et al., 
2016). These baseline characteristics, however, can be collapsed into one new variable, the pro-
pensity score, by using a logistic regression model with the exposure variable (treatment) as de-
pendent variable and the available baseline variables (possible confounders) as independent ex-
planatory variables. 
When building a propensity score model, the first step involves the selection of variables to be 
included in the propensity score. The model should preferably include variables that represent 
indications or contraindications for the treatment, risk factors for the outcome, most common di-
agnosis and procedures, as well as drugs with the potential to predict treatment (Kurth and Seeger, 
2008). Variable selection for propensity score estimation should focus on characteristics which 
influence the outcome rather than the exposure, because this decreases the variance of an estimated 
exposure effect without increasing bias (Brookhart et al., 2006). Consequently, this means that 
variables included should be associated with the outcome or both the exposure and the outcome. 
If, however, a variable is a strong predictor of only the exposure, this might result in a loss of 
efficiency, and thus should be avoided (Kurth and Seeger, 2008). The propensity score, of course, 
can only be estimated from measured baseline variables. As a consequence, confounding by un-
measured factors (so-called residual confounding) will not be removed by use of propensity score 
techniques. 
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3.3.1.3 Methods to use with propensity scores 
After estimating the propensity score (propensity for treatment) as a function of covariates in a 
first step, it is then used to account for treatment selection in a second step. For this purpose, four 
methods are available: matching, stratification, regression adjustment, and weighted regression 
adjustment. 
Matching on the propensity score 
In propensity score matching, each treated patient is assigned one (“one-to-one matching”) un-
treated patient or several (“one-to-many matching”) untreated patients with the same propensity 
score or with a propensity score that deviates only minimally within predefined limits. The 
matched population is then used to estimate the treatment effect taking into account the matching 
(Austin, 2009). Propensity score matching is most often and preferably used as it is quite intuitive 
and comprehensible. For instance, balancing of covariates becomes obvious, when baseline char-
acteristics of the treatment and control group are being compared before and after matching in a 
descriptive table that resembles the typical Table 1 of a randomised controlled study (Austin, 
2013). A disadvantage of matching is, that the sample size might be substantially reduced because 
unmatched participants are being excluded (Kurth and Seeger, 2008). 
Stratification on the propensity score 
Stratification on the propensity score can be seen as a coarser propensity score matching, because 
participants are grouped into subsets according to their propensity score (Austin, 2011). Then, the 
entire population is ranked by the propensity score and divided into equal parts, preferably into 
quintiles as proposed by Rosenbaum and Rubin (Rosenbaum and Rubin, 1984), because the use 
of five strata has shown to remove 90 % of the bias for most continuous distributions (Cochran, 
1968). In each of these parts, a treatment effect is estimated by using conventional methods to 
compare outcomes between treated and untreated participants. The resulting treatment effects are 
then summarised into an overall effect using meta-analytical approaches (Austin, 2011). In con-
trast to matching, stratification on the propensity score does not exclude unmatched participants 
from the analyses, but uses all study participants to estimate the treatment effect (Kurth and Seeger, 
2008). 
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Regression adjustment 
Covariate adjustment using the propensity score involves the calculation of a conventional regres-
sion model with the outcome variable of interest used as the dependent variable and the treatment 
effect and the propensity score used as the independent variables. The association of treatment and 
outcome variable is thereby adjusted for the propensity score and thus for all baseline patient char-
acteristics included in the propensity score (Stuart et al., 2009). It is therefore important “to model 
the association between the propensity score and the outcome correctly” (Kurth and Seeger, 2008, 
p. 7) by carefully selecting all important variables to estimate the propensity score. Regression 
adjustment has the advantage that all participants can be included in the analyses, and that many 
researchers are quite familiar with this approach. “On the other hand, regression adjustment is less 
intuitive as matching or stratification, and is prone to error through misspecifying the association 
between the propensity score and the outcome in the model in which the treatment effect is esti-
mated” (Kurth and Seeger, 2008, p. 7). 
Weighted regression adjustment based on the propensity score 
Inverse probability of treatment weighting (IPTW) using the propensity score (PS) involves that 
each patient is assigned the inverse of the probability of receiving their actual treatment as a sta-
tistical weight. A treated patient receives the weight 1/PS, an untreated patient the weight 1/ (1-PS). 
This means that a treated patient with a low propensity score (for treatment) receives a high weight, 
because he/she resembles the untreated patients in terms of their characteristics (expressed by their 
low propensity score) and therefore enables a valid comparison with these. Treatment effects are 
then evaluated using participants according to their statistical weights (Austin, 2011). Neverthe-
less, the IPTW approach causes difficulties when some treated participants have very low propen-
sity scores (low propensity to receive treatment, but treated) and some untreated participants, in 
turn, have very high propensity scores (high propensity to receive treatment, but untreated). These 
participants from the so-called tails of the propensity scores distribution receive extremely high 
weights due to inverse probability weighting. In case that the risk to experience the outcome is 
significantly different for those participants in the tails, this will highly influence the treatment 
effect in the total cohort (Kurth and Seeger, 2008). While the weighting method comes along with 
the advantage that the total study population can be used to estimate the treatment effect, it is less 
intuitive than other approaches, such as matching or stratification. 
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3.3.2 Methods of the sensitivity analysis using propensity scores 
3.3.2.1 Variable selection 
In addition to the basic covariates, age and sex, my variable selection to build the propensity score 
model included smoking status, physical activity, alcohol consumption, systolic blood pressure, 
BMI, potential kidney damage (urinary albumin ≥ 20 mg/L), diabetes mellitus, heart failure (in the 
ESTHER study only), CHD, history of myocardial infarction, history of stroke, anticholinergic 
drug use, and use of opioids. Age and systolic blood pressure were modelled continuously and all 
other co-variables with the categorizations shown in Table 19. In brief, the propensity score model 
included the same variables as the Cox regression models in the main analyses. 
3.3.2.2 Regression adjustment for the propensity score 
Once the propensity scores had been estimated, I applied the approach of regression adjustment 
for the propensity score in order to estimate the treatment effects with respect to CVM for the 
following three user groups of: 
 Laxatives 
 Diuretics overall 
 Non-potassium-sparing diuretics in specific 
 Potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potas-
sium or potassium-sparing diuretics 
Although adjusting for the propensity score is less intuitive than matching, for instance, I decided 
in favour of this approach in order to avoid exclusions due to un-matched participants, which 
would have resulted in a reduced sample size. Given the partly already small group sizes of the 
drug user groups, matching on the propensity score would have caused a substantial loss of statis-
tical power. Therefore, I used regression adjustment in the context of a sensitivity analysis. 
3.3.3 Results of the sensitivity analysis using propensity scores 
The results of the sensitivity analysis using regression adjustment for a propensity score are shown 
in Table 29. Both statistical significance and magnitude of the hazard ratios (HR) and the confi-
dence intervals (CI) did not substantially change, when compared to the main analysis using Cox 
regression with adjustment for all potential confounders as separate variables (Table 24). Again, 
laxatives use was not associated with CVM (HR [95%-CI] for meta-analysis: 1.04 [0.74; 1.46]), 
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while use of diuretics overall and the use of non-potassium-sparing diuretics in specific again 
showed 1.6-fold (HR [95%-CI] for meta-analysis: 1.58 [1.19; 2.09]), and 1.5-fold (HR [95%-CI] 
for meta-analysis: 1.46 [1.32; 1.61]) increased CVM, respectively. The group of users of potas-
sium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or po-
tassium-sparing diuretics showed the same pattern of association as observed in the Cox regres-
sion: no statistically significantly increased CVM in the users of the ESTHER study, a significantly 
3-fold increased CVM in the users of the UK Biobank, and no significantly increased estimate in 
the meta-analysis of the two studies. 
3.3.4 Discussion of the sensitivity analysis using propensity scores 
The fact that both approaches, traditional Cox regression and regression adjustment for a propen-
sity score, yielded similar results is not surprising, because the logistic regression model to esti-
mate the propensity score used exactly the same variables as were used for covariate adjustment 
in the Cox regression. Therefore, the propensity score approach could not manage to remove more 
confounding than the traditional Cox model did. Given the small number of only 15 covariates for 
the ESTHER study and 14 covariates for the UK Biobank that were collapsed into the propensity 
score, it becomes obvious that variable selection was not at its maximum. Unfortunately, the extent 
to enlarge variable selection was restricted by the fact that only a limited set of diseases and disease 
risk factors was assessed in the UK Biobank and the ESTHER study, and there were no more 
eligible variables that were assessed in both studies. For example, other important variables, such 
as NYHA grade to evaluate the severity of heart failure had not been assessed in both studies, and 
were therefore not available for a propensity score estimation. 
Inclusion of further baseline covariates into the propensity score might have removed confound-
ing to a larger extent. As a result, this would have yielded weaker effect size estimates than the 
traditional Cox regression with a limited set of adjusting factors. Nevertheless, I am confident 
that the major potential confounders were adjusted for in the main analyses and that this limita-
tion of the data sources led only to a small overestimation of treatment effects and did not sub-
stantially bias the results of the analyses.
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Table 29.  Associations with CVM comparing users and non-users of laxatives, diuretics overall, and diuretics in specific in the ESTHER study 
(Germany, baseline: 2000-2002, mean baseline age: 64 years, 14 years of mortality follow-up), in the UK Biobank (UK, baseline: 2006-
2010, mean baseline age: 62 years, 7 years of mortality follow-up) by use of propensity scores, and in a meta-analysis of the two studies 
Drug class ESTHER 
(n = 4,253; 476 cases) 
 
UK BIOBANK 
(n = 105,359 1,616 cases) 
 
META-ANALYSIS 
(n = 109,612; 2,092 cases) 
 na ncases HR (95%-CI)b  na ncases HR (95%-CI)b  na ncases HR (95%-CI)c 
Laxatives            
Non-users 3,890 433 Ref.  101,003 1,526 Ref.  104,893 1,959 Ref. 
Users 363 43 0.85 (0.61; 1.20)  4,356 90 1.21 (0.97; 1.51)  4,719 133 1.04 (0.74; 1.46) 
Diuretics overall            
Non-users 3,356 327 Ref.  67,132 887 Ref.  70,488 1,214 Ref. 
Users 897 149 1.34 (1.08; 1.68)  38,227 729 1.79 (1.61; 1.98)  39,124 878 1.58 (1.19; 2.09) 
Diuretics in specific            
Non-users 3,356 327 Ref.  67,132 887 Ref.  70,448 1,214 Ref. 
Users of non-potassium-sparing  
diuretics 
455 90 1.56 (1.19; 2.04)  35,821 597 1.44 (1.29; 1.60)  36,276 687 1.46 (1.32; 1.61) 
Users of potassium-sparing diuretics or 
combinationsd 
442 59 1.02 (0.75; 1.38)  2,406 132 3.15 (2.61; 3.81)  2,848 191 1.80 (0.60; 5.45) 
Bold printed: statistically significant (ρ < 0.05). 
a Sample sizes exemplarily taken from imputed data set no. 1. b Adjusted for a propensity score created based on the variables age, sex, smoking status, physical activity, alcohol 
consumption, systolic blood pressure, body mass index, potential kidney damage (urinary albumin ≥ 20 mg/L), diabetes mellitus, heart failure (in ESTHER study, only), coronary 
heart disease, history of myocardial infarction, history of stroke, anticholinergic drug use, and use of opioids. c Results of the two studies combined by random-effects model meta-
analysis. d Group comprises users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-sparing diuretics. 
 
CI, confidence interval; CVM, cardiovascular mortality; HR, hazard ratio; Ref.; reference; UK, United Kingdom. 
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3.4 Discussion 
3.4.1 Summary of the findings 
In this meta-analysis of elderly users of antihypertensive drugs from two large cohort studies, the 
use of diuretics overall, but not regular use of laxatives, was associated with CVM. Subgroup 
analyses suggested a particularly strongly increased CVM in users of diuretics overall who were 
male, had CHD or heart failure. There were no statistically significant differences among the spe-
cific diuretics classes in the results of the meta-analyses. However, signs for a potential drug-drug 
interaction of non-potassium-sparing diuretics and concurrent regular laxatives use were observed 
but tests for interaction did not reach statistical significance. 
3.4.2 Association of laxatives use with CVM  
This is the first observational study on cardiovascular risk of regular laxatives use in a European 
population. Regular laxatives use was not associated with CVM in any of the analyses. This did 
not support my hypothesis that hypokalemia by regular laxatives use (Kokot and Hyla-Klekot, 
2008; Xing and Soffer, 2001) may result in an increased risk for CVM as a consequence of ven-
tricular arrhythmias, for instance (Faggioni and Knollmann, 2015; John et al., 2012). One reason 
for the observed null association might be that most laxatives users had taken laxatives for a long 
time and tolerated them well without developing arrhythmias (prevalent users). Individuals with 
very high laxatives use, who are prone to arrhythmias, may have died before the study initiation. 
This phenomenon known as healthy-user/sick-stopper bias is common in studies with a prevalent 
user design (Ray, 2003) and may have biased my result towards a null association. A second ex-
planation may be that discontinuation of laxatives use could have happened during follow-up. 
Those study participants, however, remained assigned to the user group in my analysis and could 
have attenuated the effect estimate for the exposure group. The only other comparable cohort study 
investigating laxatives use and CVM also used a single assessment of laxatives at baseline only. 
This study from Japan observed statistically significantly increased associations with CHD mor-
tality and ischemic stroke mortality in men and women (Kubota et al., 2016). Besides different 
outcomes, the ethnic difference as well as the younger (age-range: 40-79 years) and healthier (free 
of history of CVD and cancer) population of the Japanese study may explain the different results. 
Therefore, more studies on laxatives use and CVM are needed to elucidate the divergent findings. 
These studies should have a new user design (with start of follow-up at the first initiation of drug 
exposure) and include repeated assessments of laxatives use. 
3.4 Discussion 111 
 
3.4.3 Association of diuretics use with CVM  
With respect to non-potassium-sparing diuretics, I observed a 1.4-fold increased CVM in the meta-
analysis of the results from the two studies. This is in line with the results of Cooper and colleagues 
(population: patients with left ventricular dysfunction; outcome: arrhythmic death) (Cooper et al., 
1999), Ahmed A. and colleagues (population: Heart failure patients; outcome: long-term mortal-
ity) (Ahmed et al., 2006) and Alharbi and colleagues (population: Cases with cardiac arrest and 
controls from the general population; outcome: cardiac arrest) (Alharbi et al., 2017). Interestingly, 
the latter study observed a comparably increased risk (about 40 %) of cardiac arrest for individuals 
receiving non-potassium-sparing diuretics. In addition, this hazard ratio point estimate was not 
higher than for individuals using a combination of antihypertensives with hypo- and hyperkalemic 
effects. I observed a similar pattern, when comparing users of non-potassium-sparing diuretics and 
users of potassium-sparing diuretics / combinations of non-potassium-sparing diuretics with po-
tassium or potassium-sparing diuretics. 
However, a network meta-analysis of clinical trials did not show higher cardiovascular risks of 
low-dose diuretics as first-line antihypertensive treatment compared to β-blockers, ACE inhibitors, 
calcium channel blockers, alpha-blockers, and ARBs; rather the opposite was observed (Psaty et 
al., 2003). 
The divergent results can have several reasons: the efficacy-effectiveness gap of clinical trials 
(Amler et al., 2015), non-comparable study populations or an insufficient control of confounding 
in observational studies. The last point is supported by the fact that my analyses were limited by 
insufficient control for confounders, such as heart failure and CHD, both presenting a higher base-
line cardiovascular risk for the affected patients. In practice, diuretics are often prescribed in com-
bination with other antihypertensive drug classes for patients with high cardiovascular risk or a 
blood pressure that cannot be controlled by one agent (Williams et al., 2018). An intensive blood 
pressure control with two or more antihypertensive drugs is particularly important in individuals 
with a history of myocardial infarction or other cardiovascular events (Wang et al., 2018; Williams 
et al., 2018). In addition, loop diuretics are most often used as part of the guideline-treatment in 
symptomatic heart failure patients (New York Heart Association (NYHA) class II to IV) (Poni-
kowski et al., 2016). Therefore, it was not surprising that diuretics users more frequently had heart 
failure, CHD and histories of myocardial infarction and stroke compared to non-users (Table 22). 
A better adjustment for heart failure and CHD would have been desirable, but NYHA classification 
and CHD severity were not available in both the UK Biobank and the ESTHER study. Therefore, 
the particularly strongly increased CVM in diuretics users with CHD or heart failure should be 
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interpreted with caution. This strong association might be rather due to the fact that individuals 
receiving diuretics probably had more severe stages of CHD or heart failure than non-users. Con-
sequently, further observational studies are needed with more detailed information on these two 
diseases. 
Confounding by indication for severe stages of CHD or heart failure may also explain some other 
findings. First, both heart diseases were more prevalent in males than females (data not shown), 
which can explain the observed stronger associations in all analyses for male diuretics users than 
female users. Second, a 3-fold CVM was detected in the UK Biobank for users of potassium-
sparing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-
sparing diuretics. Analyses in the UK Biobank showed that users of these diuretics frequently had 
a CHD and a previous myocardial infarction but lower systolic blood pressure than users of non-
potassium-sparing diuretics only (Table 23). According to the guideline for the management of 
arterial hypertension (Wang et al., 2018; Williams et al., 2018), British physicians may attempt to 
intensively control blood pressure in these high-risk cardiovascular patients with potassium-spar-
ing diuretics / combinations of non-potassium-sparing diuretics with potassium or potassium-spar-
ing diuretics. This data, however, cannot answer the question whether the reason for this strongly 
increased CVM is the aforementioned diuretics use or the underlying high cardiovascular risk of 
this patient group. 
Users of exclusively potassium-sparing diuretics in the UK Biobank also had a statistically signif-
icantly increased CVM. However, this drug exposure was rather rare in the UK Biobank popula-
tion and this finding was based on 26 cases only (Table 25). As prescriptions of potassium-sparing 
diuretics were more frequent in the ESTHER population and no increased CVM was observed, the 
UK Biobank result might have been a finding by chance. 
Finally, because poor renal function is associated with hyperkalemia (Drawz et al., 2012) and 
increased CVM (Hayes et al., 2012; Kovesdy et al., 2018), it was of interest whether results for 
diuretics use differed according to kidney function. However, diuretics users with potential kidney 
damage (urinary albumin levels ≥ 20 mg/L) did not show a stronger association with CVM. An 
explanation may be that I mainly focused on non-potassium-sparing diuretics users who are rather 
prone to hypokalemia than to hyperkalemia. The group with a possible risk of hyperkalemia (users 
of potassium-sparing diuretics), however, was not separately investigated in subgroups by urinary 
albumin. 
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3.4.4 Potential drug-drug interaction of non-potassium-sparing diuretics and laxatives 
Signs for a potential drug-drug interaction of non-potassium-sparing diuretics and concurrent reg-
ular laxatives use were observed, but tests for interaction did not reach statistical significance. This 
can mainly be explained by the low statistical power of this analysis because exposure to concur-
rent use of both drug classes was rare (1.3 % and 1.6 % among antihypertensive drug users in the 
ESTHER study and the UK Biobank, respectively). In addition, the likely underestimation of the 
cardiovascular risk of regular laxatives users in my analysis due to the healthy-user/sick-stopper 
bias discussed earlier and a prevalent user design will have limited the chance for a detection of a 
statistically significant interaction. 
3.4.5 Strengths and limitations 
The major limitations of my analyses and their potential impact on the results have been discussed 
earlier and include the prevalent user design, no repeated drug assessment, and a limited extent to 
control for confounding (in particular for the severity of heart failure and CHD).  
Furthermore, serum potassium measurements were not available from the two analysed cohort 
studies. In addition to information on potassium-influencing drug use, such measurements would 
have been quite informative to provide evidence that the increased CVM observed in my analysis 
was indeed related to a drug-induced electrolyte disorder. However, this is already evident from 
previous cohort studies, which I summarised in the systematic review about potassium measure-
ments and cardiovascular outcomes in chapter 2 (Hoppe et al., 2018). The study included of Cohen 
and colleagues, for instance, observed a 2.6-fold increased risk for a composite cardiovascular 
outcome in diuretic-treated hypertensive patients with low serum potassium levels compared to 
individuals with adequate potassium levels (Cohen et al., 2001). Furthermore, the risk of hypoka-
lemia by chronic laxative use has been well-documented by Xing and colleagues (Xing and Soffer, 
2001) as well as Kokot and colleagues (Kokot and Hyla-Klekot, 2008). 
The major strength of my study is that the analyses followed the same protocol in two large cohort 
studies with a long follow-up for CVM. Thus, statistically significant results from a derivation 
cohort (ESTHER) were confirmed in a replication cohort (UK Biobank). Moreover, this is the first 
investigation about the concurrent use of non-potassium-sparing diuretics and laxatives, which 
was only feasible due to a thorough medication assessment of OTC drugs, which are not available 
in claims databases.  
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3.4.6 Conclusion 
This is the first individual patient-data meta-analysis of two large cohort studies about the associ-
ation of potassium-influencing drugs and CVM. Concurrent use of non-potassium-sparing diuret-
ics and laxatives was associated with a 2-fold increased CVM in participants with antihypertensive 
treatment. Physicians and pharmacists should ask patients using non-potassium-sparing diuretics 
about additional laxatives use, and inform them about the cardiovascular risk of concurrent use of 
these potassium-influencing drug classes. Furthermore, in these patients, the monitoring of serum 
potassium in shorter intervals may be an opportunity for cardiovascular risk prevention. 
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4 CONCLUSION 
With my dissertation in the field of cardiovascular disease epidemiology, I provide the first sys-
tematic review and meta-analysis about the association of abnormal serum potassium levels and 
cardiovascular outcomes in specific populations. In summary, I observed associations of low se-
rum potassium levels with supraventricular arrhythmias and associations of high serum potassium 
levels with CVM in the older general population. Associations of abnormal serum potassium levels 
and cardiovascular outcomes were even more pronounced in populations with hypertension, AMI, 
heart failure, CKD or dialysis. Although the observational studies included in the systematic re-
view cannot ascertain causality of the aforementioned significant associations, their results high-
light the clinical relevance of maintaining serum potassium levels within the reference range of 
3.5 to 5.1 mmol/L. More frequent potassium-monitoring and subsequent interventions, such as 
change or withdrawal of potassium-influencing drugs, might help to restore normal values and 
prevent cardiovascular events.  
The cardiovascular risk of potassium-influencing drugs was subject of further investigations 
within the course of my dissertation. To address this issue, I focused on the exposure to diuretics 
overall, non-potassium-sparing diuretics in specific, and laxatives, and investigated their associa-
tions with CVM. A potential drug-drug interaction of non-potassium-sparing diuretics and laxa-
tives was of special interest. The analyses in two large cohort studies from Germany and the United 
Kingdom yielded consistent results with respect to an association of diuretics use but not regular 
laxatives use with CVM among older adults treated with antihypertensive drugs. Signs for a 
drug-drug interaction of non-potassium-sparing diuretics and laxatives were detected. Interactions, 
however, were not statistically significant, mainly because concurrent use was rare in the two 
studies. Nevertheless, a statistically significant 2-fold increased CVM rate was observed in con-
current users of non-potassium-sparing diuretics and laxatives.  
Therefore, pharmacists should be vigilant about the concurrent use of drugs affecting potassium 
excretion, and make patients aware of this risk when they regularly purchase laxatives in a phar-
macy. Similarly, I strongly recommend physicians to ask their patients who use non-potassium-
sparing diuretics about additional laxatives use, to inform them about the cardiovascular risk of 
concurrent use of these drug classes, and to monitor serum potassium levels in shorter intervals in 
patients using laxatives on a regular basis. Of course, serum potassium levels are already being 
routinely checked in cardiac patients (1-2 weeks after initiation of a therapy, after dosage increase, 
and every 6 months), but the risk of additional self-medication may have been underestimated in 
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clinical practice so far. Hence, a closer monitoring with shorter intervals (e.g. every 3 months) 
could provide an opportunity for cardiovascular prevention. However, before implemented in clin-
ical routine, controlled clinical trials are needed to evaluate if tighter potassium-monitoring inter-
vals have an advantage for cardiovascular patients using non-potassium-sparing diuretics and  
laxatives. 
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5 SUMMARIES 
5.1 English summary 
This dissertation provides the first systematic review and meta-analysis of observational studies 
on the association of abnormal serum potassium levels (< 3.5 or > 5.1 mmol/L) and cardiovascular 
outcomes within specific populations. For this purpose, the medical databases Medline and Web 
of Science were systematically searched from inception until November 24, 2017. Data synthesis 
of 24 relevant studies was performed using random-effects model meta-analyses, which finally 
comprised the data of 310,825 participants. 
In the older general population, low serum potassium was associated with a 1.6-fold increased risk 
of supraventricular arrhythmias (hazard ratio [95%-confidence interval]: 1.62 [1.02; 2.55]).  
Contrarily, high serum potassium was associated with increased cardiovascular mortality 
(1.38 [1.14; 1.66]). In patients with acute myocardial infarction, the risk of ventricular arrhythmias 
was increased for high serum potassium (2.33 [1.60; 3.38]). A U-shaped association was observed 
both with a composite cardiovascular outcome in hypertensive patients (2.6-fold increased risk 
with hypokalemia and 1.7-fold increased risk with hyperkalemia), and with cardiovascular mor-
tality in dialysis patients (1.1-fold increased risk with hypokalemia and 1.4-fold increased risk with 
hyperkalemia) as well as in heart failure patients (not statistically significant). Further, only hy-
perkalemia was associated with an increased risk of a composite cardiovascular outcome in dialy-
sis patients (1.12 [1.03; 1.23]) and also in chronic kidney disease patients (1.34 [1.06; 1.71]). 
Due to both a lack of studies and a variety of investigated outcomes and populations, a maximum 
of six studies was pooled per meta-analysis. The studies included also partly differed with regard 
to statistical analyses, reporting of results, and cut-off values for serum potassium. However, by 
using explicit inclusion and exclusion criteria with respect to design, statistical methods and defi-
nition of serum potassium cut-off values, the studies pooled in meta-analyses were mostly compa-
rable and similar to the cut-off values proposed by the American Heart Association (reference 
range: 3.5 to 5.1 mmol/L). Given the heterogeneous covariate adjustment among the studies in-
cluded, I suggest a key set of covariates, which future studies on this topic could use, namely age, 
sex, body mass index or other weight measure, smoking, diabetes, hypertension, history of cardi-
ovascular disease, and kidney disease. 
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In conclusion, these results suggest that some populations, especially patients with hypertension 
or heart failure, might profit from more frequent potassium-monitoring and subsequent interven-
tions, such as change or withdrawal of potassium-influencing drugs, in order to restore normal 
values and prevent cardiovascular outcomes. 
Secondly, this dissertation presents the first investigation about the associations of use of diuretics 
overall, non-potassium-sparing diuretics in specific, and laxatives with cardiovascular mortality in 
participants with antihypertensive treatment. The drug classes were first analysed distinctly and 
then jointly to detect potential drug-drug interactions in two large-scale cohort studies. While the 
German ESTHER study served as a derivation cohort to generate hypotheses, the larger UK  
Biobank was used as a replication cohort to confirm the findings. Methodologically, Cox propor-
tional hazard regression models were applied to estimate hazard ratios and 95%-confidence inter-
vals in each study. Results from both studies were then combined in an individual patient-data 
meta-analysis using the random-effects model. 
Analyses included 4,253 participants, aged 50 to 75 years, from the ESTHER study and 105,359 
participants, aged 50 to 69 years, from the UK Biobank. During 14 and 7 years of follow-up, 476 
and 1,616 cardiovascular mortality cases were observed in the ESTHER study and the UK  
Biobank, respectively. Compared to non-users, a 1.6-fold (1.57 [1.29; 1.90]), a 1.4-fold 
(1.39 [1.26; 1.53]), and no statistically significantly increased [1.13 [0.94; 1.36]) cardiovascular 
mortality rate was observed in users of diuretics overall, non-potassium-sparing diuretics in spe-
cific, and laxatives, respectively. Concurrent use of non-potassium-sparing diuretics and laxatives 
was associated with a 2-fold increased cardiovascular mortality (2.05 [1.55; 2.71]) when compared 
to users of neither diuretics nor laxatives. However, a test for interaction slightly missed statistical 
significance (p=0.075). 
The major limitations of these analyses include the prevalent user design with regard to laxatives 
users, no repeated drug assessments, and a limited extent to control for confounding, in particular 
for the severity of heart failure and coronary heart disease. 
Nevertheless, an interaction of non-potassium-sparing diuretics and laxatives appears plausible. 
Therefore, physicians are highly recommended to clarify additional laxatives use and monitor se-
rum potassium levels more closely (e.g. every 3 months) in concurrent users. 
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5.2 Deutsche Zusammenfassung 
Diese Dissertation beinhaltet die erste systematische Übersichtsarbeit und Meta-Analyse von Be-
obachtungsstudien über den Zusammenhang von abnormalen Kaliumwerten (< 3,5 oder 
> 5,1 mmol/L) und kardiovaskulären Ereignissen in spezifischen Bevölkerungsgruppen. Dazu 
wurden die medizinischen Datenbanken Medline und Web of Science systematisch durchsucht. 
Die Recherche deckte den Zeitraum bis einschließlich 24. November 2017 ab. Die Zusammenfas-
sung von 24 relevanten Studien wurde mittels Meta-Analysen nach dem Random-Effects-Modell 
durchgeführt und enthält die Daten von 310.825 Teilnehmern. 
In der älteren Allgemeinbevölkerung waren niedrige Kaliumwerte mit einem 1,6-fach erhöhten 
Risiko für supraventrikuläre Arrhythmien assoziiert (Risikoverhältnis [95%-Konfidenzintervall]: 
1,62 [1,02-2,55]). Im Gegensatz dazu gingen hohe Kaliumwerte mit einer erhöhten kardiovasku-
lären Mortalität einher (1,38 [1,14-1,66]). Bei Patienten mit akutem Myokardinfarkt war das Ri-
siko von ventrikulären Arrhythmien bei hohen Kaliumwerten erhöht (2,33 [1,60-3,38]).  
Ein U-förmiger Zusammenhang zeigte sich sowohl für kardiovaskuläre Ereignisse bei hypertensi-
ven Patienten (2,6-fach erhöhtes Risiko bei Hypokaliämie und 1,7-fach erhöhtes Risiko bei Hy-
perkaliämie) als auch für kardiovaskuläre Mortalität bei Dialysepatienten (1,1-fach erhöhtes Ri-
siko bei Hypokaliämie und 1,4-fach erhöhtes Risiko bei Hyperkaliämie) ebenso wie bei Patienten 
mit Herzinsuffizienz (nicht statistisch signifikant). Darüber hinaus erhöhte eine Hyperkaliämie das 
Risiko für kardiovaskuläre Ereignisse bei Dialysepatienten (1,12 [1,03-1,23]) sowie bei Patienten 
mit chronischer Nierenerkrankung (1,34 [1,06-1,71]). 
Aufgrund fehlender Studien sowie einer Vielzahl an untersuchten Endpunkten und Studienpopu-
lationen konnten maximal sechs Studien pro Meta-Analyse zusammengefasst werden. Die Studien 
unterschieden sich zudem teilweise bezüglich der statistischen Auswertung, der Ergebnispräsen-
tation sowie der verwendeten Grenzwerte für Serumkalium. Die Verwendung expliziter Ein- und 
Ausschlusskriterien ermöglichte jedoch, dass die in Meta-Analysen zusammengefassten Studien 
weitestgehend vergleichbar waren und mit den Grenzwerten der American Heart Association (Re-
ferenzbereich: 3,5 bis 5,1 mmol/L) übereinstimmten. Angesichts der Unterschiede in der Variab-
lenadjustierung erscheint ein Keyset von Kovariablen sinnvoll, welches in zukünftigen Studien 
verwendet werden sollte: Alter, Geschlecht, Body-Maß-Index oder andere Gewichtsmessungen, 
Rauchen, Diabetes, Bluthochdruck, Vorgeschichte von Herz-Kreislauf-Erkrankungen und Nie-
renerkrankungen. 
Abschließend deuten diese Ergebnisse darauf hin, dass einige Populationen, insbesondere Patien-
ten mit Bluthochdruck oder Herzinsuffizienz, von engmaschigeren Kontrollen des Kaliumwertes 
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und nachfolgenden Interventionen, wie beispielsweise der Wechsel oder das Absetzen kaliumbe-
einflussender Medikamente, profitieren könnten, um Normalwerte wiederherzustellen und Herz-
Kreislauf-Ereignisse zu verhindern. 
Im Weiteren behandelte diese Dissertation die Assoziationen von Diuretika im Allgemeinen, von 
nicht-kaliumsparenden Diuretika im Spezifischen und von Abführmitteln mit kardiovaskulärer 
Mortalität. Die Analysen wurden zwecks Herstellung eines vergleichbaren kardiovaskulären 
Grundrisikos bei Patienten mit antihypertensiver Therapie beschränkt. 
Die Wirkstoffklassen wurden zunächst einzeln und dann gemeinsam in zwei großen Kohortenstu-
dien analysiert, um mögliche Interaktionen zu erkennen. Während die deutsche ESTHER-Studie 
als Ableitungskohorte zur Generierung von Hypothesen fungierte, diente die UK Biobank zur Va-
lidierung der Ergebnisse. Die Ergebnisse beider Studien wurden anschließend in einer individuel-
len Patientendaten-Meta-Analyse nach dem Random-Effects-Model zusammengefasst. 
Die Analysen umfassten 4.253 ESTHER-Teilnehmer im Alter von 50 bis 75 Jahren und 105.359 
Teilnehmer im Alter von 50 bis 69 Jahren aus der UK Biobank. Innerhalb einer Nachbeobach-
tungszeit von 14 Jahren wurden in der ESTHER-Studie 476 kardiovaskuläre Todesfälle beobachtet 
und innerhalb von 7 Jahren 1.616 kardiovaskuläre Todesfälle in der UK Biobank. Im Vergleich zu 
Nichtanwendern war die kardiovaskuläre Mortalität bei Anwendern von Diuretika im Allgemei-
nen 1,6-fach (1,57 [1,29-1,90]), bei Anwendern nicht-kaliumsparender Diuretika im Spezifischen 
1,4-fach (1,39 [1,26-1,53]) und bei Anwendern von Abführmitteln nicht statistisch signifikant 
(1,13 [0,94-1,36]) erhöht. Die gleichzeitige Verwendung von nicht-kaliumsparenden Diuretika 
und Abführmitteln zeigte eine 2-fach erhöhte kardiovaskuläre Mortalität (2,05 [1,55-2,71]) im 
Vergleich zu Nichtanwendern beider Substanzgruppen. Ein Interaktionstest verfehlte jedoch 
knapp ein statistisch signifikantes Ergebnis (p=0,075). 
Die Limitationen dieser Analysen beinhalten das Prevalent-User-Design in Bezug auf Anwender 
von Abführmitteln, fehlende wiederholte Arzneimittelabfragen sowie ein begrenztes Maß zur Ad-
justierung für wichtige Kovariablen, wie beispielsweise den Schweregrad der Herzinsuffizienz 
sowie der koronaren Herzkrankheit. 
Insgesamt legen diese Ergebnisse dennoch den Schluss nahe, dass eine Arzneimittelinteraktion 
zwischen nicht-kaliumsparenden Diuretika und Abführmitteln plausibel erscheint. Deshalb ist 
Ärzten unbedingt zu empfehlen, die zusätzliche Einnahme von Abführmitteln bei ihren Patienten 
stets zu erfragen und bei gleichzeitiger Anwendung mit nicht-kaliumsparenden Diuretika eine eng-
maschigere Überwachung der Kaliumwerte (beispielsweise alle 3 Monate) vorzunehmen. 
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